id	sid	tid	token	lemma	pos
dpc-2650	1	1	dermatology	dermatology	NOUN
dpc-2650	1	2	:	:	PUNCT
dpc-2650	1	3	practical	practical	ADJ
dpc-2650	1	4	and	and	CCONJ
dpc-2650	1	5	conceptual	conceptual	ADJ
dpc-2650	1	6	original	original	ADJ
dpc-2650	1	7	article	article	NOUN
dpc-2650	1	8	|	|	ADV
dpc-2650	1	9	dermatol	dermatol	ADJ
dpc-2650	1	10	pract	pract	NOUN
dpc-2650	1	11	concept	concept	NOUN
dpc-2650	1	12	.	.	PUNCT
dpc-2650	2	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	2	2	1	1	NUM
dpc-2650	2	3	the	the	DET
dpc-2650	2	4	role	role	NOUN
dpc-2650	2	5	of	of	ADP
dpc-2650	2	6	ereg	ereg	NOUN
dpc-2650	2	7	,	,	PUNCT
dpc-2650	2	8	ptpn1	ptpn1	NOUN
dpc-2650	2	9	,	,	PUNCT
dpc-2650	2	10	and	and	CCONJ
dpc-2650	2	11	serpinb7	serpinb7	NOUN
dpc-2650	2	12	genes	gene	NOUN
dpc-2650	2	13	in	in	ADP
dpc-2650	2	14	the	the	DET
dpc-2650	2	15	pathogenesis	pathogenesis	NOUN
dpc-2650	2	16	of	of	ADP
dpc-2650	2	17	psoriasis	psoriasis	NOUN
dpc-2650	2	18	:	:	PUNCT
dpc-2650	2	19	may	may	AUX
dpc-2650	2	20	serpinb7	serpinb7	VERB
dpc-2650	2	21	be	be	AUX
dpc-2650	2	22	protective	protective	ADJ
dpc-2650	2	23	and	and	CCONJ
dpc-2650	2	24	a	a	DET
dpc-2650	2	25	marker	marker	NOUN
dpc-2650	2	26	of	of	ADP
dpc-2650	2	27	severity	severity	NOUN
dpc-2650	2	28	for	for	ADP
dpc-2650	2	29	psoriasis	psoriasis	NOUN
dpc-2650	2	30	?	?	PUNCT
dpc-2650	3	1	havva	havva	NOUN
dpc-2650	3	2	hilal	hilal	PROPN
dpc-2650	3	3	ayvaz1	ayvaz1	PROPN
dpc-2650	3	4	,	,	PUNCT
dpc-2650	3	5	kuyaş	kuyaş	PROPN
dpc-2650	3	6	hekimler	hekimler	PROPN
dpc-2650	3	7	öztürk2	öztürk2	PROPN
dpc-2650	3	8	,	,	PUNCT
dpc-2650	3	9	mehmet	mehmet	PROPN
dpc-2650	3	10	ali	ali	PROPN
dpc-2650	3	11	seyirci1	seyirci1	PROPN
dpc-2650	3	12	,	,	PUNCT
dpc-2650	3	13	emrah	emrah	PROPN
dpc-2650	3	14	atay3	atay3	PROPN
dpc-2650	3	15	,	,	PUNCT
dpc-2650	3	16	selma	selma	PROPN
dpc-2650	3	17	korkmaz1	korkmaz1	PROPN
dpc-2650	3	18	,	,	PUNCT
dpc-2650	3	19	i̇jlal	i̇jlal	NOUN
dpc-2650	3	20	erturan1	erturan1	PROPN
dpc-2650	3	21	,	,	PUNCT
dpc-2650	3	22	mehmet	mehmet	PROPN
dpc-2650	3	23	yıldırım1	yıldırım1	PROPN
dpc-2650	4	1	1	1	NUM
dpc-2650	4	2	department	department	NOUN
dpc-2650	4	3	of	of	ADP
dpc-2650	4	4	dermatology	dermatology	NOUN
dpc-2650	4	5	,	,	PUNCT
dpc-2650	4	6	faculty	faculty	NOUN
dpc-2650	4	7	of	of	ADP
dpc-2650	4	8	medicine	medicine	NOUN
dpc-2650	4	9	,	,	PUNCT
dpc-2650	4	10	suleyman	suleyman	NOUN
dpc-2650	4	11	demirel	demirel	NOUN
dpc-2650	4	12	university	university	NOUN
dpc-2650	4	13	,	,	PUNCT
dpc-2650	4	14	isparta	isparta	PROPN
dpc-2650	4	15	,	,	PUNCT
dpc-2650	4	16	turkey	turkey	NOUN
dpc-2650	4	17	2	2	NUM
dpc-2650	4	18	department	department	NOUN
dpc-2650	4	19	of	of	ADP
dpc-2650	4	20	medical	medical	ADJ
dpc-2650	4	21	genetics	genetic	NOUN
dpc-2650	4	22	,	,	PUNCT
dpc-2650	4	23	faculty	faculty	NOUN
dpc-2650	4	24	of	of	ADP
dpc-2650	4	25	medicine	medicine	NOUN
dpc-2650	4	26	,	,	PUNCT
dpc-2650	4	27	suleyman	suleyman	NOUN
dpc-2650	4	28	demirel	demirel	NOUN
dpc-2650	4	29	university	university	NOUN
dpc-2650	4	30	,	,	PUNCT
dpc-2650	4	31	isparta	isparta	PROPN
dpc-2650	4	32	,	,	PUNCT
dpc-2650	4	33	turkey	turkey	NOUN
dpc-2650	4	34	3	3	NUM
dpc-2650	4	35	public	public	ADJ
dpc-2650	4	36	health	health	NOUN
dpc-2650	4	37	expertise	expertise	NOUN
dpc-2650	4	38	,	,	PUNCT
dpc-2650	4	39	eskişehir	eskişehir	NOUN
dpc-2650	4	40	directorate	directorate	NOUN
dpc-2650	4	41	of	of	ADP
dpc-2650	4	42	health	health	NOUN
dpc-2650	4	43	,	,	PUNCT
dpc-2650	4	44	eskişehir	eskişehir	NOUN
dpc-2650	4	45	,	,	PUNCT
dpc-2650	4	46	turkey	turkey	NOUN
dpc-2650	4	47	key	key	ADJ
dpc-2650	4	48	words	word	NOUN
dpc-2650	4	49	:	:	PUNCT
dpc-2650	4	50	psoriasis	psoriasis	NOUN
dpc-2650	4	51	,	,	PUNCT
dpc-2650	4	52	epiregulin	epiregulin	NOUN
dpc-2650	4	53	,	,	PUNCT
dpc-2650	4	54	tyrosine	tyrosine	NOUN
dpc-2650	4	55	-	-	PUNCT
dpc-2650	4	56	protein	protein	NOUN
dpc-2650	4	57	phosphatase	phosphatase	NOUN
dpc-2650	4	58	non	non	ADJ
dpc-2650	4	59	-	-	ADJ
dpc-2650	4	60	receptor	receptor	ADJ
dpc-2650	4	61	type	type	NOUN
dpc-2650	4	62	1	1	NUM
dpc-2650	4	63	,	,	PUNCT
dpc-2650	4	64	serine	serine	ADJ
dpc-2650	4	65	proteinase	proteinase	NOUN
dpc-2650	4	66	inhibitors	inhibitor	NOUN
dpc-2650	4	67	citation	citation	NOUN
dpc-2650	4	68	:	:	PUNCT
dpc-2650	4	69	ayvaz	ayvaz	NOUN
dpc-2650	4	70	hh	hh	PROPN
dpc-2650	4	71	,	,	PUNCT
dpc-2650	4	72	öztürk	öztürk	PROPN
dpc-2650	4	73	kh	kh	PROPN
dpc-2650	4	74	,	,	PUNCT
dpc-2650	4	75	seyirci	seyirci	PROPN
dpc-2650	4	76	ma	ma	PROPN
dpc-2650	4	77	,	,	PUNCT
dpc-2650	4	78	et	et	PROPN
dpc-2650	4	79	al	al	PROPN
dpc-2650	4	80	.	.	PUNCT
dpc-2650	5	1	the	the	DET
dpc-2650	5	2	role	role	NOUN
dpc-2650	5	3	of	of	ADP
dpc-2650	5	4	ereg	ereg	NOUN
dpc-2650	5	5	,	,	PUNCT
dpc-2650	5	6	ptpn1	ptpn1	NOUN
dpc-2650	5	7	,	,	PUNCT
dpc-2650	5	8	and	and	CCONJ
dpc-2650	5	9	serpinb7	serpinb7	NOUN
dpc-2650	5	10	genes	gene	NOUN
dpc-2650	5	11	in	in	ADP
dpc-2650	5	12	the	the	DET
dpc-2650	5	13	pathogenesis	pathogenesis	NOUN
dpc-2650	5	14	of	of	ADP
dpc-2650	5	15	psoriasis	psoriasis	NOUN
dpc-2650	5	16	:	:	PUNCT
dpc-2650	5	17	may	may	AUX
dpc-2650	5	18	serpinb7	serpinb7	VERB
dpc-2650	5	19	be	be	AUX
dpc-2650	5	20	protective	protective	ADJ
dpc-2650	5	21	and	and	CCONJ
dpc-2650	5	22	a	a	DET
dpc-2650	5	23	marker	marker	NOUN
dpc-2650	5	24	of	of	ADP
dpc-2650	5	25	severity	severity	NOUN
dpc-2650	5	26	for	for	ADP
dpc-2650	5	27	psoriasis	psoriasis	NOUN
dpc-2650	5	28	?	?	PUNCT
dpc-2650	6	1	dermatol	dermatol	NOUN
dpc-2650	6	2	pract	pract	NOUN
dpc-2650	6	3	concept	concept	NOUN
dpc-2650	6	4	.	.	PUNCT
dpc-2650	7	1	2023;13(2):e2023085	2023;13(2):e2023085	X
dpc-2650	7	2	.	.	PUNCT
dpc-2650	7	3	doi	doi	PROPN
dpc-2650	7	4	:	:	PUNCT
dpc-2650	7	5	https://doi	https://doi	PROPN
dpc-2650	7	6	.org/10.5826	.org/10.5826	PROPN
dpc-2650	7	7	/	/	SYM
dpc-2650	7	8	dpc.1302a85	dpc.1302a85	NOUN
dpc-2650	7	9	accepted	accept	VERB
dpc-2650	7	10	:	:	PUNCT
dpc-2650	7	11	september	september	PROPN
dpc-2650	7	12	26	26	NUM
dpc-2650	7	13	,	,	PUNCT
dpc-2650	7	14	2022	2022	NUM
dpc-2650	7	15	;	;	PUNCT
dpc-2650	7	16	published	publish	VERB
dpc-2650	7	17	:	:	PUNCT
dpc-2650	8	1	april	april	PROPN
dpc-2650	8	2	2023	2023	NUM
dpc-2650	8	3	copyright	copyright	NOUN
dpc-2650	8	4	:	:	PUNCT
dpc-2650	8	5	©	©	PROPN
dpc-2650	8	6	2023	2023	NUM
dpc-2650	8	7	ayvaz	ayvaz	NOUN
dpc-2650	8	8	et	et	PROPN
dpc-2650	8	9	al	al	PROPN
dpc-2650	8	10	.	.	PUNCT
dpc-2650	9	1	this	this	PRON
dpc-2650	9	2	is	be	AUX
dpc-2650	9	3	an	an	DET
dpc-2650	9	4	open	open	ADJ
dpc-2650	9	5	-	-	PUNCT
dpc-2650	9	6	access	access	NOUN
dpc-2650	9	7	article	article	NOUN
dpc-2650	9	8	distributed	distribute	VERB
dpc-2650	9	9	under	under	ADP
dpc-2650	9	10	the	the	DET
dpc-2650	9	11	terms	term	NOUN
dpc-2650	9	12	of	of	ADP
dpc-2650	9	13	the	the	DET
dpc-2650	9	14	creative	creative	ADJ
dpc-2650	9	15	commons	common	NOUN
dpc-2650	9	16	attribution	attribution	NOUN
dpc-2650	9	17	-	-	PUNCT
dpc-2650	9	18	noncommercial	noncommercial	ADJ
dpc-2650	9	19	license	license	NOUN
dpc-2650	9	20	(	(	PUNCT
dpc-2650	9	21	by	by	ADP
dpc-2650	9	22	-	-	PUNCT
dpc-2650	9	23	nc-4.0	nc-4.0	NOUN
dpc-2650	9	24	)	)	PUNCT
dpc-2650	9	25	,	,	PUNCT
dpc-2650	9	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2650	9	27	,	,	PUNCT
dpc-2650	9	28	which	which	PRON
dpc-2650	9	29	permits	permit	VERB
dpc-2650	9	30	unrestricted	unrestricted	ADJ
dpc-2650	9	31	noncommercial	noncommercial	ADJ
dpc-2650	9	32	use	use	NOUN
dpc-2650	9	33	,	,	PUNCT
dpc-2650	9	34	distribution	distribution	NOUN
dpc-2650	9	35	,	,	PUNCT
dpc-2650	9	36	and	and	CCONJ
dpc-2650	9	37	reproduction	reproduction	NOUN
dpc-2650	9	38	in	in	ADP
dpc-2650	9	39	any	any	DET
dpc-2650	9	40	medium	medium	NOUN
dpc-2650	9	41	,	,	PUNCT
dpc-2650	9	42	provided	provide	VERB
dpc-2650	9	43	the	the	DET
dpc-2650	9	44	original	original	ADJ
dpc-2650	9	45	authors	author	NOUN
dpc-2650	9	46	and	and	CCONJ
dpc-2650	9	47	source	source	NOUN
dpc-2650	9	48	are	be	AUX
dpc-2650	9	49	credited	credit	VERB
dpc-2650	9	50	.	.	PUNCT
dpc-2650	10	1	funding	funding	NOUN
dpc-2650	10	2	:	:	PUNCT
dpc-2650	10	3	none	none	NOUN
dpc-2650	10	4	.	.	PUNCT
dpc-2650	11	1	competing	compete	VERB
dpc-2650	11	2	interests	interest	NOUN
dpc-2650	11	3	:	:	PUNCT
dpc-2650	11	4	none	none	NOUN
dpc-2650	11	5	.	.	PUNCT
dpc-2650	12	1	authorship	authorship	NOUN
dpc-2650	12	2	:	:	PUNCT
dpc-2650	12	3	all	all	DET
dpc-2650	12	4	authors	author	NOUN
dpc-2650	12	5	have	have	AUX
dpc-2650	12	6	contributed	contribute	VERB
dpc-2650	12	7	significantly	significantly	ADV
dpc-2650	12	8	to	to	ADP
dpc-2650	12	9	this	this	DET
dpc-2650	12	10	publication	publication	NOUN
dpc-2650	12	11	.	.	PUNCT
dpc-2650	13	1	corresponding	correspond	VERB
dpc-2650	13	2	author	author	NOUN
dpc-2650	13	3	:	:	PUNCT
dpc-2650	13	4	havva	havva	PROPN
dpc-2650	13	5	hilal	hilal	PROPN
dpc-2650	13	6	ayvaz	ayvaz	PROPN
dpc-2650	13	7	,	,	PUNCT
dpc-2650	13	8	çünür	çünür	PROPN
dpc-2650	13	9	mah	mah	PROPN
dpc-2650	13	10	sdü	sdü	VERB
dpc-2650	13	11	dermatology	dermatology	PROPN
dpc-2650	13	12	department	department	PROPN
dpc-2650	13	13	,	,	PUNCT
dpc-2650	13	14	32260	32260	NUM
dpc-2650	13	15	,	,	PUNCT
dpc-2650	13	16	isparta	isparta	NOUN
dpc-2650	13	17	,	,	PUNCT
dpc-2650	13	18	turkey	turkey	NOUN
dpc-2650	13	19	.	.	PUNCT
dpc-2650	14	1	e	e	X
dpc-2650	14	2	-	-	NOUN
dpc-2650	14	3	mail	mail	NOUN
dpc-2650	14	4	:	:	PUNCT
dpc-2650	15	1	drhhilalayvaz@gmail.com	drhhilalayvaz@gmail.com	X
dpc-2650	15	2	,	,	PUNCT
dpc-2650	15	3	phone	phone	NOUN
dpc-2650	15	4	number	number	NOUN
dpc-2650	15	5	:	:	PUNCT
dpc-2650	15	6	+905309505907	+905309505907	NUM
dpc-2650	15	7	introduction	introduction	NOUN
dpc-2650	15	8	:	:	PUNCT
dpc-2650	15	9	psoriasis	psoriasis	NOUN
dpc-2650	15	10	is	be	AUX
dpc-2650	15	11	a	a	DET
dpc-2650	15	12	chronic	chronic	ADJ
dpc-2650	15	13	inflammatory	inflammatory	ADJ
dpc-2650	15	14	dermatological	dermatological	ADJ
dpc-2650	15	15	disease	disease	NOUN
dpc-2650	15	16	with	with	ADP
dpc-2650	15	17	complex	complex	ADJ
dpc-2650	15	18	pathogenesis	pathogenesis	NOUN
dpc-2650	15	19	in	in	ADP
dpc-2650	15	20	which	which	PRON
dpc-2650	15	21	many	many	ADJ
dpc-2650	15	22	immune	immune	ADJ
dpc-2650	15	23	system	system	NOUN
dpc-2650	15	24	cells	cell	NOUN
dpc-2650	15	25	,	,	PUNCT
dpc-2650	15	26	including	include	VERB
dpc-2650	15	27	keratinocytes	keratinocyte	NOUN
dpc-2650	15	28	,	,	PUNCT
dpc-2650	15	29	play	play	VERB
dpc-2650	15	30	a	a	DET
dpc-2650	15	31	role	role	NOUN
dpc-2650	15	32	.	.	PUNCT
dpc-2650	16	1	many	many	ADJ
dpc-2650	16	2	genes	gene	NOUN
dpc-2650	16	3	regulate	regulate	VERB
dpc-2650	16	4	the	the	DET
dpc-2650	16	5	proliferation	proliferation	NOUN
dpc-2650	16	6	of	of	ADP
dpc-2650	16	7	keratinocytes	keratinocyte	NOUN
dpc-2650	16	8	and	and	CCONJ
dpc-2650	16	9	other	other	ADJ
dpc-2650	16	10	immune	immune	ADJ
dpc-2650	16	11	cells	cell	NOUN
dpc-2650	16	12	that	that	PRON
dpc-2650	16	13	have	have	VERB
dpc-2650	16	14	essential	essential	ADJ
dpc-2650	16	15	roles	role	NOUN
dpc-2650	16	16	in	in	ADP
dpc-2650	16	17	the	the	DET
dpc-2650	16	18	pathogenesis	pathogenesis	NOUN
dpc-2650	16	19	of	of	ADP
dpc-2650	16	20	psoriasis	psoriasis	NOUN
dpc-2650	16	21	.	.	PUNCT
dpc-2650	17	1	the	the	DET
dpc-2650	17	2	expressions	expression	NOUN
dpc-2650	17	3	of	of	ADP
dpc-2650	17	4	ereg	ereg	NOUN
dpc-2650	17	5	,	,	PUNCT
dpc-2650	17	6	ptpn1	ptpn1	NOUN
dpc-2650	17	7	,	,	PUNCT
dpc-2650	17	8	and	and	CCONJ
dpc-2650	17	9	serpinb7	serpinb7	NOUN
dpc-2650	17	10	genes	gene	NOUN
dpc-2650	17	11	were	be	AUX
dpc-2650	17	12	shown	show	VERB
dpc-2650	17	13	as	as	SCONJ
dpc-2650	17	14	upregulated	upregulate	VERB
dpc-2650	17	15	in	in	ADP
dpc-2650	17	16	psoriatic	psoriatic	ADJ
dpc-2650	17	17	skins	skin	NOUN
dpc-2650	17	18	in	in	ADP
dpc-2650	17	19	a	a	DET
dpc-2650	17	20	few	few	ADJ
dpc-2650	17	21	studies	study	NOUN
dpc-2650	17	22	previously	previously	ADV
dpc-2650	17	23	.	.	PUNCT
dpc-2650	18	1	objectives	objective	NOUN
dpc-2650	18	2	:	:	PUNCT
dpc-2650	18	3	we	we	PRON
dpc-2650	18	4	aimed	aim	VERB
dpc-2650	18	5	to	to	PART
dpc-2650	18	6	evaluate	evaluate	VERB
dpc-2650	18	7	the	the	DET
dpc-2650	18	8	expressions	expression	NOUN
dpc-2650	18	9	of	of	ADP
dpc-2650	18	10	these	these	DET
dpc-2650	18	11	genes	gene	NOUN
dpc-2650	18	12	in	in	ADP
dpc-2650	18	13	psoriatic	psoriatic	ADJ
dpc-2650	18	14	lesional	lesional	ADJ
dpc-2650	18	15	skin	skin	NOUN
dpc-2650	18	16	and	and	CCONJ
dpc-2650	18	17	compared	compare	VERB
dpc-2650	18	18	them	they	PRON
dpc-2650	18	19	with	with	ADP
dpc-2650	18	20	non	non	ADJ
dpc-2650	18	21	-	-	ADJ
dpc-2650	18	22	lesional	lesional	ADJ
dpc-2650	18	23	adjacent	adjacent	ADJ
dpc-2650	18	24	skin	skin	NOUN
dpc-2650	18	25	of	of	ADP
dpc-2650	18	26	the	the	DET
dpc-2650	18	27	same	same	ADJ
dpc-2650	18	28	patients	patient	NOUN
dpc-2650	18	29	and	and	CCONJ
dpc-2650	18	30	normal	normal	ADJ
dpc-2650	18	31	skin	skin	NOUN
dpc-2650	18	32	of	of	ADP
dpc-2650	18	33	healthy	healthy	ADJ
dpc-2650	18	34	controls	control	NOUN
dpc-2650	18	35	.	.	PUNCT
dpc-2650	19	1	results	result	NOUN
dpc-2650	19	2	:	:	PUNCT
dpc-2650	19	3	our	our	PRON
dpc-2650	19	4	results	result	NOUN
dpc-2650	19	5	revealed	reveal	VERB
dpc-2650	19	6	that	that	SCONJ
dpc-2650	19	7	the	the	DET
dpc-2650	19	8	expressions	expression	NOUN
dpc-2650	19	9	of	of	ADP
dpc-2650	19	10	ereg	ereg	NOUN
dpc-2650	19	11	and	and	CCONJ
dpc-2650	19	12	ptpn1	ptpn1	NOUN
dpc-2650	19	13	genes	gene	NOUN
dpc-2650	19	14	were	be	AUX
dpc-2650	19	15	upregulated	upregulate	VERB
dpc-2650	19	16	,	,	PUNCT
dpc-2650	19	17	whereas	whereas	SCONJ
dpc-2650	19	18	the	the	DET
dpc-2650	19	19	serpinb7	serpinb7	NOUN
dpc-2650	19	20	gene	gene	NOUN
dpc-2650	19	21	expression	expression	NOUN
dpc-2650	19	22	was	be	AUX
dpc-2650	19	23	down	down	ADV
dpc-2650	19	24	regulated	regulate	VERB
dpc-2650	19	25	in	in	ADP
dpc-2650	19	26	the	the	DET
dpc-2650	19	27	psoriatic	psoriatic	ADJ
dpc-2650	19	28	skin	skin	NOUN
dpc-2650	19	29	of	of	ADP
dpc-2650	19	30	the	the	DET
dpc-2650	19	31	patients	patient	NOUN
dpc-2650	19	32	than	than	ADP
dpc-2650	19	33	normal	normal	ADJ
dpc-2650	19	34	skin	skin	NOUN
dpc-2650	19	35	of	of	ADP
dpc-2650	19	36	controls	control	NOUN
dpc-2650	19	37	.	.	PUNCT
dpc-2650	20	1	moreover	moreover	ADV
dpc-2650	20	2	,	,	PUNCT
dpc-2650	20	3	the	the	DET
dpc-2650	20	4	expression	expression	NOUN
dpc-2650	20	5	level	level	NOUN
dpc-2650	20	6	of	of	ADP
dpc-2650	20	7	the	the	DET
dpc-2650	20	8	serpinb7	serpinb7	NOUN
dpc-2650	20	9	gene	gene	NOUN
dpc-2650	20	10	was	be	AUX
dpc-2650	20	11	also	also	ADV
dpc-2650	20	12	negatively	negatively	ADV
dpc-2650	20	13	correlated	correlate	VERB
dpc-2650	20	14	with	with	ADP
dpc-2650	20	15	the	the	DET
dpc-2650	20	16	severity	severity	NOUN
dpc-2650	20	17	of	of	ADP
dpc-2650	20	18	the	the	DET
dpc-2650	20	19	disease	disease	NOUN
dpc-2650	20	20	among	among	ADP
dpc-2650	20	21	patients	patient	NOUN
dpc-2650	20	22	.	.	PUNCT
dpc-2650	21	1	conclusions	conclusion	NOUN
dpc-2650	21	2	:	:	PUNCT
dpc-2650	21	3	according	accord	VERB
dpc-2650	21	4	to	to	ADP
dpc-2650	21	5	our	our	PRON
dpc-2650	21	6	results	result	NOUN
dpc-2650	21	7	,	,	PUNCT
dpc-2650	21	8	overexpression	overexpression	NOUN
dpc-2650	21	9	of	of	ADP
dpc-2650	21	10	ereg	ereg	NOUN
dpc-2650	21	11	and	and	CCONJ
dpc-2650	21	12	ptpn1	ptpn1	NOUN
dpc-2650	21	13	genes	gene	NOUN
dpc-2650	21	14	,	,	PUNCT
dpc-2650	21	15	and	and	CCONJ
dpc-2650	21	16	decreased	decrease	VERB
dpc-2650	21	17	expression	expression	NOUN
dpc-2650	21	18	of	of	ADP
dpc-2650	21	19	serpinb7	serpinb7	NOUN
dpc-2650	21	20	gene	gene	NOUN
dpc-2650	21	21	may	may	AUX
dpc-2650	21	22	lead	lead	VERB
dpc-2650	21	23	to	to	ADP
dpc-2650	21	24	the	the	DET
dpc-2650	21	25	development	development	NOUN
dpc-2650	21	26	of	of	ADP
dpc-2650	21	27	psoriasis	psoriasis	NOUN
dpc-2650	21	28	.	.	PUNCT
dpc-2650	22	1	abstract	abstract	ADJ
dpc-2650	22	2	2	2	NUM
dpc-2650	22	3	original	original	ADJ
dpc-2650	22	4	article	article	NOUN
dpc-2650	22	5	|	|	ADV
dpc-2650	22	6	dermatol	dermatol	ADJ
dpc-2650	22	7	pract	pract	NOUN
dpc-2650	22	8	concept	concept	NOUN
dpc-2650	22	9	.	.	PUNCT
dpc-2650	23	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	23	2	introduction	introduction	NOUN
dpc-2650	23	3	psoriasis	psoriasis	NOUN
dpc-2650	23	4	is	be	AUX
dpc-2650	23	5	an	an	DET
dpc-2650	23	6	auto	auto	NOUN
dpc-2650	23	7	-	-	PUNCT
dpc-2650	23	8	inflammatory	inflammatory	ADJ
dpc-2650	23	9	dermatological	dermatological	ADJ
dpc-2650	23	10	disease	disease	NOUN
dpc-2650	23	11	with	with	ADP
dpc-2650	23	12	complex	complex	ADJ
dpc-2650	23	13	pathogenesis	pathogenesis	NOUN
dpc-2650	23	14	,	,	PUNCT
dpc-2650	23	15	including	include	VERB
dpc-2650	23	16	immunological	immunological	ADJ
dpc-2650	23	17	,	,	PUNCT
dpc-2650	23	18	biochemical	biochemical	ADJ
dpc-2650	23	19	,	,	PUNCT
dpc-2650	23	20	vascular	vascular	ADJ
dpc-2650	23	21	,	,	PUNCT
dpc-2650	23	22	and	and	CCONJ
dpc-2650	23	23	neurological	neurological	ADJ
dpc-2650	23	24	changes	change	NOUN
dpc-2650	23	25	[	[	X
dpc-2650	23	26	1	1	NUM
dpc-2650	23	27	]	]	PUNCT
dpc-2650	23	28	.	.	PUNCT
dpc-2650	24	1	the	the	DET
dpc-2650	24	2	main	main	ADJ
dpc-2650	24	3	pathological	pathological	ADJ
dpc-2650	24	4	findings	finding	NOUN
dpc-2650	24	5	of	of	ADP
dpc-2650	24	6	psoriasis	psoriasis	NOUN
dpc-2650	24	7	are	be	AUX
dpc-2650	24	8	the	the	DET
dpc-2650	24	9	hyperproliferation	hyperproliferation	NOUN
dpc-2650	24	10	of	of	ADP
dpc-2650	24	11	epidermis	epidermis	NOUN
dpc-2650	24	12	,	,	PUNCT
dpc-2650	24	13	altered	alter	VERB
dpc-2650	24	14	keratinocytes	keratinocyte	NOUN
dpc-2650	24	15	,	,	PUNCT
dpc-2650	24	16	dermal	dermal	ADJ
dpc-2650	24	17	angiogenesis	angiogenesis	NOUN
dpc-2650	24	18	,	,	PUNCT
dpc-2650	24	19	a	a	DET
dpc-2650	24	20	dense	dense	ADJ
dpc-2650	24	21	epidermal	epidermal	ADJ
dpc-2650	24	22	and	and	CCONJ
dpc-2650	24	23	dermal	dermal	VERB
dpc-2650	24	24	infiltrate	infiltrate	NOUN
dpc-2650	24	25	consisting	consisting	NOUN
dpc-2650	24	26	of	of	ADP
dpc-2650	24	27	macrophages	macrophage	NOUN
dpc-2650	24	28	,	,	PUNCT
dpc-2650	24	29	lymphocytes	lymphocyte	NOUN
dpc-2650	24	30	,	,	PUNCT
dpc-2650	24	31	and	and	CCONJ
dpc-2650	24	32	neutrophils	neutrophil	NOUN
dpc-2650	24	33	[	[	X
dpc-2650	24	34	2	2	NUM
dpc-2650	24	35	]	]	PUNCT
dpc-2650	24	36	.	.	PUNCT
dpc-2650	25	1	keratinocytes	keratinocyte	NOUN
dpc-2650	25	2	are	be	AUX
dpc-2650	25	3	one	one	NUM
dpc-2650	25	4	of	of	ADP
dpc-2650	25	5	the	the	DET
dpc-2650	25	6	principal	principal	ADJ
dpc-2650	25	7	cells	cell	NOUN
dpc-2650	25	8	playing	play	VERB
dpc-2650	25	9	essential	essential	ADJ
dpc-2650	25	10	roles	role	NOUN
dpc-2650	25	11	in	in	ADP
dpc-2650	25	12	the	the	DET
dpc-2650	25	13	pathogenesis	pathogenesis	NOUN
dpc-2650	25	14	of	of	ADP
dpc-2650	25	15	psoriasis	psoriasis	NOUN
dpc-2650	25	16	and	and	CCONJ
dpc-2650	25	17	,	,	PUNCT
dpc-2650	25	18	many	many	ADJ
dpc-2650	25	19	cytokines	cytokine	NOUN
dpc-2650	25	20	and	and	CCONJ
dpc-2650	25	21	chemokines	chemokine	NOUN
dpc-2650	25	22	regulate	regulate	VERB
dpc-2650	25	23	the	the	DET
dpc-2650	25	24	proliferation	proliferation	NOUN
dpc-2650	25	25	of	of	ADP
dpc-2650	25	26	them	they	PRON
dpc-2650	25	27	.	.	PUNCT
dpc-2650	26	1	the	the	DET
dpc-2650	26	2	most	most	ADV
dpc-2650	26	3	important	important	ADJ
dpc-2650	26	4	signal	signal	NOUN
dpc-2650	26	5	for	for	ADP
dpc-2650	26	6	proliferation	proliferation	NOUN
dpc-2650	26	7	of	of	ADP
dpc-2650	26	8	keratinocytes	keratinocyte	NOUN
dpc-2650	26	9	comes	come	VERB
dpc-2650	26	10	from	from	ADP
dpc-2650	26	11	the	the	DET
dpc-2650	26	12	epidermal	epidermal	ADJ
dpc-2650	26	13	growth	growth	NOUN
dpc-2650	26	14	factor	factor	NOUN
dpc-2650	26	15	(	(	PUNCT
dpc-2650	26	16	egf	egf	NOUN
dpc-2650	26	17	)	)	PUNCT
dpc-2650	26	18	receptor	receptor	NOUN
dpc-2650	26	19	,	,	PUNCT
dpc-2650	26	20	and	and	CCONJ
dpc-2650	26	21	epiregulin	epiregulin	NOUN
dpc-2650	26	22	(	(	PUNCT
dpc-2650	26	23	ereg	ereg	PROPN
dpc-2650	26	24	)	)	PUNCT
dpc-2650	26	25	is	be	AUX
dpc-2650	26	26	a	a	DET
dpc-2650	26	27	member	member	NOUN
dpc-2650	26	28	of	of	ADP
dpc-2650	26	29	the	the	DET
dpc-2650	26	30	egf	egf	PROPN
dpc-2650	26	31	family	family	NOUN
dpc-2650	27	1	[	[	X
dpc-2650	27	2	3	3	NUM
dpc-2650	27	3	]	]	PUNCT
dpc-2650	27	4	.	.	PUNCT
dpc-2650	28	1	serpin	serpin	PROPN
dpc-2650	28	2	family	family	PROPN
dpc-2650	28	3	b	b	PROPN
dpc-2650	28	4	member	member	PROPN
dpc-2650	28	5	7	7	NUM
dpc-2650	28	6	(	(	PUNCT
dpc-2650	28	7	serpinb7	serpinb7	NOUN
dpc-2650	28	8	)	)	PUNCT
dpc-2650	28	9	is	be	AUX
dpc-2650	28	10	a	a	DET
dpc-2650	28	11	cytoplasmic	cytoplasmic	ADJ
dpc-2650	28	12	member	member	NOUN
dpc-2650	28	13	of	of	ADP
dpc-2650	28	14	the	the	DET
dpc-2650	28	15	serine	serine	NOUN
dpc-2650	28	16	protease	protease	NOUN
dpc-2650	28	17	inhibitor	inhibitor	NOUN
dpc-2650	28	18	family	family	NOUN
dpc-2650	28	19	that	that	PRON
dpc-2650	28	20	can	can	AUX
dpc-2650	28	21	alter	alter	VERB
dpc-2650	28	22	the	the	DET
dpc-2650	28	23	epithelium	epithelium	NOUN
dpc-2650	28	24	of	of	ADP
dpc-2650	28	25	the	the	DET
dpc-2650	28	26	skin	skin	NOUN
dpc-2650	28	27	,	,	PUNCT
dpc-2650	28	28	and	and	CCONJ
dpc-2650	28	29	also	also	ADV
dpc-2650	28	30	protects	protect	VERB
dpc-2650	28	31	keratinocytes	keratinocyte	NOUN
dpc-2650	28	32	from	from	ADP
dpc-2650	28	33	oxidative	oxidative	ADJ
dpc-2650	28	34	stress	stress	NOUN
dpc-2650	28	35	-	-	PUNCT
dpc-2650	28	36	mediated	mediate	VERB
dpc-2650	28	37	cellular	cellular	ADJ
dpc-2650	28	38	damage	damage	NOUN
dpc-2650	28	39	[	[	X
dpc-2650	28	40	4	4	NUM
dpc-2650	28	41	]	]	PUNCT
dpc-2650	28	42	.	.	PUNCT
dpc-2650	29	1	protein	protein	NOUN
dpc-2650	29	2	tyrosine	tyrosine	NOUN
dpc-2650	29	3	phosphatase	phosphatase	NOUN
dpc-2650	29	4	non	non	ADJ
dpc-2650	29	5	-	-	ADJ
dpc-2650	29	6	receptor	receptor	ADJ
dpc-2650	29	7	type	type	NOUN
dpc-2650	29	8	1	1	NUM
dpc-2650	29	9	(	(	PUNCT
dpc-2650	29	10	ptpn1	ptpn1	NOUN
dpc-2650	29	11	)	)	PUNCT
dpc-2650	29	12	is	be	AUX
dpc-2650	29	13	a	a	DET
dpc-2650	29	14	member	member	NOUN
dpc-2650	29	15	of	of	ADP
dpc-2650	29	16	the	the	DET
dpc-2650	29	17	ptp	ptp	PROPN
dpc-2650	29	18	family	family	NOUN
dpc-2650	29	19	that	that	PRON
dpc-2650	29	20	has	have	VERB
dpc-2650	29	21	regulatory	regulatory	ADJ
dpc-2650	29	22	effects	effect	NOUN
dpc-2650	29	23	on	on	ADP
dpc-2650	29	24	munc18c	munc18c	NOUN
dpc-2650	29	25	protein	protein	NOUN
dpc-2650	29	26	,	,	PUNCT
dpc-2650	29	27	which	which	PRON
dpc-2650	29	28	interacts	interact	VERB
dpc-2650	29	29	with	with	ADP
dpc-2650	29	30	snare	snare	NOUN
dpc-2650	29	31	in	in	ADP
dpc-2650	29	32	adipocytes	adipocyte	NOUN
dpc-2650	29	33	,	,	PUNCT
dpc-2650	29	34	insulin	insulin	NOUN
dpc-2650	29	35	signaling	signal	VERB
dpc-2650	29	36	pathways	pathway	NOUN
dpc-2650	29	37	,	,	PUNCT
dpc-2650	29	38	and	and	CCONJ
dpc-2650	29	39	also	also	ADV
dpc-2650	29	40	immunological	immunological	ADJ
dpc-2650	29	41	processes	process	NOUN
dpc-2650	29	42	which	which	PRON
dpc-2650	29	43	may	may	AUX
dpc-2650	29	44	also	also	ADV
dpc-2650	29	45	be	be	AUX
dpc-2650	29	46	related	relate	VERB
dpc-2650	29	47	to	to	ADP
dpc-2650	29	48	its	its	PRON
dpc-2650	29	49	role	role	NOUN
dpc-2650	29	50	in	in	ADP
dpc-2650	29	51	the	the	DET
dpc-2650	29	52	pathogenesis	pathogenesis	NOUN
dpc-2650	29	53	of	of	ADP
dpc-2650	29	54	psoriasis	psoriasis	NOUN
dpc-2650	29	55	[	[	X
dpc-2650	29	56	5,6	5,6	NUM
dpc-2650	29	57	]	]	PUNCT
dpc-2650	29	58	.	.	PUNCT
dpc-2650	30	1	objectives	objective	NOUN
dpc-2650	30	2	in	in	ADP
dpc-2650	30	3	the	the	DET
dpc-2650	30	4	literature	literature	NOUN
dpc-2650	30	5	,	,	PUNCT
dpc-2650	30	6	the	the	DET
dpc-2650	30	7	expression	expression	NOUN
dpc-2650	30	8	of	of	ADP
dpc-2650	30	9	ereg	ereg	NOUN
dpc-2650	30	10	,	,	PUNCT
dpc-2650	30	11	ptpn1	ptpn1	NOUN
dpc-2650	30	12	,	,	PUNCT
dpc-2650	30	13	and	and	CCONJ
dpc-2650	30	14	serpinb7	serpinb7	NOUN
dpc-2650	30	15	genes	gene	NOUN
dpc-2650	30	16	have	have	AUX
dpc-2650	30	17	been	be	AUX
dpc-2650	30	18	evaluated	evaluate	VERB
dpc-2650	30	19	in	in	ADP
dpc-2650	30	20	a	a	DET
dpc-2650	30	21	few	few	ADJ
dpc-2650	30	22	studies	study	NOUN
dpc-2650	30	23	,	,	PUNCT
dpc-2650	30	24	and	and	CCONJ
dpc-2650	30	25	these	these	DET
dpc-2650	30	26	genes	gene	NOUN
dpc-2650	30	27	are	be	AUX
dpc-2650	30	28	claimed	claim	VERB
dpc-2650	30	29	to	to	PART
dpc-2650	30	30	be	be	AUX
dpc-2650	30	31	novel	novel	ADJ
dpc-2650	30	32	susceptible	susceptible	ADJ
dpc-2650	30	33	genes	gene	NOUN
dpc-2650	30	34	for	for	ADP
dpc-2650	30	35	psoriasis	psoriasis	NOUN
dpc-2650	30	36	especially	especially	ADV
dpc-2650	30	37	related	relate	VERB
dpc-2650	30	38	to	to	ADP
dpc-2650	30	39	keratinocytes	keratinocyte	NOUN
dpc-2650	30	40	,	,	PUNCT
dpc-2650	30	41	adipocytes	adipocyte	NOUN
dpc-2650	30	42	,	,	PUNCT
dpc-2650	30	43	other	other	ADJ
dpc-2650	30	44	immunological	immunological	ADJ
dpc-2650	30	45	cells	cell	NOUN
dpc-2650	30	46	[	[	X
dpc-2650	30	47	2,7	2,7	NUM
dpc-2650	30	48	-	-	SYM
dpc-2650	30	49	10	10	NUM
dpc-2650	30	50	]	]	PUNCT
dpc-2650	30	51	.	.	PUNCT
dpc-2650	31	1	unlike	unlike	ADP
dpc-2650	31	2	these	these	DET
dpc-2650	31	3	studies	study	NOUN
dpc-2650	31	4	,	,	PUNCT
dpc-2650	31	5	we	we	PRON
dpc-2650	31	6	investigated	investigate	VERB
dpc-2650	31	7	all	all	DET
dpc-2650	31	8	these	these	DET
dpc-2650	31	9	genes	gene	NOUN
dpc-2650	31	10	together	together	ADV
dpc-2650	31	11	,	,	PUNCT
dpc-2650	31	12	at	at	ADP
dpc-2650	31	13	the	the	DET
dpc-2650	31	14	tissue	tissue	NOUN
dpc-2650	31	15	level	level	NOUN
dpc-2650	31	16	,	,	PUNCT
dpc-2650	31	17	and	and	CCONJ
dpc-2650	31	18	in	in	ADP
dpc-2650	31	19	more	more	ADJ
dpc-2650	31	20	samples	sample	NOUN
dpc-2650	31	21	.	.	PUNCT
dpc-2650	32	1	we	we	PRON
dpc-2650	32	2	also	also	ADV
dpc-2650	32	3	compared	compare	VERB
dpc-2650	32	4	the	the	DET
dpc-2650	32	5	genes	gene	NOUN
dpc-2650	32	6	expressions	expression	NOUN
dpc-2650	32	7	between	between	ADP
dpc-2650	32	8	lesional	lesional	ADJ
dpc-2650	32	9	skin	skin	NOUN
dpc-2650	32	10	and	and	CCONJ
dpc-2650	32	11	non	non	ADJ
dpc-2650	32	12	-	-	ADJ
dpc-2650	32	13	lesional	lesional	ADJ
dpc-2650	32	14	adjacent	adjacent	ADJ
dpc-2650	32	15	skin	skin	NOUN
dpc-2650	32	16	of	of	ADP
dpc-2650	32	17	patients	patient	NOUN
dpc-2650	32	18	with	with	ADP
dpc-2650	32	19	psoriasis	psoriasis	NOUN
dpc-2650	32	20	,	,	PUNCT
dpc-2650	32	21	and	and	CCONJ
dpc-2650	32	22	normal	normal	ADJ
dpc-2650	32	23	skin	skin	NOUN
dpc-2650	32	24	of	of	ADP
dpc-2650	32	25	healthy	healthy	ADJ
dpc-2650	32	26	controls	control	NOUN
dpc-2650	32	27	.	.	PUNCT
dpc-2650	33	1	methods	method	NOUN
dpc-2650	33	2	the	the	DET
dpc-2650	33	3	present	present	ADJ
dpc-2650	33	4	prospective	prospective	ADJ
dpc-2650	33	5	case	case	NOUN
dpc-2650	33	6	-	-	PUNCT
dpc-2650	33	7	control	control	NOUN
dpc-2650	33	8	study	study	NOUN
dpc-2650	33	9	was	be	AUX
dpc-2650	33	10	performed	perform	VERB
dpc-2650	33	11	according	accord	VERB
dpc-2650	33	12	to	to	ADP
dpc-2650	33	13	the	the	DET
dpc-2650	33	14	declaration	declaration	NOUN
dpc-2650	33	15	of	of	ADP
dpc-2650	33	16	helsinki	helsinki	PROPN
dpc-2650	33	17	guidelines	guideline	NOUN
dpc-2650	33	18	and	and	CCONJ
dpc-2650	33	19	approved	approve	VERB
dpc-2650	33	20	by	by	ADP
dpc-2650	33	21	the	the	DET
dpc-2650	33	22	ethics	ethic	NOUN
dpc-2650	33	23	committee	committee	PROPN
dpc-2650	33	24	of	of	ADP
dpc-2650	33	25	suleyman	suleyman	NOUN
dpc-2650	33	26	demirel	demirel	NOUN
dpc-2650	33	27	medical	medical	ADJ
dpc-2650	33	28	faculty	faculty	NOUN
dpc-2650	33	29	(	(	PUNCT
dpc-2650	33	30	decision	decision	NOUN
dpc-2650	33	31	11	11	NUM
dpc-2650	33	32	on	on	ADP
dpc-2650	33	33	16.01.2020	16.01.2020	NUM
dpc-2650	33	34	)	)	PUNCT
dpc-2650	33	35	.	.	PUNCT
dpc-2650	34	1	all	all	DET
dpc-2650	34	2	participants	participant	NOUN
dpc-2650	34	3	in	in	ADP
dpc-2650	34	4	the	the	DET
dpc-2650	34	5	study	study	NOUN
dpc-2650	34	6	were	be	AUX
dpc-2650	34	7	provided	provide	VERB
dpc-2650	34	8	informed	informed	ADJ
dpc-2650	34	9	consent	consent	NOUN
dpc-2650	34	10	.	.	PUNCT
dpc-2650	35	1	study	study	NOUN
dpc-2650	35	2	population	population	NOUN
dpc-2650	35	3	twenty	twenty	NUM
dpc-2650	35	4	-	-	PUNCT
dpc-2650	35	5	five	five	NUM
dpc-2650	35	6	patients	patient	NOUN
dpc-2650	35	7	diagnosed	diagnose	VERB
dpc-2650	35	8	with	with	ADP
dpc-2650	35	9	psoriasis	psoriasis	NOUN
dpc-2650	35	10	clinically	clinically	ADV
dpc-2650	35	11	and	and	CCONJ
dpc-2650	35	12	histopathologically	histopathologically	ADV
dpc-2650	35	13	,	,	PUNCT
dpc-2650	35	14	aged	aged	ADJ
dpc-2650	35	15	over	over	ADP
dpc-2650	35	16	18	18	NUM
dpc-2650	35	17	and	and	CCONJ
dpc-2650	35	18	under	under	ADP
dpc-2650	35	19	65	65	NUM
dpc-2650	35	20	years	year	NOUN
dpc-2650	35	21	,	,	PUNCT
dpc-2650	35	22	presenting	present	VERB
dpc-2650	35	23	to	to	ADP
dpc-2650	35	24	the	the	DET
dpc-2650	35	25	dermatology	dermatology	NOUN
dpc-2650	35	26	outpatient	outpatient	NOUN
dpc-2650	35	27	clinic	clinic	NOUN
dpc-2650	35	28	of	of	ADP
dpc-2650	35	29	suleyman	suleyman	NOUN
dpc-2650	35	30	demirel	demirel	NOUN
dpc-2650	35	31	medical	medical	ADJ
dpc-2650	35	32	faculty	faculty	NOUN
dpc-2650	35	33	between	between	ADP
dpc-2650	35	34	february	february	PROPN
dpc-2650	35	35	2020	2020	NUM
dpc-2650	35	36	and	and	CCONJ
dpc-2650	35	37	january	january	PROPN
dpc-2650	35	38	2021	2021	NUM
dpc-2650	35	39	,	,	PUNCT
dpc-2650	35	40	were	be	AUX
dpc-2650	35	41	considered	consider	VERB
dpc-2650	35	42	for	for	ADP
dpc-2650	35	43	this	this	DET
dpc-2650	35	44	study	study	NOUN
dpc-2650	35	45	.	.	PUNCT
dpc-2650	36	1	detailed	detailed	ADJ
dpc-2650	36	2	anamnesis	anamnesis	NOUN
dpc-2650	36	3	was	be	AUX
dpc-2650	36	4	taken	take	VERB
dpc-2650	36	5	,	,	PUNCT
dpc-2650	36	6	skin	skin	NOUN
dpc-2650	36	7	examination	examination	NOUN
dpc-2650	36	8	was	be	AUX
dpc-2650	36	9	performed	perform	VERB
dpc-2650	36	10	,	,	PUNCT
dpc-2650	36	11	and	and	CCONJ
dpc-2650	36	12	the	the	DET
dpc-2650	36	13	presence	presence	NOUN
dpc-2650	36	14	of	of	ADP
dpc-2650	36	15	arthritis	arthritis	NOUN
dpc-2650	36	16	or	or	CCONJ
dpc-2650	36	17	nail	nail	NOUN
dpc-2650	36	18	involvement	involvement	NOUN
dpc-2650	36	19	was	be	AUX
dpc-2650	36	20	also	also	ADV
dpc-2650	36	21	examined	examine	VERB
dpc-2650	36	22	and	and	CCONJ
dpc-2650	36	23	noted	note	VERB
dpc-2650	36	24	by	by	ADP
dpc-2650	36	25	the	the	DET
dpc-2650	36	26	same	same	ADJ
dpc-2650	36	27	physician	physician	NOUN
dpc-2650	36	28	.	.	PUNCT
dpc-2650	37	1	psoriasis	psoriasis	NOUN
dpc-2650	37	2	area	area	NOUN
dpc-2650	37	3	and	and	CCONJ
dpc-2650	37	4	severity	severity	NOUN
dpc-2650	37	5	index	index	NOUN
dpc-2650	37	6	(	(	PUNCT
dpc-2650	37	7	pasi	pasi	NOUN
dpc-2650	37	8	)	)	PUNCT
dpc-2650	37	9	scores	score	NOUN
dpc-2650	37	10	were	be	AUX
dpc-2650	37	11	calculated	calculate	VERB
dpc-2650	37	12	,	,	PUNCT
dpc-2650	37	13	and	and	CCONJ
dpc-2650	37	14	according	accord	VERB
dpc-2650	37	15	to	to	ADP
dpc-2650	37	16	the	the	DET
dpc-2650	37	17	pasi	pasi	NOUN
dpc-2650	37	18	scores	score	NOUN
dpc-2650	37	19	,	,	PUNCT
dpc-2650	37	20	patients	patient	NOUN
dpc-2650	37	21	were	be	AUX
dpc-2650	37	22	divided	divide	VERB
dpc-2650	37	23	into	into	ADP
dpc-2650	37	24	two	two	NUM
dpc-2650	37	25	subgroups	subgroup	NOUN
dpc-2650	37	26	:	:	PUNCT
dpc-2650	37	27	a	a	DET
dpc-2650	37	28	mild	mild	ADJ
dpc-2650	37	29	disease	disease	NOUN
dpc-2650	37	30	with	with	ADP
dpc-2650	37	31	pasi	pasi	NOUN
dpc-2650	37	32	score	score	VERB
dpc-2650	37	33	≤	≤	NUM
dpc-2650	37	34	10	10	NUM
dpc-2650	37	35	,	,	PUNCT
dpc-2650	37	36	moderate	moderate	ADJ
dpc-2650	37	37	-	-	PUNCT
dpc-2650	37	38	severe	severe	ADJ
dpc-2650	37	39	disease	disease	NOUN
dpc-2650	37	40	with	with	ADP
dpc-2650	37	41	pasi	pasi	NOUN
dpc-2650	37	42	score	score	NOUN
dpc-2650	37	43	>	>	X
dpc-2650	37	44	10	10	NUM
dpc-2650	38	1	[	[	X
dpc-2650	38	2	11	11	NUM
dpc-2650	38	3	]	]	PUNCT
dpc-2650	38	4	.	.	PUNCT
dpc-2650	39	1	all	all	DET
dpc-2650	39	2	participants	participant	NOUN
dpc-2650	39	3	were	be	AUX
dpc-2650	39	4	selected	select	VERB
dpc-2650	39	5	from	from	ADP
dpc-2650	39	6	patients	patient	NOUN
dpc-2650	39	7	not	not	PART
dpc-2650	39	8	treated	treat	VERB
dpc-2650	39	9	with	with	ADP
dpc-2650	39	10	systemic	systemic	ADJ
dpc-2650	39	11	therapy	therapy	NOUN
dpc-2650	39	12	,	,	PUNCT
dpc-2650	39	13	including	include	VERB
dpc-2650	39	14	phototherapy	phototherapy	NOUN
dpc-2650	39	15	,	,	PUNCT
dpc-2650	39	16	for	for	ADP
dpc-2650	39	17	at	at	ADV
dpc-2650	39	18	least	least	ADV
dpc-2650	39	19	eight	eight	NUM
dpc-2650	39	20	weeks	week	NOUN
dpc-2650	39	21	before	before	ADP
dpc-2650	39	22	the	the	DET
dpc-2650	39	23	study	study	NOUN
dpc-2650	39	24	entry	entry	NOUN
dpc-2650	39	25	.	.	PUNCT
dpc-2650	40	1	ageand	ageand	NOUN
dpc-2650	40	2	sex	sex	NOUN
dpc-2650	40	3	-	-	PUNCT
dpc-2650	40	4	matched	match	VERB
dpc-2650	40	5	11	11	NUM
dpc-2650	40	6	healthy	healthy	ADJ
dpc-2650	40	7	volunteers	volunteer	NOUN
dpc-2650	40	8	without	without	ADP
dpc-2650	40	9	any	any	DET
dpc-2650	40	10	systemic	systemic	ADJ
dpc-2650	40	11	inflammatory	inflammatory	ADJ
dpc-2650	40	12	diseases	disease	NOUN
dpc-2650	40	13	,	,	PUNCT
dpc-2650	40	14	including	include	VERB
dpc-2650	40	15	cardiovascular	cardiovascular	ADJ
dpc-2650	40	16	and/or	and/or	CCONJ
dpc-2650	40	17	neurovascular	neurovascular	ADJ
dpc-2650	40	18	diseases	disease	NOUN
dpc-2650	40	19	,	,	PUNCT
dpc-2650	40	20	inflammatory	inflammatory	ADJ
dpc-2650	40	21	skin	skin	NOUN
dpc-2650	40	22	disorders	disorder	NOUN
dpc-2650	40	23	,	,	PUNCT
dpc-2650	40	24	and	and	CCONJ
dpc-2650	40	25	regular	regular	ADJ
dpc-2650	40	26	drug	drug	NOUN
dpc-2650	40	27	intake	intake	NOUN
dpc-2650	40	28	for	for	ADP
dpc-2650	40	29	any	any	DET
dpc-2650	40	30	reason	reason	NOUN
dpc-2650	40	31	,	,	PUNCT
dpc-2650	40	32	were	be	AUX
dpc-2650	40	33	also	also	ADV
dpc-2650	40	34	enrolled	enrol	VERB
dpc-2650	40	35	as	as	ADP
dpc-2650	40	36	the	the	DET
dpc-2650	40	37	control	control	NOUN
dpc-2650	40	38	group	group	NOUN
dpc-2650	40	39	.	.	PUNCT
dpc-2650	41	1	patients	patient	NOUN
dpc-2650	41	2	with	with	ADP
dpc-2650	41	3	a	a	DET
dpc-2650	41	4	history	history	NOUN
dpc-2650	41	5	of	of	ADP
dpc-2650	41	6	cardiovascular	cardiovascular	ADJ
dpc-2650	41	7	or	or	CCONJ
dpc-2650	41	8	cerebrovascular	cerebrovascular	ADJ
dpc-2650	41	9	events	event	NOUN
dpc-2650	41	10	,	,	PUNCT
dpc-2650	41	11	active	active	ADJ
dpc-2650	41	12	infection	infection	NOUN
dpc-2650	41	13	,	,	PUNCT
dpc-2650	41	14	and	and	CCONJ
dpc-2650	41	15	inflammatory	inflammatory	ADJ
dpc-2650	41	16	systemic	systemic	NOUN
dpc-2650	41	17	(	(	PUNCT
dpc-2650	41	18	including	include	VERB
dpc-2650	41	19	diabetes	diabetes	NOUN
dpc-2650	41	20	mellitus	mellitus	NOUN
dpc-2650	42	1	[	[	X
dpc-2650	42	2	dm	dm	X
dpc-2650	42	3	]	]	X
dpc-2650	42	4	)	)	PUNCT
dpc-2650	42	5	or	or	CCONJ
dpc-2650	42	6	skin	skin	NOUN
dpc-2650	42	7	diseases	disease	NOUN
dpc-2650	42	8	,	,	PUNCT
dpc-2650	42	9	other	other	ADJ
dpc-2650	42	10	autoimmune	autoimmune	ADJ
dpc-2650	42	11	diseases	disease	NOUN
dpc-2650	42	12	,	,	PUNCT
dpc-2650	42	13	and/	and/	NOUN
dpc-2650	42	14	or	or	CCONJ
dpc-2650	42	15	malignancy	malignancy	NOUN
dpc-2650	42	16	in	in	ADP
dpc-2650	42	17	the	the	DET
dpc-2650	42	18	last	last	ADJ
dpc-2650	42	19	5	5	NUM
dpc-2650	42	20	years	year	NOUN
dpc-2650	42	21	were	be	AUX
dpc-2650	42	22	excluded	exclude	VERB
dpc-2650	42	23	.	.	PUNCT
dpc-2650	43	1	skin	skin	NOUN
dpc-2650	43	2	samples	sample	NOUN
dpc-2650	43	3	,	,	PUNCT
dpc-2650	43	4	3	3	NUM
dpc-2650	43	5	mm	mm	NOUN
dpc-2650	43	6	in	in	ADP
dpc-2650	43	7	size	size	NOUN
dpc-2650	43	8	,	,	PUNCT
dpc-2650	43	9	were	be	AUX
dpc-2650	43	10	collected	collect	VERB
dpc-2650	43	11	from	from	ADP
dpc-2650	43	12	25	25	NUM
dpc-2650	43	13	patients	patient	NOUN
dpc-2650	43	14	with	with	ADP
dpc-2650	43	15	psoriasis	psoriasis	NOUN
dpc-2650	43	16	and	and	CCONJ
dpc-2650	43	17	11	11	NUM
dpc-2650	43	18	healthy	healthy	ADJ
dpc-2650	43	19	controls	control	NOUN
dpc-2650	43	20	.	.	PUNCT
dpc-2650	44	1	the	the	DET
dpc-2650	44	2	lesional	lesional	ADJ
dpc-2650	44	3	and	and	CCONJ
dpc-2650	44	4	non	non	ADJ
dpc-2650	44	5	-	-	ADJ
dpc-2650	44	6	lesional	lesional	ADJ
dpc-2650	44	7	psoriatic	psoriatic	ADJ
dpc-2650	44	8	skin	skin	NOUN
dpc-2650	44	9	(	(	PUNCT
dpc-2650	44	10	each	each	DET
dpc-2650	44	11	3	3	NUM
dpc-2650	44	12	mm	mm	NOUN
dpc-2650	44	13	in	in	ADP
dpc-2650	44	14	size	size	NOUN
dpc-2650	44	15	)	)	PUNCT
dpc-2650	44	16	were	be	AUX
dpc-2650	44	17	taken	take	VERB
dpc-2650	44	18	from	from	ADP
dpc-2650	44	19	each	each	DET
dpc-2650	44	20	patient	patient	NOUN
dpc-2650	44	21	with	with	ADP
dpc-2650	44	22	psoriasis	psoriasis	NOUN
dpc-2650	44	23	and	and	CCONJ
dpc-2650	44	24	one	one	NUM
dpc-2650	44	25	skin	skin	NOUN
dpc-2650	44	26	sample	sample	NOUN
dpc-2650	44	27	in	in	ADP
dpc-2650	44	28	similar	similar	ADJ
dpc-2650	44	29	size	size	NOUN
dpc-2650	44	30	from	from	ADP
dpc-2650	44	31	healthy	healthy	ADJ
dpc-2650	44	32	controls	control	NOUN
dpc-2650	44	33	.	.	PUNCT
dpc-2650	45	1	these	these	DET
dpc-2650	45	2	skin	skin	NOUN
dpc-2650	45	3	tissues	tissue	NOUN
dpc-2650	45	4	were	be	AUX
dpc-2650	45	5	taken	take	VERB
dpc-2650	45	6	into	into	ADP
dpc-2650	45	7	dnase	dnase	NOUN
dpc-2650	45	8	rnase	rnase	PROPN
dpc-2650	45	9	-	-	PUNCT
dpc-2650	45	10	free	free	ADJ
dpc-2650	45	11	1.5	1.5	NUM
dpc-2650	45	12	ml	ml	ADP
dpc-2650	45	13	eppendorf	eppendorf	PROPN
dpc-2650	45	14	tubes	tube	NOUN
dpc-2650	45	15	and	and	CCONJ
dpc-2650	45	16	stored	store	VERB
dpc-2650	45	17	in	in	ADP
dpc-2650	45	18	the	the	DET
dpc-2650	45	19	refrigerator	refrigerator	NOUN
dpc-2650	45	20	at	at	ADP
dpc-2650	45	21	-80˚c	-80˚c	PROPN
dpc-2650	45	22	.	.	PUNCT
dpc-2650	46	1	mrna	mrna	PROPN
dpc-2650	46	2	extraction	extraction	NOUN
dpc-2650	46	3	and	and	CCONJ
dpc-2650	46	4	cdna	cdna	PROPN
dpc-2650	46	5	synthesis	synthesis	NOUN
dpc-2650	46	6	mrna	mrna	PROPN
dpc-2650	46	7	isolation	isolation	NOUN
dpc-2650	46	8	from	from	ADP
dpc-2650	46	9	tissue	tissue	NOUN
dpc-2650	46	10	samples	sample	NOUN
dpc-2650	46	11	belonging	belong	VERB
dpc-2650	46	12	to	to	ADP
dpc-2650	46	13	the	the	DET
dpc-2650	46	14	study	study	NOUN
dpc-2650	46	15	group	group	NOUN
dpc-2650	46	16	was	be	AUX
dpc-2650	46	17	performed	perform	VERB
dpc-2650	46	18	with	with	ADP
dpc-2650	46	19	hybrid	hybrid	NOUN
dpc-2650	46	20	-	-	PUNCT
dpc-2650	46	21	rtm	rtm	NOUN
dpc-2650	46	22	mrna	mrna	NOUN
dpc-2650	46	23	isolation	isolation	NOUN
dpc-2650	46	24	kit	kit	NOUN
dpc-2650	46	25	(	(	PUNCT
dpc-2650	46	26	geneall	geneall	NOUN
dpc-2650	46	27	biotechnology	biotechnology	NOUN
dpc-2650	46	28	)	)	PUNCT
dpc-2650	46	29	according	accord	VERB
dpc-2650	46	30	to	to	ADP
dpc-2650	46	31	the	the	DET
dpc-2650	46	32	manufacturer	manufacturer	NOUN
dpc-2650	46	33	instructions	instruction	NOUN
dpc-2650	46	34	.	.	PUNCT
dpc-2650	47	1	the	the	DET
dpc-2650	47	2	concentration	concentration	NOUN
dpc-2650	47	3	and	and	CCONJ
dpc-2650	47	4	purity	purity	NOUN
dpc-2650	47	5	of	of	ADP
dpc-2650	47	6	isolated	isolated	ADJ
dpc-2650	47	7	total	total	ADJ
dpc-2650	47	8	mrnas	mrna	NOUN
dpc-2650	47	9	were	be	AUX
dpc-2650	47	10	measured	measure	VERB
dpc-2650	47	11	with	with	ADP
dpc-2650	47	12	a	a	DET
dpc-2650	47	13	thermo	thermo	NOUN
dpc-2650	47	14	fisher	fisher	PROPN
dpc-2650	47	15	nanodroptm	nanodroptm	NOUN
dpc-2650	47	16	spectrophotometer	spectrophotometer	PROPN
dpc-2650	47	17	.	.	PUNCT
dpc-2650	48	1	wizscript	wizscript	PROPN
dpc-2650	48	2	™	™	VERB
dpc-2650	48	3	cdna	cdna	PROPN
dpc-2650	48	4	synthesis	synthesis	NOUN
dpc-2650	48	5	kit	kit	NOUN
dpc-2650	48	6	(	(	PUNCT
dpc-2650	48	7	wizbio	wizbio	NOUN
dpc-2650	48	8	)	)	PUNCT
dpc-2650	48	9	was	be	AUX
dpc-2650	48	10	used	use	VERB
dpc-2650	48	11	to	to	PART
dpc-2650	48	12	obtain	obtain	VERB
dpc-2650	48	13	cdna	cdna	PROPN
dpc-2650	48	14	from	from	ADP
dpc-2650	48	15	the	the	DET
dpc-2650	48	16	obtained	obtain	VERB
dpc-2650	48	17	mrna	mrna	PROPN
dpc-2650	48	18	.	.	PUNCT
dpc-2650	49	1	reverse	reverse	ADJ
dpc-2650	49	2	transcription	transcription	NOUN
dpc-2650	49	3	was	be	AUX
dpc-2650	49	4	performed	perform	VERB
dpc-2650	49	5	using	use	VERB
dpc-2650	49	6	the	the	DET
dpc-2650	49	7	simpliamp	simpliamp	ADJ
dpc-2650	49	8	thermal	thermal	ADJ
dpc-2650	49	9	cycler	cycler	NOUN
dpc-2650	49	10	(	(	PUNCT
dpc-2650	49	11	thermo	thermo	NOUN
dpc-2650	49	12	fisher	fisher	PROPN
dpc-2650	49	13	scientific	scientific	PROPN
dpc-2650	49	14	)	)	PUNCT
dpc-2650	49	15	according	accord	VERB
dpc-2650	49	16	to	to	ADP
dpc-2650	49	17	the	the	DET
dpc-2650	49	18	manufacturer	manufacturer	NOUN
dpc-2650	49	19	instructions	instruction	NOUN
dpc-2650	49	20	.	.	PUNCT
dpc-2650	50	1	obtained	obtain	VERB
dpc-2650	50	2	cdna	cdna	PROPN
dpc-2650	50	3	samples	sample	NOUN
dpc-2650	50	4	were	be	AUX
dpc-2650	50	5	stored	store	VERB
dpc-2650	50	6	at	at	ADP
dpc-2650	50	7	-80ºc	-80ºc	PROPN
dpc-2650	50	8	until	until	ADP
dpc-2650	50	9	real	real	ADJ
dpc-2650	50	10	-	-	PUNCT
dpc-2650	50	11	time	time	NOUN
dpc-2650	50	12	(	(	PUNCT
dpc-2650	50	13	rt)-pcr	rt)-pcr	ADJ
dpc-2650	50	14	analysis	analysis	NOUN
dpc-2650	50	15	.	.	PUNCT
dpc-2650	51	1	primary	primary	ADJ
dpc-2650	51	2	sequences	sequence	NOUN
dpc-2650	51	3	and	and	CCONJ
dpc-2650	51	4	quantitation	quantitation	NOUN
dpc-2650	51	5	of	of	ADP
dpc-2650	51	6	genes	gene	NOUN
dpc-2650	51	7	the	the	DET
dpc-2650	51	8	sequence	sequence	NOUN
dpc-2650	51	9	used	use	VERB
dpc-2650	51	10	for	for	ADP
dpc-2650	51	11	ereg	ereg	NOUN
dpc-2650	51	12	(	(	PUNCT
dpc-2650	51	13	accession	accession	NOUN
dpc-2650	51	14	no	no	INTJ
dpc-2650	51	15	:	:	PUNCT
dpc-2650	51	16	nm_001432	nm_001432	NUM
dpc-2650	51	17	)	)	PUNCT
dpc-2650	51	18	includes	include	VERB
dpc-2650	51	19	primers	primer	NOUN
dpc-2650	51	20	as	as	SCONJ
dpc-2650	51	21	follows	follow	VERB
dpc-2650	51	22	.	.	PUNCT
dpc-2650	52	1	f	f	X
dpc-2650	52	2	:	:	PUNCT
dpc-2650	52	3	ggacagtgcatctatctggtgg	ggacagtgcatctatctggtgg	NOUN
dpc-2650	52	4	,	,	PUNCT
dpc-2650	52	5	r	r	NOUN
dpc-2650	52	6	:	:	PUNCT
dpc-2650	52	7	ttggtggacggttaaaaagaagt	ttggtggacggttaaaaagaagt	NOUN
dpc-2650	52	8	,	,	PUNCT
dpc-2650	52	9	for	for	ADP
dpc-2650	52	10	ptpn1	ptpn1	NOUN
dpc-2650	52	11	(	(	PUNCT
dpc-2650	52	12	accession	accession	NOUN
dpc-2650	52	13	no	no	INTJ
dpc-2650	52	14	:	:	PUNCT
dpc-2650	52	15	nm_002827	nm_002827	SYM
dpc-2650	52	16	)	)	PUNCT
dpc-2650	53	1	f	f	NOUN
dpc-2650	53	2	:	:	PUNCT
dpc-2650	53	3	gcagatcgacaagtccggg	gcagatcgacaagtccggg	NOUN
dpc-2650	53	4	,	,	PUNCT
dpc-2650	53	5	r	r	NOUN
dpc-2650	53	6	:	:	PUNCT
dpc-2650	53	7	gccactctacatgggaagtcac	gccactctacatgggaagtcac	NOUN
dpc-2650	53	8	,	,	PUNCT
dpc-2650	53	9	for	for	ADP
dpc-2650	53	10	serpinb7	serpinb7	NOUN
dpc-2650	53	11	(	(	PUNCT
dpc-2650	53	12	accession	accession	NOUN
dpc-2650	53	13	no	no	INTJ
dpc-2650	53	14	:	:	PUNCT
dpc-2650	53	15	nm_001040147	nm_001040147	NOUN
dpc-2650	53	16	)	)	PUNCT
dpc-2650	54	1	f	f	X
dpc-2650	54	2	:	:	PUNCT
dpc-2650	54	3	taagctcatctgctgtaatggtg	taagctcatctgctgtaatggtg	PROPN
dpc-2650	54	4	,	,	PUNCT
dpc-2650	54	5	r	r	NOUN
dpc-2650	54	6	:	:	PUNCT
dpc-2650	54	7	ggcaatttatggtttcgctcttg	ggcaatttatggtttcgctcttg	NOUN
dpc-2650	54	8	,	,	PUNCT
dpc-2650	54	9	for	for	ADP
dpc-2650	54	10	actb	actb	NOUN
dpc-2650	54	11	(	(	PUNCT
dpc-2650	54	12	accession	accession	NOUN
dpc-2650	54	13	no	no	INTJ
dpc-2650	54	14	:	:	PUNCT
dpc-2650	54	15	nm_001101	nm_001101	NOUN
dpc-2650	54	16	)	)	PUNCT
dpc-2650	55	1	f	f	X
dpc-2650	55	2	:	:	PUNCT
dpc-2650	55	3	catgtacgttgctatccaggc	catgtacgttgctatccaggc	NOUN
dpc-2650	55	4	r	r	NOUN
dpc-2650	55	5	:	:	PUNCT
dpc-2650	55	6	ctccttaatgtcacgcacgat	ctccttaatgtcacgcacgat	ADJ
dpc-2650	55	7	.	.	PUNCT
dpc-2650	56	1	quantitation	quantitation	NOUN
dpc-2650	56	2	of	of	ADP
dpc-2650	56	3	the	the	DET
dpc-2650	56	4	obtained	obtain	VERB
dpc-2650	56	5	mrnas	mrna	NOUN
dpc-2650	56	6	was	be	AUX
dpc-2650	56	7	performed	perform	VERB
dpc-2650	56	8	with	with	ADP
dpc-2650	56	9	rotor	rotor	NOUN
dpc-2650	56	10	-	-	PUNCT
dpc-2650	56	11	gene	gene	NOUN
dpc-2650	56	12	q	q	NOUN
dpc-2650	56	13	(	(	PUNCT
dpc-2650	56	14	qiagen	qiagen	PROPN
dpc-2650	56	15	,	,	PUNCT
dpc-2650	56	16	hiden	hiden	PROPN
dpc-2650	56	17	)	)	PUNCT
dpc-2650	56	18	according	accord	VERB
dpc-2650	56	19	to	to	ADP
dpc-2650	56	20	the	the	DET
dpc-2650	56	21	manufacturer	manufacturer	NOUN
dpc-2650	56	22	instructions	instruction	NOUN
dpc-2650	56	23	.	.	PUNCT
dpc-2650	57	1	mrnas	mrna	NOUN
dpc-2650	57	2	were	be	AUX
dpc-2650	57	3	analyzed	analyze	VERB
dpc-2650	57	4	by	by	ADP
dpc-2650	57	5	sybr	sybr	PROPN
dpc-2650	57	6	green	green	ADJ
dpc-2650	57	7	original	original	ADJ
dpc-2650	57	8	article	article	NOUN
dpc-2650	57	9	|	|	ADV
dpc-2650	57	10	dermatol	dermatol	ADJ
dpc-2650	57	11	pract	pract	NOUN
dpc-2650	57	12	concept	concept	NOUN
dpc-2650	57	13	.	.	PUNCT
dpc-2650	58	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	58	2	3	3	NUM
dpc-2650	58	3	method	method	NOUN
dpc-2650	58	4	using	use	VERB
dpc-2650	58	5	β	β	NOUN
dpc-2650	58	6	-	-	NOUN
dpc-2650	58	7	actin	actin	NOUN
dpc-2650	58	8	(	(	PUNCT
dpc-2650	58	9	actb	actb	ADV
dpc-2650	58	10	as	as	ADP
dpc-2650	58	11	an	an	DET
dpc-2650	58	12	internal	internal	ADJ
dpc-2650	58	13	control	control	NOUN
dpc-2650	58	14	,	,	PUNCT
dpc-2650	58	15	housekeeping	housekeeping	NOUN
dpc-2650	58	16	gene	gene	NOUN
dpc-2650	58	17	)	)	PUNCT
dpc-2650	58	18	.	.	PUNCT
dpc-2650	59	1	cycle	cycle	NOUN
dpc-2650	59	2	threshold	threshold	NOUN
dpc-2650	59	3	(	(	PUNCT
dpc-2650	59	4	ct	ct	NOUN
dpc-2650	59	5	)	)	PUNCT
dpc-2650	59	6	values	value	NOUN
dpc-2650	59	7	of	of	ADP
dpc-2650	59	8	mrnas	mrna	NOUN
dpc-2650	59	9	were	be	AUX
dpc-2650	59	10	determined	determine	VERB
dpc-2650	59	11	,	,	PUNCT
dpc-2650	59	12	and	and	CCONJ
dpc-2650	59	13	the	the	DET
dpc-2650	59	14	obtained	obtain	VERB
dpc-2650	59	15	ct	ct	NUM
dpc-2650	59	16	values	value	NOUN
dpc-2650	59	17	were	be	AUX
dpc-2650	59	18	normalized	normalize	VERB
dpc-2650	59	19	to	to	ADP
dpc-2650	59	20	actb	actb	ADV
dpc-2650	59	21	.	.	PUNCT
dpc-2650	60	1	the	the	DET
dpc-2650	60	2	fold	fold	ADJ
dpc-2650	60	3	change	change	NOUN
dpc-2650	60	4	of	of	ADP
dpc-2650	60	5	each	each	DET
dpc-2650	60	6	mrna	mrna	NOUN
dpc-2650	60	7	expression	expression	NOUN
dpc-2650	60	8	was	be	AUX
dpc-2650	60	9	calculated	calculate	VERB
dpc-2650	60	10	using	use	VERB
dpc-2650	60	11	the	the	DET
dpc-2650	60	12	2−δδct	2−δδct	NUM
dpc-2650	60	13	equation	equation	NOUN
dpc-2650	60	14	.	.	PUNCT
dpc-2650	61	1	statistical	statistical	ADJ
dpc-2650	61	2	analysis	analysis	NOUN
dpc-2650	61	3	data	datum	NOUN
dpc-2650	61	4	were	be	AUX
dpc-2650	61	5	analyzed	analyze	VERB
dpc-2650	61	6	using	use	VERB
dpc-2650	61	7	ibm	ibm	PROPN
dpc-2650	61	8	spss	spss	PROPN
dpc-2650	61	9	statistics	statistic	NOUN
dpc-2650	61	10	27.0	27.0	NUM
dpc-2650	61	11	.	.	PUNCT
dpc-2650	62	1	the	the	DET
dpc-2650	62	2	descriptive	descriptive	ADJ
dpc-2650	62	3	values	value	NOUN
dpc-2650	62	4	of	of	ADP
dpc-2650	62	5	participants	participant	NOUN
dpc-2650	62	6	were	be	AUX
dpc-2650	62	7	presented	present	VERB
dpc-2650	62	8	as	as	ADP
dpc-2650	62	9	mean	mean	NOUN
dpc-2650	62	10	±	±	NUM
dpc-2650	62	11	standard	standard	ADJ
dpc-2650	62	12	deviation	deviation	NOUN
dpc-2650	62	13	(	(	PUNCT
dpc-2650	62	14	sd	sd	NOUN
dpc-2650	62	15	)	)	PUNCT
dpc-2650	62	16	(	(	PUNCT
dpc-2650	62	17	also	also	ADV
dpc-2650	62	18	minimum	minimum	ADJ
dpc-2650	62	19	and	and	CCONJ
dpc-2650	62	20	maximum	maximum	ADJ
dpc-2650	62	21	values	value	NOUN
dpc-2650	62	22	)	)	PUNCT
dpc-2650	62	23	.	.	PUNCT
dpc-2650	63	1	the	the	DET
dpc-2650	63	2	categorical	categorical	ADJ
dpc-2650	63	3	variables	variable	NOUN
dpc-2650	63	4	were	be	AUX
dpc-2650	63	5	presented	present	VERB
dpc-2650	63	6	as	as	ADP
dpc-2650	63	7	frequency	frequency	NOUN
dpc-2650	63	8	and	and	CCONJ
dpc-2650	63	9	percentage	percentage	NOUN
dpc-2650	63	10	.	.	PUNCT
dpc-2650	64	1	chi	chi	ADJ
dpc-2650	64	2	-	-	PUNCT
dpc-2650	64	3	square	square	NOUN
dpc-2650	64	4	analysis	analysis	NOUN
dpc-2650	64	5	was	be	AUX
dpc-2650	64	6	used	use	VERB
dpc-2650	64	7	for	for	ADP
dpc-2650	64	8	categorical	categorical	ADJ
dpc-2650	64	9	variables	variable	NOUN
dpc-2650	64	10	.	.	PUNCT
dpc-2650	65	1	the	the	DET
dpc-2650	65	2	distribution	distribution	NOUN
dpc-2650	65	3	characteristics	characteristic	NOUN
dpc-2650	65	4	were	be	AUX
dpc-2650	65	5	first	first	ADV
dpc-2650	65	6	examined	examine	VERB
dpc-2650	65	7	with	with	ADP
dpc-2650	65	8	the	the	DET
dpc-2650	65	9	shapiro	shapiro	PROPN
dpc-2650	65	10	wilk	wilk	PROPN
dpc-2650	65	11	test	test	NOUN
dpc-2650	65	12	to	to	PART
dpc-2650	65	13	analyze	analyze	VERB
dpc-2650	65	14	continuous	continuous	ADJ
dpc-2650	65	15	variables	variable	NOUN
dpc-2650	65	16	across	across	ADP
dpc-2650	65	17	groups	group	NOUN
dpc-2650	65	18	.	.	PUNCT
dpc-2650	66	1	mann	mann	PROPN
dpc-2650	66	2	whitney	whitney	PROPN
dpc-2650	66	3	u	u	PROPN
dpc-2650	66	4	or	or	CCONJ
dpc-2650	66	5	kruskal	kruskal	PROPN
dpc-2650	66	6	wallis	wallis	PROPN
dpc-2650	66	7	test	test	PROPN
dpc-2650	66	8	was	be	AUX
dpc-2650	66	9	used	use	VERB
dpc-2650	66	10	for	for	ADP
dpc-2650	66	11	non	non	ADJ
dpc-2650	66	12	-	-	ADJ
dpc-2650	66	13	parametric	parametric	ADJ
dpc-2650	66	14	distributions	distribution	NOUN
dpc-2650	66	15	according	accord	VERB
dpc-2650	66	16	to	to	ADP
dpc-2650	66	17	the	the	DET
dpc-2650	66	18	number	number	NOUN
dpc-2650	66	19	of	of	ADP
dpc-2650	66	20	groups	group	NOUN
dpc-2650	66	21	.	.	PUNCT
dpc-2650	67	1	for	for	ADP
dpc-2650	67	2	analysis	analysis	NOUN
dpc-2650	67	3	of	of	ADP
dpc-2650	67	4	2	2	NUM
dpc-2650	67	5	scale	scale	NOUN
dpc-2650	67	6	/	/	SYM
dpc-2650	67	7	continuous	continuous	ADJ
dpc-2650	67	8	type	type	NOUN
dpc-2650	67	9	variables	variable	NOUN
dpc-2650	67	10	,	,	PUNCT
dpc-2650	67	11	spearman	spearman	NOUN
dpc-2650	67	12	correlation	correlation	NOUN
dpc-2650	67	13	analysis	analysis	NOUN
dpc-2650	67	14	was	be	AUX
dpc-2650	67	15	used	use	VERB
dpc-2650	67	16	.	.	PUNCT
dpc-2650	68	1	p	p	NOUN
dpc-2650	68	2	value	value	NOUN
dpc-2650	68	3	<	<	X
dpc-2650	68	4	0.05	0.05	NUM
dpc-2650	68	5	was	be	AUX
dpc-2650	68	6	accepted	accept	VERB
dpc-2650	68	7	as	as	ADP
dpc-2650	68	8	statistically	statistically	ADV
dpc-2650	68	9	significant	significant	ADJ
dpc-2650	68	10	for	for	ADP
dpc-2650	68	11	all	all	DET
dpc-2650	68	12	analyses	analysis	NOUN
dpc-2650	68	13	.	.	PUNCT
dpc-2650	69	1	results	result	VERB
dpc-2650	69	2	twenty	twenty	NUM
dpc-2650	69	3	-	-	PUNCT
dpc-2650	69	4	five	five	NUM
dpc-2650	69	5	patients	patient	NOUN
dpc-2650	69	6	(	(	PUNCT
dpc-2650	69	7	13	13	NUM
dpc-2650	69	8	females	female	NOUN
dpc-2650	69	9	and	and	CCONJ
dpc-2650	69	10	12	12	NUM
dpc-2650	69	11	males	male	NOUN
dpc-2650	69	12	)	)	PUNCT
dpc-2650	69	13	with	with	ADP
dpc-2650	69	14	a	a	DET
dpc-2650	69	15	mean	mean	ADJ
dpc-2650	69	16	age	age	NOUN
dpc-2650	69	17	of	of	ADP
dpc-2650	69	18	39.8	39.8	NUM
dpc-2650	69	19	±	±	NUM
dpc-2650	69	20	13.72	13.72	NUM
dpc-2650	69	21	years	year	NOUN
dpc-2650	69	22	and	and	CCONJ
dpc-2650	69	23	11	11	NUM
dpc-2650	69	24	control	control	NOUN
dpc-2650	69	25	(	(	PUNCT
dpc-2650	69	26	6	6	NUM
dpc-2650	69	27	females	female	NOUN
dpc-2650	69	28	and	and	CCONJ
dpc-2650	69	29	5	5	NUM
dpc-2650	69	30	 	 	SPACE
dpc-2650	69	31	males	male	NOUN
dpc-2650	69	32	)	)	PUNCT
dpc-2650	69	33	subjects	subject	NOUN
dpc-2650	69	34	with	with	ADP
dpc-2650	69	35	a	a	DET
dpc-2650	69	36	mean	mean	ADJ
dpc-2650	69	37	age	age	NOUN
dpc-2650	69	38	of	of	ADP
dpc-2650	69	39	40.6	40.6	NUM
dpc-2650	69	40	±	±	NUM
dpc-2650	69	41	14.07	14.07	NUM
dpc-2650	69	42	years	year	NOUN
dpc-2650	69	43	were	be	AUX
dpc-2650	69	44	included	include	VERB
dpc-2650	69	45	in	in	ADP
dpc-2650	69	46	the	the	DET
dpc-2650	69	47	study	study	NOUN
dpc-2650	69	48	.	.	PUNCT
dpc-2650	70	1	no	no	DET
dpc-2650	70	2	significant	significant	ADJ
dpc-2650	70	3	difference	difference	NOUN
dpc-2650	70	4	was	be	AUX
dpc-2650	70	5	found	find	VERB
dpc-2650	70	6	between	between	ADP
dpc-2650	70	7	the	the	DET
dpc-2650	70	8	groups	group	NOUN
dpc-2650	70	9	regarding	regard	VERB
dpc-2650	70	10	mean	mean	NOUN
dpc-2650	70	11	age	age	NOUN
dpc-2650	70	12	and	and	CCONJ
dpc-2650	70	13	sex	sex	NOUN
dpc-2650	70	14	(	(	PUNCT
dpc-2650	70	15	p	p	X
dpc-2650	70	16	 	 	SPACE
dpc-2650	70	17	=	=	NOUN
dpc-2650	70	18	 	 	SPACE
dpc-2650	70	19	0.866	0.866	NUM
dpc-2650	70	20	,	,	PUNCT
dpc-2650	70	21	p	p	NOUN
dpc-2650	70	22	=	=	NOUN
dpc-2650	70	23	 	 	SPACE
dpc-2650	70	24	0.999	0.999	NUM
dpc-2650	70	25	respectively	respectively	ADV
dpc-2650	70	26	)	)	PUNCT
dpc-2650	70	27	.	.	PUNCT
dpc-2650	71	1	the	the	DET
dpc-2650	71	2	mean	mean	ADJ
dpc-2650	71	3	duration	duration	NOUN
dpc-2650	71	4	of	of	ADP
dpc-2650	71	5	the	the	DET
dpc-2650	71	6	disease	disease	NOUN
dpc-2650	71	7	in	in	ADP
dpc-2650	71	8	the	the	DET
dpc-2650	71	9	patient	patient	NOUN
dpc-2650	71	10	group	group	NOUN
dpc-2650	71	11	was	be	AUX
dpc-2650	71	12	9.8	9.8	NUM
dpc-2650	71	13	years	year	NOUN
dpc-2650	71	14	,	,	PUNCT
dpc-2650	71	15	and	and	CCONJ
dpc-2650	71	16	the	the	DET
dpc-2650	71	17	mean	mean	ADJ
dpc-2650	71	18	pasi	pasi	NOUN
dpc-2650	71	19	score	score	NOUN
dpc-2650	71	20	was	be	AUX
dpc-2650	71	21	13.3	13.3	NUM
dpc-2650	71	22	±	±	NUM
dpc-2650	71	23	6.1	6.1	NUM
dpc-2650	71	24	.	.	PUNCT
dpc-2650	72	1	according	accord	VERB
dpc-2650	72	2	to	to	ADP
dpc-2650	72	3	the	the	DET
dpc-2650	72	4	pasi	pasi	NOUN
dpc-2650	72	5	scores	score	NOUN
dpc-2650	72	6	,	,	PUNCT
dpc-2650	72	7	12	12	NUM
dpc-2650	72	8	(	(	PUNCT
dpc-2650	72	9	48	48	NUM
dpc-2650	72	10	%	%	NOUN
dpc-2650	72	11	)	)	PUNCT
dpc-2650	72	12	patients	patient	NOUN
dpc-2650	72	13	had	have	VERB
dpc-2650	72	14	mild	mild	ADJ
dpc-2650	72	15	,	,	PUNCT
dpc-2650	72	16	and	and	CCONJ
dpc-2650	72	17	13	13	NUM
dpc-2650	72	18	(	(	PUNCT
dpc-2650	72	19	52	52	NUM
dpc-2650	72	20	%	%	NOUN
dpc-2650	72	21	)	)	PUNCT
dpc-2650	72	22	patients	patient	NOUN
dpc-2650	72	23	had	have	VERB
dpc-2650	72	24	moderate	moderate	ADJ
dpc-2650	72	25	-	-	PUNCT
dpc-2650	72	26	severe	severe	ADJ
dpc-2650	72	27	psoriasis	psoriasis	NOUN
dpc-2650	72	28	.	.	PUNCT
dpc-2650	73	1	furthermore	furthermore	ADV
dpc-2650	73	2	,	,	PUNCT
dpc-2650	73	3	13	13	NUM
dpc-2650	73	4	patients	patient	NOUN
dpc-2650	73	5	(	(	PUNCT
dpc-2650	73	6	52	52	NUM
dpc-2650	73	7	%	%	NOUN
dpc-2650	73	8	)	)	PUNCT
dpc-2650	73	9	had	have	VERB
dpc-2650	73	10	nail	nail	NOUN
dpc-2650	73	11	involvement	involvement	NOUN
dpc-2650	73	12	,	,	PUNCT
dpc-2650	73	13	10	10	NUM
dpc-2650	73	14	(	(	PUNCT
dpc-2650	73	15	40	40	NUM
dpc-2650	73	16	%	%	NOUN
dpc-2650	73	17	)	)	PUNCT
dpc-2650	73	18	had	have	VERB
dpc-2650	73	19	psoriatic	psoriatic	ADJ
dpc-2650	73	20	arthritis	arthritis	NOUN
dpc-2650	73	21	,	,	PUNCT
dpc-2650	73	22	and	and	CCONJ
dpc-2650	73	23	14	14	NUM
dpc-2650	73	24	(	(	PUNCT
dpc-2650	73	25	56	56	NUM
dpc-2650	73	26	%	%	NOUN
dpc-2650	73	27	)	)	PUNCT
dpc-2650	73	28	had	have	VERB
dpc-2650	73	29	a	a	DET
dpc-2650	73	30	positive	positive	ADJ
dpc-2650	73	31	family	family	NOUN
dpc-2650	73	32	history	history	NOUN
dpc-2650	73	33	.	.	PUNCT
dpc-2650	74	1	patients	patient	NOUN
dpc-2650	74	2	and	and	CCONJ
dpc-2650	74	3	controls	control	NOUN
dpc-2650	74	4	had	have	VERB
dpc-2650	74	5	approximately	approximately	ADV
dpc-2650	74	6	similar	similar	ADJ
dpc-2650	74	7	body	body	NOUN
dpc-2650	74	8	mass	mass	NOUN
dpc-2650	74	9	index	index	NOUN
dpc-2650	74	10	(	(	PUNCT
dpc-2650	74	11	26.06	26.06	NUM
dpc-2650	74	12	kg	kg	NOUN
dpc-2650	74	13	/	/	SYM
dpc-2650	74	14	m2	m2	PROPN
dpc-2650	74	15	versus	versus	ADP
dpc-2650	74	16	26.76	26.76	NUM
dpc-2650	74	17	kg	kg	PROPN
dpc-2650	74	18	/	/	SYM
dpc-2650	74	19	m2	m2	PROPN
dpc-2650	74	20	)	)	PUNCT
dpc-2650	74	21	(	(	PUNCT
dpc-2650	74	22	p	p	X
dpc-2650	74	23	  	  	SPACE
dpc-2650	74	24	=	=	NOUN
dpc-2650	74	25	0.946	0.946	NUM
dpc-2650	74	26	)	)	PUNCT
dpc-2650	74	27	.	.	PUNCT
dpc-2650	75	1	descriptive	descriptive	ADJ
dpc-2650	75	2	features	feature	NOUN
dpc-2650	75	3	of	of	ADP
dpc-2650	75	4	the	the	DET
dpc-2650	75	5	participants	participant	NOUN
dpc-2650	75	6	were	be	AUX
dpc-2650	75	7	given	give	VERB
dpc-2650	75	8	in	in	ADP
dpc-2650	75	9	table	table	NOUN
dpc-2650	75	10	1	1	NUM
dpc-2650	75	11	.	.	PUNCT
dpc-2650	75	12	gene	gene	NOUN
dpc-2650	75	13	expression	expression	NOUN
dpc-2650	75	14	levels	level	NOUN
dpc-2650	75	15	in	in	ADP
dpc-2650	75	16	tissue	tissue	NOUN
dpc-2650	75	17	samples	sample	NOUN
dpc-2650	75	18	in	in	ADP
dpc-2650	75	19	the	the	DET
dpc-2650	75	20	real	real	ADJ
dpc-2650	75	21	time	time	NOUN
dpc-2650	75	22	(	(	PUNCT
dpc-2650	75	23	rt)-pcr	rt)-pcr	ADJ
dpc-2650	75	24	analysis	analysis	NOUN
dpc-2650	75	25	,	,	PUNCT
dpc-2650	75	26	we	we	PRON
dpc-2650	75	27	observed	observe	VERB
dpc-2650	75	28	that	that	SCONJ
dpc-2650	75	29	the	the	DET
dpc-2650	75	30	ereg	ereg	NOUN
dpc-2650	75	31	gene	gene	NOUN
dpc-2650	75	32	expression	expression	NOUN
dpc-2650	75	33	level	level	NOUN
dpc-2650	75	34	was	be	AUX
dpc-2650	75	35	significantly	significantly	ADV
dpc-2650	75	36	upregulated	upregulate	VERB
dpc-2650	75	37	in	in	ADP
dpc-2650	75	38	the	the	DET
dpc-2650	75	39	lesional	lesional	ADJ
dpc-2650	75	40	psoriatic	psoriatic	ADJ
dpc-2650	75	41	skin	skin	NOUN
dpc-2650	75	42	tissue	tissue	NOUN
dpc-2650	75	43	compared	compare	VERB
dpc-2650	75	44	to	to	ADP
dpc-2650	75	45	the	the	DET
dpc-2650	75	46	non	non	ADJ
dpc-2650	75	47	-	-	ADJ
dpc-2650	75	48	lesional	lesional	ADJ
dpc-2650	75	49	psoriatic	psoriatic	ADJ
dpc-2650	75	50	tissue	tissue	NOUN
dpc-2650	75	51	(	(	PUNCT
dpc-2650	75	52	fc=1.60	fc=1.60	PROPN
dpc-2650	75	53	,	,	PUNCT
dpc-2650	75	54	p	p	X
dpc-2650	75	55	=	=	NOUN
dpc-2650	75	56	0.010	0.010	NUM
dpc-2650	75	57	)	)	PUNCT
dpc-2650	75	58	.	.	PUNCT
dpc-2650	76	1	in	in	ADP
dpc-2650	76	2	addition	addition	NOUN
dpc-2650	76	3	,	,	PUNCT
dpc-2650	76	4	a	a	DET
dpc-2650	76	5	significant	significant	ADJ
dpc-2650	76	6	down	down	NOUN
dpc-2650	76	7	-	-	PUNCT
dpc-2650	76	8	regulation	regulation	NOUN
dpc-2650	76	9	was	be	AUX
dpc-2650	76	10	demonstrated	demonstrate	VERB
dpc-2650	76	11	in	in	ADP
dpc-2650	76	12	the	the	DET
dpc-2650	76	13	expression	expression	NOUN
dpc-2650	76	14	levels	level	NOUN
dpc-2650	76	15	of	of	ADP
dpc-2650	76	16	the	the	DET
dpc-2650	76	17	ereg	ereg	NOUN
dpc-2650	76	18	gene	gene	NOUN
dpc-2650	76	19	in	in	ADP
dpc-2650	76	20	the	the	DET
dpc-2650	76	21	adjacent	adjacent	ADJ
dpc-2650	76	22	non	non	ADJ
dpc-2650	76	23	-	-	ADJ
dpc-2650	76	24	lesional	lesional	ADJ
dpc-2650	76	25	skin	skin	NOUN
dpc-2650	76	26	tissue	tissue	NOUN
dpc-2650	76	27	of	of	ADP
dpc-2650	76	28	patients	patient	NOUN
dpc-2650	76	29	compared	compare	VERB
dpc-2650	76	30	to	to	ADP
dpc-2650	76	31	the	the	DET
dpc-2650	76	32	healthy	healthy	ADJ
dpc-2650	76	33	skin	skin	NOUN
dpc-2650	76	34	tissue	tissue	NOUN
dpc-2650	76	35	of	of	ADP
dpc-2650	76	36	controls	control	NOUN
dpc-2650	76	37	(	(	PUNCT
dpc-2650	76	38	fc	fc	X
dpc-2650	76	39	=	=	PUNCT
dpc-2650	76	40	-1.82	-1.82	NOUN
dpc-2650	76	41	,	,	PUNCT
dpc-2650	76	42	p	p	NOUN
dpc-2650	76	43	=	=	NOUN
dpc-2650	76	44	0.001	0.001	NUM
dpc-2650	76	45	)	)	PUNCT
dpc-2650	76	46	(	(	PUNCT
dpc-2650	76	47	table	table	NOUN
dpc-2650	76	48	2	2	NUM
dpc-2650	76	49	)	)	PUNCT
dpc-2650	76	50	.	.	PUNCT
dpc-2650	77	1	it	it	PRON
dpc-2650	77	2	was	be	AUX
dpc-2650	77	3	observed	observe	VERB
dpc-2650	77	4	that	that	SCONJ
dpc-2650	77	5	ptpn1	ptpn1	NOUN
dpc-2650	77	6	gene	gene	NOUN
dpc-2650	77	7	expression	expression	NOUN
dpc-2650	77	8	level	level	NOUN
dpc-2650	77	9	was	be	AUX
dpc-2650	77	10	significantly	significantly	ADV
dpc-2650	77	11	increased	increase	VERB
dpc-2650	77	12	in	in	ADP
dpc-2650	77	13	the	the	DET
dpc-2650	77	14	lesional	lesional	ADJ
dpc-2650	77	15	tissue	tissue	NOUN
dpc-2650	77	16	compared	compare	VERB
dpc-2650	77	17	to	to	ADP
dpc-2650	77	18	healthy	healthy	ADJ
dpc-2650	77	19	control	control	NOUN
dpc-2650	77	20	tissue	tissue	NOUN
dpc-2650	77	21	(	(	PUNCT
dpc-2650	77	22	fc	fc	X
dpc-2650	77	23	=	=	SYM
dpc-2650	77	24	2.44	2.44	NUM
dpc-2650	77	25	,	,	PUNCT
dpc-2650	77	26	p	p	X
dpc-2650	77	27	<	<	X
dpc-2650	77	28	0.001	0.001	NUM
dpc-2650	77	29	)	)	PUNCT
dpc-2650	77	30	.	.	PUNCT
dpc-2650	78	1	in	in	ADP
dpc-2650	78	2	addition	addition	NOUN
dpc-2650	78	3	,	,	PUNCT
dpc-2650	78	4	no	no	DET
dpc-2650	78	5	difference	difference	NOUN
dpc-2650	78	6	was	be	AUX
dpc-2650	78	7	found	find	VERB
dpc-2650	78	8	in	in	ADP
dpc-2650	78	9	the	the	DET
dpc-2650	78	10	expression	expression	NOUN
dpc-2650	78	11	levels	level	NOUN
dpc-2650	78	12	of	of	ADP
dpc-2650	78	13	the	the	DET
dpc-2650	78	14	ptpn1	ptpn1	NOUN
dpc-2650	78	15	gene	gene	NOUN
dpc-2650	78	16	in	in	ADP
dpc-2650	78	17	the	the	DET
dpc-2650	78	18	adjacent	adjacent	ADJ
dpc-2650	78	19	non	non	ADJ
dpc-2650	78	20	-	-	ADJ
dpc-2650	78	21	lesional	lesional	ADJ
dpc-2650	78	22	skin	skin	NOUN
dpc-2650	78	23	tissue	tissue	NOUN
dpc-2650	78	24	of	of	ADP
dpc-2650	78	25	psoriasis	psoriasis	NOUN
dpc-2650	78	26	patients	patient	NOUN
dpc-2650	78	27	compared	compare	VERB
dpc-2650	78	28	to	to	ADP
dpc-2650	78	29	the	the	DET
dpc-2650	78	30	healthy	healthy	ADJ
dpc-2650	78	31	skin	skin	NOUN
dpc-2650	78	32	tissue	tissue	NOUN
dpc-2650	78	33	of	of	ADP
dpc-2650	78	34	controls	control	NOUN
dpc-2650	78	35	(	(	PUNCT
dpc-2650	78	36	fc	fc	X
dpc-2650	78	37	=	=	SYM
dpc-2650	78	38	-1.35	-1.35	PROPN
dpc-2650	78	39	,	,	PUNCT
dpc-2650	78	40	p	p	X
dpc-2650	78	41	>	>	X
dpc-2650	78	42	0.05	0.05	NUM
dpc-2650	78	43	)	)	PUNCT
dpc-2650	78	44	(	(	PUNCT
dpc-2650	78	45	table	table	NOUN
dpc-2650	78	46	2	2	NUM
dpc-2650	78	47	)	)	PUNCT
dpc-2650	78	48	.	.	PUNCT
dpc-2650	79	1	it	it	PRON
dpc-2650	79	2	was	be	AUX
dpc-2650	79	3	observed	observe	VERB
dpc-2650	79	4	that	that	SCONJ
dpc-2650	79	5	the	the	DET
dpc-2650	79	6	expression	expression	NOUN
dpc-2650	79	7	level	level	NOUN
dpc-2650	79	8	of	of	ADP
dpc-2650	79	9	the	the	DET
dpc-2650	79	10	serpinb7	serpinb7	NOUN
dpc-2650	79	11	gene	gene	NOUN
dpc-2650	79	12	was	be	AUX
dpc-2650	79	13	significantly	significantly	ADV
dpc-2650	79	14	decreased	decrease	VERB
dpc-2650	79	15	in	in	ADP
dpc-2650	79	16	psoriatic	psoriatic	ADJ
dpc-2650	79	17	tissue	tissue	NOUN
dpc-2650	79	18	compared	compare	VERB
dpc-2650	79	19	to	to	ADP
dpc-2650	79	20	the	the	DET
dpc-2650	79	21	healthy	healthy	ADJ
dpc-2650	79	22	control	control	NOUN
dpc-2650	79	23	tissue	tissue	NOUN
dpc-2650	79	24	(	(	PUNCT
dpc-2650	79	25	fc	fc	X
dpc-2650	79	26	 	 	SPACE
dpc-2650	79	27	=	=	NOUN
dpc-2650	79	28	-2.33	-2.33	PROPN
dpc-2650	79	29	,	,	PUNCT
dpc-2650	79	30	p	p	X
dpc-2650	79	31	<	<	X
dpc-2650	79	32	0.001	0.001	NUM
dpc-2650	79	33	)	)	PUNCT
dpc-2650	79	34	.	.	PUNCT
dpc-2650	80	1	moreover	moreover	ADV
dpc-2650	80	2	,	,	PUNCT
dpc-2650	80	3	no	no	DET
dpc-2650	80	4	significant	significant	ADJ
dpc-2650	80	5	difference	difference	NOUN
dpc-2650	80	6	was	be	AUX
dpc-2650	80	7	seen	see	VERB
dpc-2650	80	8	in	in	ADP
dpc-2650	80	9	the	the	DET
dpc-2650	80	10	expression	expression	NOUN
dpc-2650	80	11	levels	level	NOUN
dpc-2650	80	12	of	of	ADP
dpc-2650	80	13	the	the	DET
dpc-2650	80	14	serpinb7	serpinb7	NOUN
dpc-2650	80	15	gene	gene	NOUN
dpc-2650	80	16	in	in	ADP
dpc-2650	80	17	the	the	DET
dpc-2650	80	18	adjacent	adjacent	ADJ
dpc-2650	80	19	non	non	ADJ
dpc-2650	80	20	-	-	ADJ
dpc-2650	80	21	lesional	lesional	ADJ
dpc-2650	80	22	skin	skin	NOUN
dpc-2650	80	23	tissue	tissue	NOUN
dpc-2650	80	24	of	of	ADP
dpc-2650	80	25	psoriasis	psoriasis	NOUN
dpc-2650	80	26	patients	patient	NOUN
dpc-2650	80	27	compared	compare	VERB
dpc-2650	80	28	to	to	ADP
dpc-2650	80	29	the	the	DET
dpc-2650	80	30	healthy	healthy	ADJ
dpc-2650	80	31	skin	skin	NOUN
dpc-2650	80	32	tissue	tissue	NOUN
dpc-2650	80	33	of	of	ADP
dpc-2650	80	34	controls	control	NOUN
dpc-2650	80	35	(	(	PUNCT
dpc-2650	80	36	fc	fc	PROPN
dpc-2650	80	37	=	=	SYM
dpc-2650	80	38	-9.1	-9.1	PROPN
dpc-2650	80	39	,	,	PUNCT
dpc-2650	80	40	p	p	X
dpc-2650	80	41	>	>	X
dpc-2650	80	42	0.05	0.05	NUM
dpc-2650	80	43	)	)	PUNCT
dpc-2650	80	44	(	(	PUNCT
dpc-2650	80	45	table	table	NOUN
dpc-2650	80	46	2	2	NUM
dpc-2650	80	47	)	)	PUNCT
dpc-2650	80	48	.	.	PUNCT
dpc-2650	81	1	according	accord	VERB
dpc-2650	81	2	to	to	ADP
dpc-2650	81	3	these	these	DET
dpc-2650	81	4	results	result	NOUN
dpc-2650	81	5	,	,	PUNCT
dpc-2650	81	6	the	the	DET
dpc-2650	81	7	expression	expression	NOUN
dpc-2650	81	8	levels	level	NOUN
dpc-2650	81	9	of	of	ADP
dpc-2650	81	10	all	all	DET
dpc-2650	81	11	genes	gene	NOUN
dpc-2650	81	12	were	be	AUX
dpc-2650	81	13	significantly	significantly	ADV
dpc-2650	81	14	different	different	ADJ
dpc-2650	81	15	between	between	ADP
dpc-2650	81	16	psoriatic	psoriatic	ADJ
dpc-2650	81	17	skin	skin	NOUN
dpc-2650	81	18	and	and	CCONJ
dpc-2650	81	19	healthy	healthy	ADJ
dpc-2650	81	20	control	control	NOUN
dpc-2650	81	21	skin	skin	NOUN
dpc-2650	81	22	(	(	PUNCT
dpc-2650	81	23	for	for	ADP
dpc-2650	81	24	all	all	PRON
dpc-2650	81	25	p	p	X
dpc-2650	81	26	<	<	X
dpc-2650	81	27	0.05	0.05	NUM
dpc-2650	81	28	)	)	PUNCT
dpc-2650	81	29	(	(	PUNCT
dpc-2650	81	30	figure	figure	NOUN
dpc-2650	81	31	1	1	NUM
dpc-2650	81	32	)	)	PUNCT
dpc-2650	81	33	.	.	PUNCT
dpc-2650	82	1	table	table	NOUN
dpc-2650	82	2	1	1	NUM
dpc-2650	82	3	.	.	PUNCT
dpc-2650	82	4	baseline	baseline	PROPN
dpc-2650	82	5	characteristics	characteristic	NOUN
dpc-2650	82	6	of	of	ADP
dpc-2650	82	7	the	the	DET
dpc-2650	82	8	study	study	NOUN
dpc-2650	82	9	groups	group	NOUN
dpc-2650	82	10	.	.	PUNCT
dpc-2650	83	1	patient	patient	ADJ
dpc-2650	83	2	group	group	NOUN
dpc-2650	83	3	(	(	PUNCT
dpc-2650	83	4	n	n	NOUN
dpc-2650	83	5	=	=	SYM
dpc-2650	83	6	25	25	NUM
dpc-2650	83	7	)	)	PUNCT
dpc-2650	83	8	control	control	NOUN
dpc-2650	83	9	group	group	NOUN
dpc-2650	83	10	(	(	PUNCT
dpc-2650	83	11	n	n	NOUN
dpc-2650	83	12	=	=	SYM
dpc-2650	83	13	11	11	NUM
dpc-2650	83	14	)	)	PUNCT
dpc-2650	83	15	pa	pa	PROPN
dpc-2650	83	16	age	age	NOUN
dpc-2650	83	17	,	,	PUNCT
dpc-2650	83	18	years	year	NOUN
dpc-2650	83	19	,	,	PUNCT
dpc-2650	83	20	mean	mean	VERB
dpc-2650	83	21	±	±	NUM
dpc-2650	83	22	sd	sd	ADP
dpc-2650	83	23	39.8	39.8	NUM
dpc-2650	83	24	±	±	NUM
dpc-2650	83	25	13.72	13.72	NUM
dpc-2650	83	26	40.6	40.6	NUM
dpc-2650	83	27	±	±	NUM
dpc-2650	83	28	14.07	14.07	NUM
dpc-2650	83	29	.866	.866	NUM
dpc-2650	84	1	sex	sex	NOUN
dpc-2650	84	2	female	female	NOUN
dpc-2650	84	3	,	,	PUNCT
dpc-2650	84	4	n	n	CCONJ
dpc-2650	84	5	(	(	PUNCT
dpc-2650	84	6	%	%	INTJ
dpc-2650	84	7	)	)	PUNCT
dpc-2650	84	8	male	male	NOUN
dpc-2650	84	9	,	,	PUNCT
dpc-2650	84	10	n	n	CCONJ
dpc-2650	84	11	(	(	PUNCT
dpc-2650	84	12	%	%	INTJ
dpc-2650	84	13	)	)	PUNCT
dpc-2650	84	14	13	13	NUM
dpc-2650	84	15	(	(	PUNCT
dpc-2650	84	16	52	52	NUM
dpc-2650	84	17	%	%	NOUN
dpc-2650	84	18	)	)	PUNCT
dpc-2650	84	19	12	12	NUM
dpc-2650	84	20	(	(	PUNCT
dpc-2650	84	21	48	48	NUM
dpc-2650	84	22	%	%	NOUN
dpc-2650	84	23	)	)	PUNCT
dpc-2650	84	24	6	6	NUM
dpc-2650	84	25	(	(	PUNCT
dpc-2650	84	26	45.5	45.5	NUM
dpc-2650	84	27	%	%	NOUN
dpc-2650	84	28	)	)	PUNCT
dpc-2650	84	29	5	5	NUM
dpc-2650	84	30	(	(	PUNCT
dpc-2650	84	31	54.5	54.5	NUM
dpc-2650	84	32	%	%	NOUN
dpc-2650	84	33	)	)	PUNCT
dpc-2650	84	34	.999	.999	NUM
dpc-2650	84	35	bmi	bmi	NOUN
dpc-2650	84	36	,	,	PUNCT
dpc-2650	84	37	mean	mean	VERB
dpc-2650	84	38	±	±	NUM
dpc-2650	84	39	sd	sd	ADP
dpc-2650	84	40	26.06	26.06	NUM
dpc-2650	84	41	±	±	NUM
dpc-2650	84	42	4.8	4.8	NUM
dpc-2650	84	43	26.19±	26.19±	NUM
dpc-2650	84	44	3.18	3.18	NUM
dpc-2650	84	45	.946	.946	NUM
dpc-2650	84	46	duration	duration	NOUN
dpc-2650	84	47	of	of	ADP
dpc-2650	84	48	disease	disease	NOUN
dpc-2650	84	49	,	,	PUNCT
dpc-2650	84	50	years	year	NOUN
dpc-2650	84	51	,	,	PUNCT
dpc-2650	84	52	mean	mean	NOUN
dpc-2650	84	53	±	±	NUM
dpc-2650	84	54	sd	sd	ADP
dpc-2650	84	55	9.8	9.8	NUM
dpc-2650	84	56	±	±	NUM
dpc-2650	84	57	9.2	9.2	NUM
dpc-2650	84	58	(	(	PUNCT
dpc-2650	84	59	1	1	NUM
dpc-2650	84	60	-	-	SYM
dpc-2650	84	61	35)b	35)b	NUM
dpc-2650	84	62	pasi	pasi	NOUN
dpc-2650	84	63	scores	score	NOUN
dpc-2650	84	64	,	,	PUNCT
dpc-2650	84	65	mean	mean	VERB
dpc-2650	84	66	±	±	NUM
dpc-2650	84	67	sd	sd	ADP
dpc-2650	84	68	13.3	13.3	NUM
dpc-2650	84	69	±	±	NUM
dpc-2650	84	70	6.1	6.1	NUM
dpc-2650	84	71	arthritis	arthritis	NOUN
dpc-2650	84	72	,	,	PUNCT
dpc-2650	84	73	n	n	CCONJ
dpc-2650	84	74	(	(	PUNCT
dpc-2650	84	75	%	%	INTJ
dpc-2650	84	76	)	)	PUNCT
dpc-2650	84	77	10	10	NUM
dpc-2650	84	78	(	(	PUNCT
dpc-2650	84	79	40	40	NUM
dpc-2650	84	80	%	%	NOUN
dpc-2650	84	81	)	)	PUNCT
dpc-2650	84	82	nail	nail	NOUN
dpc-2650	84	83	involvement	involvement	NOUN
dpc-2650	84	84	,	,	PUNCT
dpc-2650	84	85	n	n	CCONJ
dpc-2650	84	86	(	(	PUNCT
dpc-2650	84	87	%	%	INTJ
dpc-2650	84	88	)	)	PUNCT
dpc-2650	84	89	13	13	NUM
dpc-2650	84	90	(	(	PUNCT
dpc-2650	84	91	52	52	NUM
dpc-2650	84	92	%	%	NOUN
dpc-2650	84	93	)	)	PUNCT
dpc-2650	84	94	positive	positive	ADJ
dpc-2650	84	95	family	family	NOUN
dpc-2650	84	96	history	history	NOUN
dpc-2650	84	97	,	,	PUNCT
dpc-2650	84	98	n	n	CCONJ
dpc-2650	84	99	(	(	PUNCT
dpc-2650	84	100	%	%	INTJ
dpc-2650	84	101	)	)	PUNCT
dpc-2650	84	102	14	14	NUM
dpc-2650	84	103	(	(	PUNCT
dpc-2650	84	104	56	56	NUM
dpc-2650	84	105	%	%	NOUN
dpc-2650	84	106	)	)	PUNCT
dpc-2650	84	107	severity	severity	NOUN
dpc-2650	84	108	of	of	ADP
dpc-2650	84	109	the	the	DET
dpc-2650	84	110	disease	disease	NOUN
dpc-2650	84	111	mild	mild	ADJ
dpc-2650	84	112	disease	disease	NOUN
dpc-2650	84	113	,	,	PUNCT
dpc-2650	84	114	n	n	CCONJ
dpc-2650	84	115	(	(	PUNCT
dpc-2650	84	116	%	%	INTJ
dpc-2650	84	117	)	)	PUNCT
dpc-2650	84	118	moderate	moderate	ADJ
dpc-2650	84	119	-	-	PUNCT
dpc-2650	84	120	severe	severe	ADJ
dpc-2650	84	121	disease	disease	NOUN
dpc-2650	84	122	,	,	PUNCT
dpc-2650	84	123	n	n	CCONJ
dpc-2650	84	124	(	(	PUNCT
dpc-2650	84	125	%	%	INTJ
dpc-2650	84	126	)	)	PUNCT
dpc-2650	84	127	12	12	NUM
dpc-2650	84	128	(	(	PUNCT
dpc-2650	84	129	48	48	NUM
dpc-2650	84	130	%	%	NOUN
dpc-2650	84	131	)	)	PUNCT
dpc-2650	84	132	13	13	NUM
dpc-2650	84	133	(	(	PUNCT
dpc-2650	84	134	52	52	NUM
dpc-2650	84	135	%	%	NOUN
dpc-2650	84	136	)	)	PUNCT
dpc-2650	84	137	bmi	bmi	NOUN
dpc-2650	84	138	=	=	SYM
dpc-2650	84	139	body	body	PROPN
dpc-2650	84	140	mass	mass	PROPN
dpc-2650	84	141	index	index	NOUN
dpc-2650	84	142	;	;	PUNCT
dpc-2650	84	143	pasi	pasi	NOUN
dpc-2650	84	144	=	=	SYM
dpc-2650	84	145	psoriasis	psoriasis	NOUN
dpc-2650	84	146	area	area	NOUN
dpc-2650	84	147	and	and	CCONJ
dpc-2650	84	148	severity	severity	NOUN
dpc-2650	84	149	index	index	NOUN
dpc-2650	84	150	;	;	PUNCT
dpc-2650	84	151	sd	sd	NOUN
dpc-2650	84	152	=	=	SYM
dpc-2650	84	153	standard	standard	ADJ
dpc-2650	84	154	deviation	deviation	NOUN
dpc-2650	84	155	.	.	PUNCT
dpc-2650	85	1	a	a	DET
dpc-2650	85	2	p	p	NOUN
dpc-2650	85	3	value	value	NOUN
dpc-2650	85	4	is	be	AUX
dpc-2650	85	5	significant	significant	ADJ
dpc-2650	85	6	at	at	ADP
dpc-2650	85	7	the	the	DET
dpc-2650	85	8	0.05	0.05	NUM
dpc-2650	85	9	level	level	NOUN
dpc-2650	85	10	b	b	NOUN
dpc-2650	85	11	minimum	minimum	ADJ
dpc-2650	85	12	and	and	CCONJ
dpc-2650	85	13	maximum	maximum	ADJ
dpc-2650	85	14	values	value	NOUN
dpc-2650	85	15	4	4	NUM
dpc-2650	85	16	original	original	ADJ
dpc-2650	85	17	article	article	NOUN
dpc-2650	85	18	|	|	ADV
dpc-2650	85	19	dermatol	dermatol	ADJ
dpc-2650	85	20	pract	pract	NOUN
dpc-2650	85	21	concept	concept	NOUN
dpc-2650	85	22	.	.	PUNCT
dpc-2650	86	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	86	2	table	table	NOUN
dpc-2650	86	3	2	2	NUM
dpc-2650	86	4	.	.	PUNCT
dpc-2650	86	5	comparison	comparison	NOUN
dpc-2650	86	6	of	of	ADP
dpc-2650	86	7	the	the	DET
dpc-2650	86	8	expression	expression	NOUN
dpc-2650	86	9	of	of	ADP
dpc-2650	86	10	ereg	ereg	NOUN
dpc-2650	86	11	,	,	PUNCT
dpc-2650	86	12	ptpn1	ptpn1	NOUN
dpc-2650	86	13	,	,	PUNCT
dpc-2650	86	14	and	and	CCONJ
dpc-2650	86	15	serpinb7	serpinb7	NOUN
dpc-2650	86	16	genes	gene	NOUN
dpc-2650	86	17	between	between	ADP
dpc-2650	86	18	the	the	DET
dpc-2650	86	19	lesional	lesional	ADJ
dpc-2650	86	20	and	and	CCONJ
dpc-2650	86	21	non	non	ADJ
dpc-2650	86	22	-	-	ADJ
dpc-2650	86	23	lesional	lesional	ADJ
dpc-2650	86	24	skins	skin	NOUN
dpc-2650	86	25	of	of	ADP
dpc-2650	86	26	the	the	DET
dpc-2650	86	27	psoriatic	psoriatic	ADJ
dpc-2650	86	28	patients	patient	NOUN
dpc-2650	86	29	and	and	CCONJ
dpc-2650	86	30	normal	normal	ADJ
dpc-2650	86	31	skins	skin	NOUN
dpc-2650	86	32	of	of	ADP
dpc-2650	86	33	healthy	healthy	ADJ
dpc-2650	86	34	controls	control	NOUN
dpc-2650	86	35	.	.	PUNCT
dpc-2650	87	1	lesional	lesional	ADJ
dpc-2650	87	2	skin	skin	NOUN
dpc-2650	87	3	of	of	ADP
dpc-2650	87	4	psoriatic	psoriatic	ADJ
dpc-2650	87	5	patients	patient	NOUN
dpc-2650	87	6	non	non	ADJ
dpc-2650	87	7	-	-	ADJ
dpc-2650	87	8	lesional	lesional	ADJ
dpc-2650	87	9	skin	skin	NOUN
dpc-2650	87	10	of	of	ADP
dpc-2650	87	11	psoriatic	psoriatic	ADJ
dpc-2650	87	12	patients	patient	NOUN
dpc-2650	87	13	controls	control	VERB
dpc-2650	87	14	pa	pa	PROPN
dpc-2650	87	15	pb	pb	ADP
dpc-2650	87	16	ereg	ereg	NOUN
dpc-2650	87	17	,	,	PUNCT
dpc-2650	87	18	mean	mean	VERB
dpc-2650	87	19	±	±	NUM
dpc-2650	87	20	sd	sd	NOUN
dpc-2650	87	21	(	(	PUNCT
dpc-2650	87	22	min	min	NOUN
dpc-2650	87	23	-	-	PUNCT
dpc-2650	87	24	max	max	NOUN
dpc-2650	87	25	)	)	PUNCT
dpc-2650	87	26	1.82	1.82	NUM
dpc-2650	87	27	±	±	NUM
dpc-2650	87	28	0.95	0.95	NUM
dpc-2650	87	29	(	(	PUNCT
dpc-2650	87	30	0.6	0.6	NUM
dpc-2650	87	31	-	-	SYM
dpc-2650	87	32	4.11	4.11	NUM
dpc-2650	87	33	)	)	PUNCT
dpc-2650	87	34	0.57	0.57	NUM
dpc-2650	87	35	±	±	NUM
dpc-2650	87	36	0.2	0.2	NUM
dpc-2650	87	37	(	(	PUNCT
dpc-2650	87	38	0.34	0.34	NUM
dpc-2650	87	39	-	-	SYM
dpc-2650	87	40	1.06	1.06	NUM
dpc-2650	87	41	)	)	PUNCT
dpc-2650	87	42	1.03	1.03	NUM
dpc-2650	87	43	±	±	NUM
dpc-2650	87	44	0.3	0.3	NUM
dpc-2650	87	45	(	(	PUNCT
dpc-2650	87	46	0.7	0.7	NUM
dpc-2650	87	47	-	-	SYM
dpc-2650	87	48	1.68	1.68	NUM
dpc-2650	87	49	)	)	PUNCT
dpc-2650	87	50	0.012	0.012	NUM
dpc-2650	87	51	ab:<0.001	ab:<0.001	ADJ
dpc-2650	87	52	ac:0.345	ac:0.345	PROPN
dpc-2650	87	53	bc:0.004	bc:0.004	PROPN
dpc-2650	87	54	ptpn1	ptpn1	PROPN
dpc-2650	87	55	,	,	PUNCT
dpc-2650	87	56	mean	mean	VERB
dpc-2650	87	57	±	±	NUM
dpc-2650	87	58	sd	sd	ADP
dpc-2650	87	59	(	(	PUNCT
dpc-2650	87	60	min	min	NOUN
dpc-2650	87	61	-	-	PUNCT
dpc-2650	87	62	max	max	NOUN
dpc-2650	87	63	)	)	PUNCT
dpc-2650	87	64	3.76	3.76	NUM
dpc-2650	87	65	±	±	NUM
dpc-2650	87	66	1.89	1.89	NUM
dpc-2650	87	67	(	(	PUNCT
dpc-2650	87	68	1.26	1.26	NUM
dpc-2650	87	69	-	-	SYM
dpc-2650	87	70	10.6	10.6	NUM
dpc-2650	87	71	)	)	PUNCT
dpc-2650	87	72	1.18	1.18	NUM
dpc-2650	87	73	±	±	NUM
dpc-2650	87	74	0.57	0.57	NUM
dpc-2650	87	75	(	(	PUNCT
dpc-2650	87	76	0.24	0.24	NUM
dpc-2650	87	77	-	-	SYM
dpc-2650	87	78	2.19	2.19	NUM
dpc-2650	87	79	)	)	PUNCT
dpc-2650	87	80	1	1	NUM
dpc-2650	87	81	±	±	NUM
dpc-2650	87	82	0.13	0.13	NUM
dpc-2650	87	83	(	(	PUNCT
dpc-2650	87	84	0.86	0.86	NUM
dpc-2650	87	85	-	-	NUM
dpc-2650	87	86	1.24	1.24	NUM
dpc-2650	87	87	)	)	PUNCT
dpc-2650	87	88	<	<	X
dpc-2650	87	89	0.001	0.001	NUM
dpc-2650	87	90	ab:<0.001	ab:<0.001	ADJ
dpc-2650	87	91	ac:<0.001	ac:<0.001	PROPN
dpc-2650	87	92	bc:0.999	bc:0.999	NOUN
dpc-2650	87	93	serpinb7	serpinb7	NOUN
dpc-2650	87	94	,	,	PUNCT
dpc-2650	87	95	mean	mean	VERB
dpc-2650	87	96	±	±	NUM
dpc-2650	87	97	sd	sd	NOUN
dpc-2650	87	98	(	(	PUNCT
dpc-2650	87	99	min	min	NOUN
dpc-2650	87	100	-	-	PUNCT
dpc-2650	87	101	max	max	NOUN
dpc-2650	87	102	)	)	PUNCT
dpc-2650	87	103	2.54	2.54	NUM
dpc-2650	87	104	±	±	NUM
dpc-2650	87	105	0.61	0.61	NUM
dpc-2650	87	106	(	(	PUNCT
dpc-2650	87	107	1.5	1.5	NUM
dpc-2650	87	108	-	-	SYM
dpc-2650	87	109	4.14	4.14	NUM
dpc-2650	87	110	)	)	PUNCT
dpc-2650	87	111	4.49	4.49	NUM
dpc-2650	87	112	±	±	NUM
dpc-2650	87	113	0.42	0.42	NUM
dpc-2650	87	114	(	(	PUNCT
dpc-2650	87	115	3.95	3.95	NUM
dpc-2650	87	116	-	-	SYM
dpc-2650	87	117	5.31	5.31	NUM
dpc-2650	87	118	)	)	PUNCT
dpc-2650	87	119	4.29	4.29	NUM
dpc-2650	87	120	±	±	NUM
dpc-2650	87	121	0.32	0.32	NUM
dpc-2650	87	122	(	(	PUNCT
dpc-2650	87	123	3.79	3.79	NUM
dpc-2650	87	124	-	-	SYM
dpc-2650	87	125	4.72	4.72	NUM
dpc-2650	87	126	)	)	PUNCT
dpc-2650	87	127	<	<	X
dpc-2650	87	128	0.001	0.001	NUM
dpc-2650	87	129	ab:<0.001	ab:<0.001	ADJ
dpc-2650	87	130	ac:<0.001	ac:<0.001	PROPN
dpc-2650	87	131	bc:0.999	bc:0.999	NOUN
dpc-2650	87	132	a	a	DET
dpc-2650	87	133	=	=	SYM
dpc-2650	87	134	lesional	lesional	ADJ
dpc-2650	87	135	skin	skin	NOUN
dpc-2650	87	136	of	of	ADP
dpc-2650	87	137	patients	patient	NOUN
dpc-2650	87	138	;	;	PUNCT
dpc-2650	87	139	b	b	X
dpc-2650	87	140	=	=	SYM
dpc-2650	87	141	non	non	ADJ
dpc-2650	87	142	-	-	ADJ
dpc-2650	87	143	lesional	lesional	ADJ
dpc-2650	87	144	skin	skin	NOUN
dpc-2650	87	145	of	of	ADP
dpc-2650	87	146	patients	patient	NOUN
dpc-2650	87	147	;	;	PUNCT
dpc-2650	88	1	c	c	NOUN
dpc-2650	88	2	=	=	SYM
dpc-2650	88	3	normal	normal	ADJ
dpc-2650	88	4	skin	skin	NOUN
dpc-2650	88	5	of	of	ADP
dpc-2650	88	6	controls	control	NOUN
dpc-2650	88	7	;	;	PUNCT
dpc-2650	88	8	ereg	ereg	NOUN
dpc-2650	88	9	=	=	SYM
dpc-2650	88	10	epiregulin	epiregulin	NOUN
dpc-2650	88	11	;	;	PUNCT
dpc-2650	88	12	ptpn1	ptpn1	NOUN
dpc-2650	88	13	=	=	SYM
dpc-2650	88	14	tyrosine	tyrosine	NOUN
dpc-2650	88	15	-	-	PUNCT
dpc-2650	88	16	protein	protein	NOUN
dpc-2650	88	17	phosphatase	phosphatase	NOUN
dpc-2650	88	18	non	non	ADJ
dpc-2650	88	19	-	-	ADJ
dpc-2650	88	20	receptor	receptor	ADJ
dpc-2650	88	21	type	type	NOUN
dpc-2650	88	22	1	1	NUM
dpc-2650	88	23	;	;	PUNCT
dpc-2650	88	24	sd	sd	NOUN
dpc-2650	88	25	=	=	PUNCT
dpc-2650	88	26	standard	standard	ADJ
dpc-2650	88	27	deviation	deviation	NOUN
dpc-2650	88	28	;	;	PUNCT
dpc-2650	88	29	serpinb7	serpinb7	NOUN
dpc-2650	88	30	=	=	SYM
dpc-2650	88	31	serpin	serpin	PROPN
dpc-2650	88	32	family	family	PROPN
dpc-2650	88	33	b	b	PROPN
dpc-2650	88	34	member	member	PROPN
dpc-2650	88	35	7	7	NUM
dpc-2650	88	36	.	.	PUNCT
dpc-2650	89	1	a	a	DET
dpc-2650	89	2	triple	triple	ADJ
dpc-2650	89	3	comparison	comparison	NOUN
dpc-2650	89	4	of	of	ADP
dpc-2650	89	5	the	the	DET
dpc-2650	89	6	groups	group	NOUN
dpc-2650	89	7	(	(	PUNCT
dpc-2650	89	8	with	with	ADP
dpc-2650	89	9	kruskal	kruskal	PROPN
dpc-2650	89	10	-	-	PUNCT
dpc-2650	89	11	wallis	wallis	PROPN
dpc-2650	89	12	,	,	PUNCT
dpc-2650	89	13	p	p	X
dpc-2650	89	14	<	<	X
dpc-2650	89	15	0.05	0.05	NUM
dpc-2650	89	16	is	be	AUX
dpc-2650	89	17	accepted	accept	VERB
dpc-2650	89	18	as	as	ADP
dpc-2650	89	19	statistically	statistically	ADV
dpc-2650	89	20	significant	significant	ADJ
dpc-2650	89	21	)	)	PUNCT
dpc-2650	89	22	b	b	NOUN
dpc-2650	89	23	pairwise	pairwise	NOUN
dpc-2650	89	24	comparison	comparison	NOUN
dpc-2650	89	25	of	of	ADP
dpc-2650	89	26	the	the	DET
dpc-2650	89	27	groups	group	NOUN
dpc-2650	89	28	(	(	PUNCT
dpc-2650	89	29	bonferroni	bonferroni	NOUN
dpc-2650	89	30	correction	correction	NOUN
dpc-2650	89	31	was	be	AUX
dpc-2650	89	32	used	use	VERB
dpc-2650	89	33	,	,	PUNCT
dpc-2650	89	34	and	and	CCONJ
dpc-2650	89	35	p	p	X
dpc-2650	89	36	<	<	X
dpc-2650	89	37	0.05	0.05	NUM
dpc-2650	89	38	is	be	AUX
dpc-2650	89	39	accepted	accept	VERB
dpc-2650	89	40	as	as	SCONJ
dpc-2650	89	41	statistically	statistically	ADV
dpc-2650	89	42	significant	significant	ADJ
dpc-2650	89	43	)	)	PUNCT
dpc-2650	89	44	non	non	ADJ
dpc-2650	89	45	-	-	ADJ
dpc-2650	89	46	lesional	lesional	ADJ
dpc-2650	89	47	adjacent	adjacent	ADJ
dpc-2650	89	48	skin	skin	NOUN
dpc-2650	89	49	normal	normal	ADJ
dpc-2650	89	50	skin	skin	NOUN
dpc-2650	89	51	ereg	ereg	VERB
dpc-2650	89	52	ptpn1	ptpn1	NOUN
dpc-2650	90	1	5,00	5,00	ADJ
dpc-2650	90	2	4,50	4,50	NUM
dpc-2650	90	3	4,00	4,00	NUM
dpc-2650	90	4	3,50	3,50	NUM
dpc-2650	90	5	3,00	3,00	NUM
dpc-2650	90	6	2,50	2,50	NUM
dpc-2650	90	7	2,00	2,00	X
dpc-2650	90	8	1,50	1,50	NUM
dpc-2650	90	9	1,00	1,00	X
dpc-2650	90	10	0,50	0,50	X
dpc-2650	91	1	0,00	0,00	PUNCT
dpc-2650	91	2	-0,50	-0,50	PUNCT
dpc-2650	92	1	serpinb7	serpinb7	ADJ
dpc-2650	92	2	lesional	lesional	ADJ
dpc-2650	92	3	skin	skin	NOUN
dpc-2650	92	4	m	m	PROPN
dpc-2650	92	5	rn	rn	PROPN
dpc-2650	92	6	a	a	PROPN
dpc-2650	92	7	f	f	X
dpc-2650	92	8	o	o	X
dpc-2650	92	9	ld	ld	PROPN
dpc-2650	92	10	c	c	PROPN
dpc-2650	92	11	h	h	NOUN
dpc-2650	92	12	a	a	DET
dpc-2650	92	13	n	n	CCONJ
dpc-2650	92	14	g	g	NOUN
dpc-2650	92	15	e	e	NOUN
dpc-2650	92	16	figure	figure	NOUN
dpc-2650	92	17	1	1	NUM
dpc-2650	92	18	.	.	PUNCT
dpc-2650	92	19	comparison	comparison	NOUN
dpc-2650	92	20	of	of	ADP
dpc-2650	92	21	the	the	DET
dpc-2650	92	22	expression	expression	NOUN
dpc-2650	92	23	levels	level	NOUN
dpc-2650	92	24	of	of	ADP
dpc-2650	92	25	ereg	ereg	NOUN
dpc-2650	92	26	,	,	PUNCT
dpc-2650	92	27	ptpn1	ptpn1	NOUN
dpc-2650	92	28	,	,	PUNCT
dpc-2650	92	29	serpinb7	serpinb7	NOUN
dpc-2650	92	30	genes	gene	NOUN
dpc-2650	92	31	between	between	ADP
dpc-2650	92	32	the	the	DET
dpc-2650	92	33	lesional	lesional	ADJ
dpc-2650	92	34	and	and	CCONJ
dpc-2650	92	35	non	non	ADJ
dpc-2650	92	36	lesional	lesional	ADJ
dpc-2650	92	37	skins	skin	NOUN
dpc-2650	92	38	of	of	ADP
dpc-2650	92	39	the	the	DET
dpc-2650	92	40	psoriatic	psoriatic	ADJ
dpc-2650	92	41	patients	patient	NOUN
dpc-2650	92	42	and	and	CCONJ
dpc-2650	92	43	the	the	DET
dpc-2650	92	44	normal	normal	ADJ
dpc-2650	92	45	skin	skin	NOUN
dpc-2650	92	46	of	of	ADP
dpc-2650	92	47	healthy	healthy	ADJ
dpc-2650	92	48	controls	control	NOUN
dpc-2650	92	49	.	.	PUNCT
dpc-2650	93	1	rt	rt	ADJ
dpc-2650	93	2	-	-	PUNCT
dpc-2650	93	3	pcr	pcr	NOUN
dpc-2650	93	4	analysis	analysis	NOUN
dpc-2650	93	5	of	of	ADP
dpc-2650	93	6	the	the	DET
dpc-2650	93	7	indicated	indicate	VERB
dpc-2650	93	8	genes	gene	NOUN
dpc-2650	93	9	in	in	ADP
dpc-2650	93	10	indicated	indicate	VERB
dpc-2650	93	11	skin	skin	NOUN
dpc-2650	93	12	tissues	tissue	NOUN
dpc-2650	93	13	was	be	AUX
dpc-2650	93	14	performed	perform	VERB
dpc-2650	93	15	.	.	PUNCT
dpc-2650	94	1	*	*	PUNCT
dpc-2650	95	1	p	p	X
dpc-2650	95	2	<	<	X
dpc-2650	95	3	0.05	0.05	NUM
dpc-2650	95	4	;	;	PUNCT
dpc-2650	95	5	*	*	PUNCT
dpc-2650	95	6	*	*	PUNCT
dpc-2650	95	7	p	p	X
dpc-2650	95	8	<	<	X
dpc-2650	95	9	0.001	0.001	NUM
dpc-2650	95	10	ereg	ereg	NOUN
dpc-2650	95	11	=	=	SYM
dpc-2650	95	12	epiregulin	epiregulin	NOUN
dpc-2650	95	13	;	;	PUNCT
dpc-2650	95	14	ptpn1	ptpn1	NOUN
dpc-2650	95	15	=	=	SYM
dpc-2650	95	16	tyrosine	tyrosine	NOUN
dpc-2650	95	17	-	-	PUNCT
dpc-2650	95	18	protein	protein	NOUN
dpc-2650	95	19	phosphatase	phosphatase	NOUN
dpc-2650	95	20	non	non	ADJ
dpc-2650	95	21	-	-	ADJ
dpc-2650	95	22	receptor	receptor	ADJ
dpc-2650	95	23	type	type	NOUN
dpc-2650	95	24	1	1	NUM
dpc-2650	95	25	;	;	PUNCT
dpc-2650	95	26	serpinb7	serpinb7	NOUN
dpc-2650	95	27	=	=	SYM
dpc-2650	95	28	serpin	serpin	PROPN
dpc-2650	95	29	family	family	PROPN
dpc-2650	95	30	b	b	PROPN
dpc-2650	95	31	member	member	PROPN
dpc-2650	95	32	7	7	NUM
dpc-2650	95	33	.	.	PUNCT
dpc-2650	96	1	furthermore	furthermore	ADV
dpc-2650	96	2	,	,	PUNCT
dpc-2650	96	3	the	the	DET
dpc-2650	96	4	decrease	decrease	NOUN
dpc-2650	96	5	of	of	ADP
dpc-2650	96	6	the	the	DET
dpc-2650	96	7	expression	expression	NOUN
dpc-2650	96	8	of	of	ADP
dpc-2650	96	9	the	the	DET
dpc-2650	96	10	serpinb7	serpinb7	NOUN
dpc-2650	96	11	gene	gene	NOUN
dpc-2650	96	12	was	be	AUX
dpc-2650	96	13	correlated	correlate	VERB
dpc-2650	96	14	with	with	ADP
dpc-2650	96	15	pasi	pasi	NOUN
dpc-2650	96	16	scores	score	NOUN
dpc-2650	96	17	in	in	ADP
dpc-2650	96	18	the	the	DET
dpc-2650	96	19	patient	patient	NOUN
dpc-2650	96	20	group	group	NOUN
dpc-2650	96	21	(	(	PUNCT
dpc-2650	96	22	p	p	X
dpc-2650	96	23	=	=	NOUN
dpc-2650	96	24	0.038	0.038	NUM
dpc-2650	96	25	,	,	PUNCT
dpc-2650	96	26	r	r	NOUN
dpc-2650	96	27	=	=	NOUN
dpc-2650	96	28	0.417	0.417	NUM
dpc-2650	96	29	)	)	PUNCT
dpc-2650	96	30	(	(	PUNCT
dpc-2650	96	31	figure	figure	NOUN
dpc-2650	96	32	2	2	NUM
dpc-2650	96	33	)	)	PUNCT
dpc-2650	96	34	.	.	PUNCT
dpc-2650	97	1	there	there	PRON
dpc-2650	97	2	was	be	VERB
dpc-2650	97	3	no	no	DET
dpc-2650	97	4	correlation	correlation	NOUN
dpc-2650	97	5	between	between	ADP
dpc-2650	97	6	other	other	ADJ
dpc-2650	97	7	genes	gene	NOUN
dpc-2650	97	8	’	'	PUNCT
dpc-2650	97	9	expression	expression	NOUN
dpc-2650	97	10	levels	level	NOUN
dpc-2650	97	11	and	and	CCONJ
dpc-2650	97	12	pasi	pasi	NOUN
dpc-2650	97	13	scores	score	NOUN
dpc-2650	97	14	(	(	PUNCT
dpc-2650	97	15	figures	figure	NOUN
dpc-2650	97	16	3	3	NUM
dpc-2650	97	17	and	and	CCONJ
dpc-2650	97	18	4	4	NUM
dpc-2650	97	19	)	)	PUNCT
dpc-2650	97	20	.	.	PUNCT
dpc-2650	98	1	in	in	ADP
dpc-2650	98	2	addition	addition	NOUN
dpc-2650	98	3	,	,	PUNCT
dpc-2650	98	4	there	there	PRON
dpc-2650	98	5	were	be	VERB
dpc-2650	98	6	no	no	DET
dpc-2650	98	7	correlations	correlation	NOUN
dpc-2650	98	8	between	between	ADP
dpc-2650	98	9	the	the	DET
dpc-2650	98	10	expression	expression	NOUN
dpc-2650	98	11	levels	level	NOUN
dpc-2650	98	12	of	of	ADP
dpc-2650	98	13	the	the	DET
dpc-2650	98	14	genes	gene	NOUN
dpc-2650	98	15	and	and	CCONJ
dpc-2650	98	16	nail	nail	NOUN
dpc-2650	98	17	involvement	involvement	NOUN
dpc-2650	98	18	,	,	PUNCT
dpc-2650	98	19	positive	positive	ADJ
dpc-2650	98	20	family	family	NOUN
dpc-2650	98	21	history	history	NOUN
dpc-2650	98	22	,	,	PUNCT
dpc-2650	98	23	and	and	CCONJ
dpc-2650	98	24	presence	presence	NOUN
dpc-2650	98	25	of	of	ADP
dpc-2650	98	26	arthritis	arthritis	NOUN
dpc-2650	98	27	,	,	PUNCT
dpc-2650	98	28	either	either	ADV
dpc-2650	98	29	.	.	PUNCT
dpc-2650	99	1	conclusions	conclusion	NOUN
dpc-2650	99	2	over	over	ADP
dpc-2650	99	3	the	the	DET
dpc-2650	99	4	years	year	NOUN
dpc-2650	99	5	,	,	PUNCT
dpc-2650	99	6	as	as	ADP
dpc-2650	99	7	our	our	PRON
dpc-2650	99	8	knowledge	knowledge	NOUN
dpc-2650	99	9	of	of	ADP
dpc-2650	99	10	the	the	DET
dpc-2650	99	11	pathogenesis	pathogenesis	NOUN
dpc-2650	99	12	of	of	ADP
dpc-2650	99	13	psoriasis	psoriasis	NOUN
dpc-2650	99	14	has	have	AUX
dpc-2650	99	15	increased	increase	VERB
dpc-2650	99	16	considerably	considerably	ADV
dpc-2650	99	17	,	,	PUNCT
dpc-2650	99	18	we	we	PRON
dpc-2650	99	19	know	know	VERB
dpc-2650	99	20	that	that	SCONJ
dpc-2650	99	21	it	it	PRON
dpc-2650	99	22	includes	include	VERB
dpc-2650	99	23	complex	complex	ADJ
dpc-2650	99	24	,	,	PUNCT
dpc-2650	99	25	multiple	multiple	ADJ
dpc-2650	99	26	factors	factor	NOUN
dpc-2650	99	27	covering	cover	VERB
dpc-2650	99	28	the	the	DET
dpc-2650	99	29	genetic	genetic	ADJ
dpc-2650	99	30	factors	factor	NOUN
dpc-2650	99	31	that	that	PRON
dpc-2650	99	32	only	only	ADV
dpc-2650	99	33	explain	explain	VERB
dpc-2650	99	34	about	about	ADP
dpc-2650	99	35	70	70	NUM
dpc-2650	99	36	%	%	NOUN
dpc-2650	99	37	of	of	ADP
dpc-2650	99	38	disease	disease	NOUN
dpc-2650	99	39	susceptibility	susceptibility	NOUN
dpc-2650	99	40	[	[	X
dpc-2650	99	41	12	12	NUM
dpc-2650	99	42	]	]	PUNCT
dpc-2650	99	43	.	.	PUNCT
dpc-2650	100	1	up	up	ADP
dpc-2650	100	2	to	to	ADP
dpc-2650	100	3	now	now	ADV
dpc-2650	100	4	,	,	PUNCT
dpc-2650	100	5	many	many	ADJ
dpc-2650	100	6	single	single	ADJ
dpc-2650	100	7	nucleotide	nucleotide	ADJ
dpc-2650	100	8	polymorphism	polymorphism	NOUN
dpc-2650	100	9	microarray	microarray	NOUN
dpc-2650	100	10	and	and	CCONJ
dpc-2650	100	11	genome	genome	NOUN
dpc-2650	100	12	-	-	PUNCT
dpc-2650	100	13	wide	wide	ADJ
dpc-2650	100	14	association	association	NOUN
dpc-2650	100	15	studies	study	NOUN
dpc-2650	100	16	have	have	AUX
dpc-2650	100	17	been	be	AUX
dpc-2650	100	18	performed	perform	VERB
dpc-2650	100	19	original	original	ADJ
dpc-2650	100	20	article	article	NOUN
dpc-2650	100	21	|	|	ADV
dpc-2650	100	22	dermatol	dermatol	ADJ
dpc-2650	100	23	pract	pract	NOUN
dpc-2650	100	24	concept	concept	NOUN
dpc-2650	100	25	.	.	PUNCT
dpc-2650	101	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	101	2	5	5	NUM
dpc-2650	101	3	p*=0.038	p*=0.038	NOUN
dpc-2650	101	4	r=0.417	r=0.417	NUM
dpc-2650	101	5	1.00	1.00	NUM
dpc-2650	101	6	2.00	2.00	NUM
dpc-2650	101	7	3.00	3.00	NUM
dpc-2650	101	8	4.00	4.00	NUM
dpc-2650	101	9	.0	.0	NUM
dpc-2650	101	10	10.0	10.0	NUM
dpc-2650	101	11	20.0	20.0	NUM
dpc-2650	101	12	pasi	pasi	NOUN
dpc-2650	101	13	30.0	30.0	NUM
dpc-2650	101	14	40.0	40.0	NUM
dpc-2650	101	15	se	se	X
dpc-2650	101	16	rp	rp	NOUN
dpc-2650	101	17	in	in	ADP
dpc-2650	101	18	b7	b7	PROPN
dpc-2650	101	19	figure	figure	NOUN
dpc-2650	101	20	2	2	NUM
dpc-2650	101	21	.	.	PUNCT
dpc-2650	102	1	the	the	DET
dpc-2650	102	2	correlation	correlation	NOUN
dpc-2650	102	3	graph	graph	NOUN
dpc-2650	102	4	between	between	ADP
dpc-2650	102	5	serpinb7	serpinb7	NOUN
dpc-2650	102	6	gene	gene	NOUN
dpc-2650	102	7	expression	expression	NOUN
dpc-2650	102	8	levels	level	NOUN
dpc-2650	102	9	and	and	CCONJ
dpc-2650	102	10	pasi	pasi	NOUN
dpc-2650	102	11	scores	score	NOUN
dpc-2650	102	12	*	*	PUNCT
dpc-2650	102	13	p	p	X
dpc-2650	102	14	<	<	X
dpc-2650	102	15	0.05	0.05	NUM
dpc-2650	102	16	.	.	PUNCT
dpc-2650	102	17	pasi	pasi	NOUN
dpc-2650	102	18	=	=	SYM
dpc-2650	102	19	psoriasis	psoriasis	NOUN
dpc-2650	102	20	area	area	NOUN
dpc-2650	102	21	and	and	CCONJ
dpc-2650	102	22	severity	severity	NOUN
dpc-2650	102	23	index	index	NOUN
dpc-2650	102	24	;	;	PUNCT
dpc-2650	102	25	serpinb7	serpinb7	NOUN
dpc-2650	102	26	=	=	SYM
dpc-2650	102	27	serpin	serpin	PROPN
dpc-2650	102	28	family	family	PROPN
dpc-2650	102	29	b	b	PROPN
dpc-2650	102	30	member	member	PROPN
dpc-2650	102	31	7	7	NUM
dpc-2650	102	32	.	.	PUNCT
dpc-2650	102	33	pasi	pasi	PROPN
dpc-2650	102	34	p=0.639	p=0.639	PROPN
dpc-2650	102	35	r=0.098	r=0.098	NOUN
dpc-2650	102	36	,	,	PUNCT
dpc-2650	102	37	0	0	NUM
dpc-2650	102	38	10,0	10,0	NUM
dpc-2650	102	39	20,0	20,0	NUM
dpc-2650	102	40	30,0	30,0	NUM
dpc-2650	102	41	40,0	40,0	NOUN
dpc-2650	102	42	pt	pt	X
dpc-2650	102	43	pn	pn	NOUN
dpc-2650	102	44	1	1	NUM
dpc-2650	102	45	,	,	PUNCT
dpc-2650	102	46	00	00	NUM
dpc-2650	102	47	12,00	12,00	NUM
dpc-2650	102	48	10,00	10,00	NUM
dpc-2650	102	49	8,00	8,00	NUM
dpc-2650	102	50	6,00	6,00	NUM
dpc-2650	102	51	4,00	4,00	NUM
dpc-2650	102	52	2,00	2,00	NUM
dpc-2650	102	53	figure	figure	NOUN
dpc-2650	102	54	3	3	NUM
dpc-2650	102	55	.	.	PUNCT
dpc-2650	103	1	the	the	DET
dpc-2650	103	2	correlation	correlation	NOUN
dpc-2650	103	3	graph	graph	NOUN
dpc-2650	103	4	between	between	ADP
dpc-2650	103	5	ptpn1	ptpn1	NOUN
dpc-2650	103	6	gene	gene	NOUN
dpc-2650	103	7	expression	expression	NOUN
dpc-2650	103	8	levels	level	NOUN
dpc-2650	103	9	and	and	CCONJ
dpc-2650	103	10	pasi	pasi	NOUN
dpc-2650	103	11	scores	score	NOUN
dpc-2650	103	12	(	(	PUNCT
dpc-2650	103	13	spearman	spearman	NOUN
dpc-2650	103	14	correlation	correlation	NOUN
dpc-2650	103	15	)	)	PUNCT
dpc-2650	103	16	.	.	PUNCT
dpc-2650	104	1	pasi	pasi	NOUN
dpc-2650	104	2	=	=	SYM
dpc-2650	104	3	psoriasis	psoriasis	NOUN
dpc-2650	104	4	area	area	NOUN
dpc-2650	104	5	and	and	CCONJ
dpc-2650	104	6	severity	severity	NOUN
dpc-2650	104	7	index	index	NOUN
dpc-2650	104	8	;	;	PUNCT
dpc-2650	104	9	ptpn1	ptpn1	NOUN
dpc-2650	104	10	=	=	SYM
dpc-2650	104	11	tyrosine	tyrosine	NOUN
dpc-2650	104	12	-	-	PUNCT
dpc-2650	104	13	protein	protein	NOUN
dpc-2650	104	14	phosphatase	phosphatase	NOUN
dpc-2650	104	15	non	non	ADJ
dpc-2650	104	16	-	-	ADJ
dpc-2650	104	17	receptor	receptor	ADJ
dpc-2650	104	18	type	type	NOUN
dpc-2650	104	19	1	1	NUM
dpc-2650	104	20	.	.	PUNCT
dpc-2650	105	1	[	[	X
dpc-2650	105	2	13	13	NUM
dpc-2650	105	3	-	-	SYM
dpc-2650	105	4	15	15	NUM
dpc-2650	105	5	]	]	PUNCT
dpc-2650	105	6	.	.	PUNCT
dpc-2650	106	1	however	however	ADV
dpc-2650	106	2	,	,	PUNCT
dpc-2650	106	3	there	there	PRON
dpc-2650	106	4	is	be	VERB
dpc-2650	106	5	still	still	ADV
dpc-2650	106	6	a	a	DET
dpc-2650	106	7	gap	gap	NOUN
dpc-2650	106	8	between	between	ADP
dpc-2650	106	9	genetic	genetic	ADJ
dpc-2650	106	10	basis	basis	NOUN
dpc-2650	106	11	and	and	CCONJ
dpc-2650	106	12	environmental	environmental	ADJ
dpc-2650	106	13	triggers	trigger	NOUN
dpc-2650	106	14	in	in	ADP
dpc-2650	106	15	pathogenesis	pathogenesis	NOUN
dpc-2650	106	16	.	.	PUNCT
dpc-2650	107	1	there	there	PRON
dpc-2650	107	2	have	have	AUX
dpc-2650	107	3	been	be	AUX
dpc-2650	107	4	many	many	ADJ
dpc-2650	107	5	identified	identify	VERB
dpc-2650	107	6	potential	potential	ADJ
dpc-2650	107	7	susceptibility	susceptibility	NOUN
dpc-2650	107	8	genes	gene	NOUN
dpc-2650	107	9	for	for	ADP
dpc-2650	107	10	psoriasis	psoriasis	NOUN
dpc-2650	107	11	,	,	PUNCT
dpc-2650	107	12	and	and	CCONJ
dpc-2650	107	13	this	this	DET
dpc-2650	107	14	discovery	discovery	NOUN
dpc-2650	107	15	has	have	AUX
dpc-2650	107	16	been	be	AUX
dpc-2650	107	17	continued	continue	VERB
dpc-2650	107	18	[	[	PUNCT
dpc-2650	107	19	8,13	8,13	NUM
dpc-2650	107	20	-	-	SYM
dpc-2650	107	21	15	15	NUM
dpc-2650	107	22	]	]	PUNCT
dpc-2650	107	23	.	.	PUNCT
dpc-2650	108	1	shirakata	shirakata	PROPN
dpc-2650	108	2	et	et	PROPN
dpc-2650	108	3	al	al	PROPN
dpc-2650	108	4	compared	compare	VERB
dpc-2650	108	5	ereg	ereg	VERB
dpc-2650	108	6	gene	gene	NOUN
dpc-2650	108	7	expressions	expression	NOUN
dpc-2650	108	8	of	of	ADP
dpc-2650	108	9	12	12	NUM
dpc-2650	108	10	psoriatic	psoriatic	ADJ
dpc-2650	108	11	skin	skin	NOUN
dpc-2650	108	12	samples	sample	NOUN
dpc-2650	108	13	and	and	CCONJ
dpc-2650	108	14	10	10	NUM
dpc-2650	108	15	healthy	healthy	ADJ
dpc-2650	108	16	skin	skin	NOUN
dpc-2650	108	17	samples	sample	NOUN
dpc-2650	108	18	[	[	X
dpc-2650	108	19	2	2	NUM
dpc-2650	108	20	]	]	PUNCT
dpc-2650	108	21	.	.	PUNCT
dpc-2650	109	1	they	they	PRON
dpc-2650	109	2	observed	observe	VERB
dpc-2650	109	3	that	that	SCONJ
dpc-2650	109	4	ereg	ereg	PROPN
dpc-2650	109	5	mrna	mrna	PROPN
dpc-2650	109	6	was	be	AUX
dpc-2650	109	7	expressed	express	VERB
dpc-2650	109	8	very	very	ADV
dpc-2650	109	9	faintly	faintly	ADV
dpc-2650	109	10	in	in	ADP
dpc-2650	109	11	the	the	DET
dpc-2650	109	12	basal	basal	ADJ
dpc-2650	109	13	layer	layer	NOUN
dpc-2650	109	14	of	of	ADP
dpc-2650	109	15	the	the	DET
dpc-2650	109	16	epidermis	epidermis	NOUN
dpc-2650	109	17	of	of	ADP
dpc-2650	109	18	normal	normal	ADJ
dpc-2650	109	19	control	control	NOUN
dpc-2650	109	20	skin	skin	NOUN
dpc-2650	109	21	,	,	PUNCT
dpc-2650	109	22	whereas	whereas	SCONJ
dpc-2650	109	23	it	it	PRON
dpc-2650	109	24	was	be	AUX
dpc-2650	109	25	overexpressed	overexpresse	VERB
dpc-2650	109	26	in	in	ADP
dpc-2650	109	27	the	the	DET
dpc-2650	109	28	spinous	spinous	ADJ
dpc-2650	109	29	layer	layer	NOUN
dpc-2650	109	30	of	of	ADP
dpc-2650	109	31	the	the	DET
dpc-2650	109	32	epidermis	epidermis	NOUN
dpc-2650	109	33	of	of	ADP
dpc-2650	109	34	the	the	DET
dpc-2650	109	35	psoriatic	psoriatic	ADJ
dpc-2650	109	36	skin	skin	NOUN
dpc-2650	109	37	.	.	PUNCT
dpc-2650	110	1	thus	thus	ADV
dpc-2650	110	2	,	,	PUNCT
dpc-2650	110	3	they	they	PRON
dpc-2650	110	4	reported	report	VERB
dpc-2650	110	5	ereg	ereg	NOUN
dpc-2650	110	6	might	might	AUX
dpc-2650	110	7	lead	lead	VERB
dpc-2650	110	8	hyperproliferation	hyperproliferation	NOUN
dpc-2650	110	9	of	of	ADP
dpc-2650	110	10	epidermis	epidermis	NOUN
dpc-2650	110	11	via	via	ADP
dpc-2650	110	12	possible	possible	ADJ
dpc-2650	110	13	intracellular	intracellular	ADJ
dpc-2650	110	14	signaling	signal	VERB
dpc-2650	110	15	systems	system	NOUN
dpc-2650	110	16	such	such	ADJ
dpc-2650	110	17	as	as	ADP
dpc-2650	110	18	stat3	stat3	NOUN
dpc-2650	110	19	and	and	CCONJ
dpc-2650	110	20	may	may	AUX
dpc-2650	110	21	have	have	VERB
dpc-2650	110	22	essential	essential	ADJ
dpc-2650	110	23	for	for	ADP
dpc-2650	110	24	the	the	DET
dpc-2650	110	25	development	development	NOUN
dpc-2650	110	26	of	of	ADP
dpc-2650	110	27	psoriasis	psoriasis	NOUN
dpc-2650	110	28	-	-	PUNCT
dpc-2650	110	29	like	like	ADJ
dpc-2650	110	30	phenotype	phenotype	NOUN
dpc-2650	110	31	.	.	PUNCT
dpc-2650	111	1	in	in	ADP
dpc-2650	111	2	the	the	DET
dpc-2650	111	3	same	same	ADJ
dpc-2650	111	4	way	way	NOUN
dpc-2650	111	5	,	,	PUNCT
dpc-2650	111	6	iwata	iwata	PROPN
dpc-2650	111	7	et	et	PROPN
dpc-2650	111	8	al	al	PROPN
dpc-2650	111	9	reported	report	VERB
dpc-2650	111	10	that	that	SCONJ
dpc-2650	111	11	the	the	DET
dpc-2650	111	12	expression	expression	NOUN
dpc-2650	111	13	of	of	ADP
dpc-2650	111	14	ereg	ereg	NOUN
dpc-2650	111	15	in	in	ADP
dpc-2650	111	16	dermal	dermal	ADJ
dpc-2650	111	17	fibroblasts	fibroblast	NOUN
dpc-2650	111	18	was	be	AUX
dpc-2650	111	19	significantly	significantly	ADV
dpc-2650	111	20	upregulated	upregulate	VERB
dpc-2650	111	21	approximately	approximately	ADV
dpc-2650	111	22	50	50	NUM
dpc-2650	111	23	times	time	NOUN
dpc-2650	111	24	fold	fold	VERB
dpc-2650	111	25	by	by	ADP
dpc-2650	111	26	co	co	NOUN
dpc-2650	111	27	-	-	NOUN
dpc-2650	111	28	stimulation	stimulation	NOUN
dpc-2650	111	29	with	with	ADP
dpc-2650	111	30	il-17a	il-17a	PROPN
dpc-2650	111	31	and	and	CCONJ
dpc-2650	111	32	tnf	tnf	PROPN
dpc-2650	111	33	-	-	PUNCT
dpc-2650	111	34	α	α	PROPN
dpc-2650	111	35	,	,	PUNCT
dpc-2650	111	36	and	and	CCONJ
dpc-2650	111	37	6	6	NUM
dpc-2650	111	38	original	original	ADJ
dpc-2650	111	39	article	article	NOUN
dpc-2650	111	40	|	|	ADV
dpc-2650	111	41	dermatol	dermatol	ADJ
dpc-2650	111	42	pract	pract	NOUN
dpc-2650	111	43	concept	concept	NOUN
dpc-2650	111	44	.	.	PUNCT
dpc-2650	112	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	112	2	which	which	PRON
dpc-2650	112	3	is	be	AUX
dpc-2650	112	4	an	an	DET
dpc-2650	112	5	inhibitor	inhibitor	NOUN
dpc-2650	112	6	of	of	ADP
dpc-2650	112	7	insulin	insulin	NOUN
dpc-2650	112	8	signaling	signal	VERB
dpc-2650	112	9	pathway	pathway	NOUN
dpc-2650	112	10	in	in	ADP
dpc-2650	112	11	many	many	ADJ
dpc-2650	112	12	studies	study	NOUN
dpc-2650	112	13	[	[	X
dpc-2650	112	14	6,21	6,21	NUM
dpc-2650	112	15	-	-	SYM
dpc-2650	112	16	23	23	NUM
dpc-2650	112	17	]	]	PUNCT
dpc-2650	112	18	.	.	PUNCT
dpc-2650	113	1	in	in	ADP
dpc-2650	113	2	chronic	chronic	ADJ
dpc-2650	113	3	inflammatory	inflammatory	ADJ
dpc-2650	113	4	situations	situation	NOUN
dpc-2650	113	5	such	such	ADJ
dpc-2650	113	6	as	as	ADP
dpc-2650	113	7	psoriasis	psoriasis	NOUN
dpc-2650	113	8	,	,	PUNCT
dpc-2650	113	9	it	it	PRON
dpc-2650	113	10	was	be	AUX
dpc-2650	113	11	demonstrated	demonstrate	VERB
dpc-2650	113	12	that	that	SCONJ
dpc-2650	113	13	high	high	ADJ
dpc-2650	113	14	levels	level	NOUN
dpc-2650	113	15	of	of	ADP
dpc-2650	113	16	proinflammatory	proinflammatory	ADJ
dpc-2650	113	17	cytokines	cytokine	NOUN
dpc-2650	113	18	activate	activate	VERB
dpc-2650	113	19	p38mapk	p38mapk	NOUN
dpc-2650	113	20	,	,	PUNCT
dpc-2650	113	21	which	which	PRON
dpc-2650	113	22	induces	induce	VERB
dpc-2650	113	23	insulin	insulin	NOUN
dpc-2650	113	24	receptors	receptor	NOUN
dpc-2650	113	25	,	,	PUNCT
dpc-2650	113	26	and	and	CCONJ
dpc-2650	113	27	leads	lead	VERB
dpc-2650	113	28	to	to	ADP
dpc-2650	113	29	blockade	blockade	NOUN
dpc-2650	113	30	of	of	ADP
dpc-2650	113	31	differentiation	differentiation	NOUN
dpc-2650	113	32	and	and	CCONJ
dpc-2650	113	33	hyperproliferation	hyperproliferation	NOUN
dpc-2650	113	34	of	of	ADP
dpc-2650	113	35	basal	basal	ADJ
dpc-2650	113	36	keratinocytes	keratinocyte	NOUN
dpc-2650	113	37	.	.	PUNCT
dpc-2650	114	1	in	in	ADP
dpc-2650	114	2	addition	addition	NOUN
dpc-2650	114	3	,	,	PUNCT
dpc-2650	114	4	as	as	ADP
dpc-2650	114	5	a	a	DET
dpc-2650	114	6	result	result	NOUN
dpc-2650	114	7	of	of	ADP
dpc-2650	114	8	the	the	DET
dpc-2650	114	9	insulin	insulin	NOUN
dpc-2650	114	10	receptor	receptor	NOUN
dpc-2650	114	11	induction	induction	NOUN
dpc-2650	114	12	,	,	PUNCT
dpc-2650	114	13	much	much	ADV
dpc-2650	114	14	more	more	ADJ
dpc-2650	114	15	insulin	insulin	NOUN
dpc-2650	114	16	was	be	AUX
dpc-2650	114	17	produced	produce	VERB
dpc-2650	114	18	than	than	ADP
dpc-2650	114	19	normal	normal	ADJ
dpc-2650	114	20	.	.	PUNCT
dpc-2650	115	1	this	this	DET
dpc-2650	115	2	condition	condition	NOUN
dpc-2650	115	3	,	,	PUNCT
dpc-2650	115	4	called	call	VERB
dpc-2650	115	5	hyperinsulinemia	hyperinsulinemia	NOUN
dpc-2650	115	6	,	,	PUNCT
dpc-2650	115	7	accelerates	accelerate	VERB
dpc-2650	115	8	lipogenesis	lipogenesis	NOUN
dpc-2650	115	9	with	with	ADP
dpc-2650	115	10	increased	increase	VERB
dpc-2650	115	11	production	production	NOUN
dpc-2650	115	12	of	of	ADP
dpc-2650	115	13	free	free	ADJ
dpc-2650	115	14	fatty	fatty	NOUN
dpc-2650	115	15	acids	acid	NOUN
dpc-2650	115	16	,	,	PUNCT
dpc-2650	115	17	though	though	SCONJ
dpc-2650	115	18	[	[	X
dpc-2650	115	19	24	24	NUM
dpc-2650	115	20	]	]	PUNCT
dpc-2650	115	21	.	.	PUNCT
dpc-2650	116	1	we	we	PRON
dpc-2650	116	2	know	know	VERB
dpc-2650	116	3	that	that	SCONJ
dpc-2650	116	4	psoriatic	psoriatic	ADJ
dpc-2650	116	5	patients	patient	NOUN
dpc-2650	116	6	have	have	VERB
dpc-2650	116	7	a	a	DET
dpc-2650	116	8	higher	high	ADJ
dpc-2650	116	9	risk	risk	NOUN
dpc-2650	116	10	of	of	ADP
dpc-2650	116	11	having	have	VERB
dpc-2650	116	12	type	type	NOUN
dpc-2650	116	13	2	2	NUM
dpc-2650	116	14	dm	dm	NOUN
dpc-2650	116	15	compared	compare	VERB
dpc-2650	116	16	to	to	ADP
dpc-2650	116	17	controls	control	NOUN
dpc-2650	116	18	[	[	X
dpc-2650	116	19	25	25	NUM
dpc-2650	116	20	]	]	PUNCT
dpc-2650	116	21	.	.	PUNCT
dpc-2650	117	1	in	in	ADP
dpc-2650	117	2	addition	addition	NOUN
dpc-2650	117	3	,	,	PUNCT
dpc-2650	117	4	as	as	SCONJ
dpc-2650	117	5	mentioned	mention	VERB
dpc-2650	117	6	before	before	ADV
dpc-2650	117	7	,	,	PUNCT
dpc-2650	117	8	the	the	DET
dpc-2650	117	9	regulatory	regulatory	ADJ
dpc-2650	117	10	effect	effect	NOUN
dpc-2650	117	11	of	of	ADP
dpc-2650	117	12	ptpn1	ptpn1	NOUN
dpc-2650	117	13	on	on	ADP
dpc-2650	117	14	munc18c	munc18c	NOUN
dpc-2650	117	15	protein	protein	NOUN
dpc-2650	117	16	affects	affect	VERB
dpc-2650	117	17	adipocytes	adipocyte	NOUN
dpc-2650	117	18	which	which	PRON
dpc-2650	117	19	are	be	AUX
dpc-2650	117	20	also	also	ADV
dpc-2650	117	21	attendant	attendant	ADJ
dpc-2650	117	22	cells	cell	NOUN
dpc-2650	117	23	to	to	ADP
dpc-2650	117	24	the	the	DET
dpc-2650	117	25	psoriasis	psoriasis	NOUN
dpc-2650	117	26	pathogenesis	pathogenesis	NOUN
dpc-2650	117	27	[	[	X
dpc-2650	117	28	24	24	NUM
dpc-2650	117	29	]	]	PUNCT
dpc-2650	117	30	.	.	PUNCT
dpc-2650	118	1	in	in	ADP
dpc-2650	118	2	our	our	PRON
dpc-2650	118	3	study	study	NOUN
dpc-2650	118	4	we	we	PRON
dpc-2650	118	5	excluded	exclude	VERB
dpc-2650	118	6	the	the	DET
dpc-2650	118	7	psoriatic	psoriatic	ADJ
dpc-2650	118	8	patients	patient	NOUN
dpc-2650	118	9	who	who	PRON
dpc-2650	118	10	also	also	ADV
dpc-2650	118	11	have	have	VERB
dpc-2650	118	12	systemic	systemic	ADJ
dpc-2650	118	13	inflammatory	inflammatory	ADJ
dpc-2650	118	14	diseases	disease	NOUN
dpc-2650	118	15	or	or	CCONJ
dpc-2650	118	16	conditions	condition	NOUN
dpc-2650	118	17	such	such	ADJ
dpc-2650	118	18	as	as	ADP
dpc-2650	118	19	dm	dm	PROPN
dpc-2650	118	20	and	and	CCONJ
dpc-2650	118	21	hyperlipidemia	hyperlipidemia	NOUN
dpc-2650	118	22	,	,	PUNCT
dpc-2650	118	23	thus	thus	ADV
dpc-2650	118	24	we	we	PRON
dpc-2650	118	25	did	do	AUX
dpc-2650	118	26	not	not	PART
dpc-2650	118	27	evaluate	evaluate	VERB
dpc-2650	118	28	the	the	DET
dpc-2650	118	29	association	association	NOUN
dpc-2650	118	30	of	of	ADP
dpc-2650	118	31	psoriasis	psoriasis	NOUN
dpc-2650	118	32	and	and	CCONJ
dpc-2650	118	33	them	they	PRON
dpc-2650	118	34	at	at	ADV
dpc-2650	118	35	all	all	ADV
dpc-2650	118	36	.	.	PUNCT
dpc-2650	119	1	however	however	ADV
dpc-2650	119	2	,	,	PUNCT
dpc-2650	119	3	since	since	SCONJ
dpc-2650	119	4	the	the	DET
dpc-2650	119	5	expression	expression	NOUN
dpc-2650	119	6	of	of	ADP
dpc-2650	119	7	the	the	DET
dpc-2650	119	8	ptpn1	ptpn1	NOUN
dpc-2650	119	9	gene	gene	NOUN
dpc-2650	119	10	was	be	AUX
dpc-2650	119	11	observed	observe	VERB
dpc-2650	119	12	significantly	significantly	ADV
dpc-2650	119	13	upregulated	upregulate	VERB
dpc-2650	119	14	in	in	ADP
dpc-2650	119	15	the	the	DET
dpc-2650	119	16	lesional	lesional	ADJ
dpc-2650	119	17	skin	skin	NOUN
dpc-2650	119	18	of	of	ADP
dpc-2650	119	19	patients	patient	NOUN
dpc-2650	119	20	compared	compare	VERB
dpc-2650	119	21	to	to	ADP
dpc-2650	119	22	normal	normal	ADJ
dpc-2650	119	23	skin	skin	NOUN
dpc-2650	119	24	of	of	ADP
dpc-2650	119	25	controls	control	NOUN
dpc-2650	119	26	,	,	PUNCT
dpc-2650	119	27	there	there	PRON
dpc-2650	119	28	could	could	AUX
dpc-2650	119	29	be	be	AUX
dpc-2650	119	30	an	an	DET
dpc-2650	119	31	underlying	underlying	ADJ
dpc-2650	119	32	undiagnosed	undiagnosed	ADJ
dpc-2650	119	33	insulin	insulin	NOUN
dpc-2650	119	34	resistance	resistance	NOUN
dpc-2650	119	35	or	or	CCONJ
dpc-2650	119	36	glucose	glucose	NOUN
dpc-2650	119	37	intolerance	intolerance	NOUN
dpc-2650	119	38	conditions	condition	NOUN
dpc-2650	119	39	or	or	CCONJ
dpc-2650	119	40	altered	alter	VERB
dpc-2650	119	41	lipid	lipid	NOUN
dpc-2650	119	42	metabolism	metabolism	NOUN
dpc-2650	119	43	pathways	pathway	NOUN
dpc-2650	119	44	in	in	ADP
dpc-2650	119	45	our	our	PRON
dpc-2650	119	46	patient	patient	NOUN
dpc-2650	119	47	group	group	NOUN
dpc-2650	119	48	enrolled	enrol	VERB
dpc-2650	119	49	in	in	ADP
dpc-2650	119	50	the	the	DET
dpc-2650	119	51	study	study	NOUN
dpc-2650	119	52	.	.	PUNCT
dpc-2650	120	1	besides	besides	SCONJ
dpc-2650	120	2	these	these	PRON
dpc-2650	120	3	,	,	PUNCT
dpc-2650	120	4	yin	yin	PROPN
dpc-2650	120	5	et	et	PROPN
dpc-2650	120	6	al	al	PROPN
dpc-2650	120	7	evaluated	evaluate	VERB
dpc-2650	120	8	the	the	DET
dpc-2650	120	9	common	common	ADJ
dpc-2650	120	10	genetic	genetic	ADJ
dpc-2650	120	11	factors	factor	NOUN
dpc-2650	120	12	shared	share	VERB
dpc-2650	120	13	between	between	ADP
dpc-2650	120	14	psoriasis	psoriasis	NOUN
dpc-2650	120	15	and	and	CCONJ
dpc-2650	120	16	schizophrenia	schizophrenia	NOUN
dpc-2650	120	17	.	.	PUNCT
dpc-2650	121	1	even	even	ADV
dpc-2650	121	2	though	though	SCONJ
dpc-2650	121	3	they	they	PRON
dpc-2650	121	4	reported	report	VERB
dpc-2650	121	5	that	that	SCONJ
dpc-2650	121	6	any	any	DET
dpc-2650	121	7	common	common	ADJ
dpc-2650	121	8	variant	variant	NOUN
dpc-2650	121	9	was	be	AUX
dpc-2650	121	10	not	not	PART
dpc-2650	121	11	found	find	VERB
dpc-2650	121	12	between	between	ADP
dpc-2650	121	13	two	two	NUM
dpc-2650	121	14	diseases	disease	NOUN
dpc-2650	121	15	,	,	PUNCT
dpc-2650	121	16	they	they	PRON
dpc-2650	121	17	claimed	claim	VERB
dpc-2650	121	18	that	that	SCONJ
dpc-2650	121	19	ptpn1	ptpn1	NOUN
dpc-2650	121	20	gene	gene	NOUN
dpc-2650	121	21	may	may	AUX
dpc-2650	121	22	be	be	AUX
dpc-2650	121	23	a	a	DET
dpc-2650	121	24	novel	novel	NOUN
dpc-2650	121	25	-	-	PUNCT
dpc-2650	121	26	susceptible	susceptible	ADJ
dpc-2650	121	27	gene	gene	NOUN
dpc-2650	121	28	for	for	ADP
dpc-2650	121	29	psoriasis	psoriasis	NOUN
dpc-2650	121	30	which	which	PRON
dpc-2650	121	31	interacts	interact	VERB
dpc-2650	121	32	with	with	ADP
dpc-2650	121	33	well	well	ADV
dpc-2650	121	34	-	-	PUNCT
dpc-2650	121	35	known	know	VERB
dpc-2650	121	36	susceptible	susceptible	ADJ
dpc-2650	121	37	genes	gene	NOUN
dpc-2650	121	38	for	for	ADP
dpc-2650	121	39	psoriasis	psoriasis	NOUN
dpc-2650	121	40	such	such	ADJ
dpc-2650	121	41	as	as	ADP
dpc-2650	121	42	nfkba	nfkba	PROPN
dpc-2650	121	43	,	,	PUNCT
dpc-2650	121	44	stat3	stat3	NOUN
dpc-2650	121	45	,	,	PUNCT
dpc-2650	121	46	and	and	CCONJ
dpc-2650	121	47	tyk2	tyk2	VERB
dpc-2650	121	48	genes	gene	NOUN
dpc-2650	121	49	[	[	X
dpc-2650	121	50	7	7	NUM
dpc-2650	121	51	]	]	PUNCT
dpc-2650	121	52	.	.	PUNCT
dpc-2650	122	1	similarly	similarly	ADV
dpc-2650	122	2	,	,	PUNCT
dpc-2650	122	3	we	we	PRON
dpc-2650	122	4	showed	show	VERB
dpc-2650	122	5	this	this	DET
dpc-2650	122	6	upregulation	upregulation	NOUN
dpc-2650	122	7	of	of	ADP
dpc-2650	122	8	ereg	ereg	NOUN
dpc-2650	122	9	leads	lead	VERB
dpc-2650	122	10	to	to	ADP
dpc-2650	122	11	keratinocyte	keratinocyte	NOUN
dpc-2650	122	12	proliferation	proliferation	NOUN
dpc-2650	122	13	in	in	ADP
dpc-2650	122	14	vitro	vitro	X
dpc-2650	123	1	[	[	X
dpc-2650	123	2	16	16	NUM
dpc-2650	123	3	]	]	PUNCT
dpc-2650	123	4	.	.	PUNCT
dpc-2650	124	1	thus	thus	ADV
dpc-2650	124	2	,	,	PUNCT
dpc-2650	124	3	both	both	DET
dpc-2650	124	4	study	study	NOUN
dpc-2650	124	5	showed	show	VERB
dpc-2650	124	6	that	that	SCONJ
dpc-2650	124	7	ereg	ereg	NOUN
dpc-2650	124	8	is	be	AUX
dpc-2650	124	9	a	a	DET
dpc-2650	124	10	vital	vital	ADJ
dpc-2650	124	11	stimulator	stimulator	NOUN
dpc-2650	124	12	of	of	ADP
dpc-2650	124	13	keratinocyte	keratinocyte	NOUN
dpc-2650	124	14	proliferation	proliferation	NOUN
dpc-2650	124	15	which	which	PRON
dpc-2650	124	16	is	be	AUX
dpc-2650	124	17	crucial	crucial	ADJ
dpc-2650	124	18	feature	feature	NOUN
dpc-2650	124	19	of	of	ADP
dpc-2650	124	20	immunopathogenesis	immunopathogenesis	NOUN
dpc-2650	124	21	of	of	ADP
dpc-2650	124	22	psoriasis	psoriasis	NOUN
dpc-2650	124	23	as	as	ADV
dpc-2650	124	24	well	well	ADV
dpc-2650	124	25	.	.	PUNCT
dpc-2650	125	1	although	although	SCONJ
dpc-2650	125	2	we	we	PRON
dpc-2650	125	3	could	could	AUX
dpc-2650	125	4	not	not	PART
dpc-2650	125	5	show	show	VERB
dpc-2650	125	6	expression	expression	NOUN
dpc-2650	125	7	levels	level	NOUN
dpc-2650	125	8	of	of	ADP
dpc-2650	125	9	the	the	DET
dpc-2650	125	10	ereg	ereg	NOUN
dpc-2650	125	11	gene	gene	NOUN
dpc-2650	125	12	according	accord	VERB
dpc-2650	125	13	to	to	ADP
dpc-2650	125	14	the	the	DET
dpc-2650	125	15	layers	layer	NOUN
dpc-2650	125	16	of	of	ADP
dpc-2650	125	17	the	the	DET
dpc-2650	125	18	skin	skin	NOUN
dpc-2650	125	19	,	,	PUNCT
dpc-2650	125	20	since	since	SCONJ
dpc-2650	125	21	it	it	PRON
dpc-2650	125	22	is	be	AUX
dpc-2650	125	23	known	know	VERB
dpc-2650	125	24	histopathologically	histopathologically	ADV
dpc-2650	125	25	that	that	SCONJ
dpc-2650	125	26	the	the	DET
dpc-2650	125	27	spinous	spinous	ADJ
dpc-2650	125	28	layer	layer	NOUN
dpc-2650	125	29	is	be	AUX
dpc-2650	125	30	hyperproliferated	hyperproliferate	VERB
dpc-2650	125	31	in	in	ADP
dpc-2650	125	32	psoriasis	psoriasis	NOUN
dpc-2650	125	33	[	[	X
dpc-2650	125	34	17	17	NUM
dpc-2650	125	35	]	]	PUNCT
dpc-2650	125	36	,	,	PUNCT
dpc-2650	125	37	it	it	PRON
dpc-2650	125	38	might	might	AUX
dpc-2650	125	39	be	be	AUX
dpc-2650	125	40	thought	think	VERB
dpc-2650	125	41	that	that	SCONJ
dpc-2650	125	42	overexpression	overexpression	NOUN
dpc-2650	125	43	of	of	ADP
dpc-2650	125	44	ereg	ereg	NOUN
dpc-2650	125	45	gene	gene	NOUN
dpc-2650	125	46	seems	seem	VERB
dpc-2650	125	47	to	to	PART
dpc-2650	125	48	be	be	AUX
dpc-2650	125	49	related	relate	VERB
dpc-2650	125	50	to	to	ADP
dpc-2650	125	51	this	this	DET
dpc-2650	125	52	change	change	NOUN
dpc-2650	125	53	.	.	PUNCT
dpc-2650	126	1	our	our	PRON
dpc-2650	126	2	study	study	NOUN
dpc-2650	126	3	supports	support	VERB
dpc-2650	126	4	these	these	DET
dpc-2650	126	5	notions	notion	NOUN
dpc-2650	126	6	about	about	ADP
dpc-2650	126	7	ereg	ereg	NOUN
dpc-2650	126	8	gene	gene	NOUN
dpc-2650	126	9	with	with	ADP
dpc-2650	126	10	the	the	DET
dpc-2650	126	11	result	result	NOUN
dpc-2650	126	12	of	of	ADP
dpc-2650	126	13	overexpressed	overexpressed	ADJ
dpc-2650	126	14	ereg	ereg	NOUN
dpc-2650	126	15	gene	gene	NOUN
dpc-2650	126	16	in	in	ADP
dpc-2650	126	17	the	the	DET
dpc-2650	126	18	lesional	lesional	ADJ
dpc-2650	126	19	skin	skin	NOUN
dpc-2650	126	20	of	of	ADP
dpc-2650	126	21	psoriatic	psoriatic	ADJ
dpc-2650	126	22	patients	patient	NOUN
dpc-2650	126	23	.	.	PUNCT
dpc-2650	127	1	furthermore	furthermore	ADV
dpc-2650	127	2	,	,	PUNCT
dpc-2650	127	3	the	the	DET
dpc-2650	127	4	non	non	ADJ
dpc-2650	127	5	-	-	ADJ
dpc-2650	127	6	lesional	lesional	ADJ
dpc-2650	127	7	skin	skin	NOUN
dpc-2650	127	8	of	of	ADP
dpc-2650	127	9	patients	patient	NOUN
dpc-2650	127	10	with	with	ADP
dpc-2650	127	11	psoriasis	psoriasis	NOUN
dpc-2650	127	12	has	have	VERB
dpc-2650	127	13	significantly	significantly	ADV
dpc-2650	127	14	down	down	ADV
dpc-2650	127	15	-	-	PUNCT
dpc-2650	127	16	regulated	regulate	VERB
dpc-2650	127	17	expression	expression	NOUN
dpc-2650	127	18	of	of	ADP
dpc-2650	127	19	the	the	DET
dpc-2650	127	20	ereg	ereg	NOUN
dpc-2650	127	21	gene	gene	NOUN
dpc-2650	127	22	than	than	ADP
dpc-2650	127	23	the	the	DET
dpc-2650	127	24	healthy	healthy	ADJ
dpc-2650	127	25	skin	skin	NOUN
dpc-2650	127	26	of	of	ADP
dpc-2650	127	27	controls	control	NOUN
dpc-2650	127	28	,	,	PUNCT
dpc-2650	127	29	which	which	PRON
dpc-2650	127	30	may	may	AUX
dpc-2650	127	31	be	be	AUX
dpc-2650	127	32	caused	cause	VERB
dpc-2650	127	33	by	by	ADP
dpc-2650	127	34	the	the	DET
dpc-2650	127	35	migration	migration	NOUN
dpc-2650	127	36	of	of	ADP
dpc-2650	127	37	immune	immune	ADJ
dpc-2650	127	38	cells	cell	NOUN
dpc-2650	127	39	including	include	VERB
dpc-2650	127	40	fibroblasts	fibroblast	NOUN
dpc-2650	127	41	to	to	ADP
dpc-2650	127	42	the	the	DET
dpc-2650	127	43	inflammation	inflammation	ADJ
dpc-2650	127	44	regions	region	NOUN
dpc-2650	127	45	in	in	ADP
dpc-2650	127	46	the	the	DET
dpc-2650	127	47	psoriatic	psoriatic	ADJ
dpc-2650	127	48	patients	patient	NOUN
dpc-2650	127	49	.	.	PUNCT
dpc-2650	128	1	in	in	ADP
dpc-2650	128	2	2004	2004	NUM
dpc-2650	128	3	,	,	PUNCT
dpc-2650	128	4	shirasawa	shirasawa	PROPN
dpc-2650	128	5	et	et	PROPN
dpc-2650	128	6	al	al	PROPN
dpc-2650	128	7	showed	show	VERB
dpc-2650	128	8	that	that	SCONJ
dpc-2650	128	9	ereg	ereg	NOUN
dpc-2650	128	10	is	be	AUX
dpc-2650	128	11	expressed	express	VERB
dpc-2650	128	12	not	not	PART
dpc-2650	128	13	only	only	ADV
dpc-2650	128	14	in	in	ADP
dpc-2650	128	15	keratinocytes	keratinocyte	NOUN
dpc-2650	128	16	but	but	CCONJ
dpc-2650	128	17	also	also	ADV
dpc-2650	128	18	in	in	ADP
dpc-2650	128	19	tissue	tissue	NOUN
dpc-2650	128	20	-	-	PUNCT
dpc-2650	128	21	resident	resident	NOUN
dpc-2650	128	22	macrophages	macrophage	NOUN
dpc-2650	128	23	which	which	PRON
dpc-2650	128	24	are	be	AUX
dpc-2650	128	25	important	important	ADJ
dpc-2650	128	26	cells	cell	NOUN
dpc-2650	128	27	for	for	ADP
dpc-2650	128	28	the	the	DET
dpc-2650	128	29	immune	immune	ADJ
dpc-2650	128	30	balance	balance	NOUN
dpc-2650	128	31	in	in	ADP
dpc-2650	128	32	the	the	DET
dpc-2650	128	33	skin	skin	NOUN
dpc-2650	128	34	.	.	PUNCT
dpc-2650	129	1	they	they	PRON
dpc-2650	129	2	claimed	claim	VERB
dpc-2650	129	3	that	that	SCONJ
dpc-2650	129	4	ereg	ereg	NOUN
dpc-2650	129	5	is	be	AUX
dpc-2650	129	6	physiologically	physiologically	ADV
dpc-2650	129	7	a	a	DET
dpc-2650	129	8	critical	critical	ADJ
dpc-2650	129	9	molecule	molecule	NOUN
dpc-2650	129	10	for	for	ADP
dpc-2650	129	11	tight	tight	ADJ
dpc-2650	129	12	regulation	regulation	NOUN
dpc-2650	129	13	of	of	ADP
dpc-2650	129	14	il-18	il-18	NOUN
dpc-2650	129	15	in	in	ADP
dpc-2650	129	16	keratinocytes	keratinocyte	NOUN
dpc-2650	129	17	and	and	CCONJ
dpc-2650	129	18	proper	proper	ADJ
dpc-2650	129	19	production	production	NOUN
dpc-2650	129	20	of	of	ADP
dpc-2650	129	21	proinflammatory	proinflammatory	ADJ
dpc-2650	129	22	cytokines	cytokine	NOUN
dpc-2650	129	23	by	by	ADP
dpc-2650	129	24	macrophages	macrophage	NOUN
dpc-2650	129	25	[	[	X
dpc-2650	129	26	18	18	NUM
dpc-2650	129	27	]	]	PUNCT
dpc-2650	129	28	.	.	PUNCT
dpc-2650	130	1	il-18	il-18	PUNCT
dpc-2650	130	2	belongs	belong	VERB
dpc-2650	130	3	to	to	ADP
dpc-2650	130	4	il-1	il-1	ADP
dpc-2650	130	5	cytokine	cytokine	ADJ
dpc-2650	130	6	family	family	NOUN
dpc-2650	130	7	that	that	PRON
dpc-2650	130	8	plays	play	VERB
dpc-2650	130	9	a	a	DET
dpc-2650	130	10	pathogenetically	pathogenetically	ADV
dpc-2650	130	11	important	important	ADJ
dpc-2650	130	12	role	role	NOUN
dpc-2650	130	13	in	in	ADP
dpc-2650	130	14	chronic	chronic	ADJ
dpc-2650	130	15	inflammatory	inflammatory	ADJ
dpc-2650	130	16	conditions	condition	NOUN
dpc-2650	130	17	of	of	ADP
dpc-2650	130	18	skin	skin	NOUN
dpc-2650	130	19	such	such	ADJ
dpc-2650	130	20	as	as	ADP
dpc-2650	130	21	psoriasis	psoriasis	NOUN
dpc-2650	130	22	[	[	X
dpc-2650	130	23	19,20	19,20	X
dpc-2650	130	24	]	]	X
dpc-2650	130	25	.	.	PUNCT
dpc-2650	131	1	therefore	therefore	ADV
dpc-2650	131	2	,	,	PUNCT
dpc-2650	131	3	we	we	PRON
dpc-2650	131	4	assume	assume	VERB
dpc-2650	131	5	that	that	SCONJ
dpc-2650	131	6	upregulation	upregulation	NOUN
dpc-2650	131	7	of	of	ADP
dpc-2650	131	8	ereg	ereg	NOUN
dpc-2650	131	9	gene	gene	NOUN
dpc-2650	131	10	causes	cause	VERB
dpc-2650	131	11	hyperproliferation	hyperproliferation	NOUN
dpc-2650	131	12	of	of	ADP
dpc-2650	131	13	keratinocytes	keratinocyte	NOUN
dpc-2650	131	14	and	and	CCONJ
dpc-2650	131	15	chronic	chronic	ADJ
dpc-2650	131	16	inflammation	inflammation	NOUN
dpc-2650	131	17	in	in	ADP
dpc-2650	131	18	psoriasis	psoriasis	NOUN
dpc-2650	131	19	via	via	ADP
dpc-2650	131	20	intracellular	intracellular	ADJ
dpc-2650	131	21	signaling	signal	VERB
dpc-2650	131	22	pathways	pathway	NOUN
dpc-2650	131	23	.	.	PUNCT
dpc-2650	132	1	up	up	ADP
dpc-2650	132	2	to	to	ADP
dpc-2650	132	3	now	now	ADV
dpc-2650	132	4	,	,	PUNCT
dpc-2650	132	5	ptpn1	ptpn1	PROPN
dpc-2650	132	6	was	be	AUX
dpc-2650	132	7	shown	show	VERB
dpc-2650	132	8	as	as	ADP
dpc-2650	132	9	associated	associate	VERB
dpc-2650	132	10	with	with	ADP
dpc-2650	132	11	dyslipidemia	dyslipidemia	NOUN
dpc-2650	132	12	,	,	PUNCT
dpc-2650	132	13	insulin	insulin	NOUN
dpc-2650	132	14	resistance	resistance	NOUN
dpc-2650	132	15	,	,	PUNCT
dpc-2650	132	16	type	type	NOUN
dpc-2650	132	17	2	2	NUM
dpc-2650	132	18	dm	dm	NOUN
dpc-2650	132	19	,	,	PUNCT
dpc-2650	132	20	and	and	CCONJ
dpc-2650	132	21	obesity	obesity	NOUN
dpc-2650	132	22	via	via	ADP
dpc-2650	132	23	ptp1b	ptp1b	PROPN
dpc-2650	132	24	pasi	pasi	PROPN
dpc-2650	132	25	p=0.103	p=0.103	X
dpc-2650	132	26	r=0.333	r=0.333	NOUN
dpc-2650	132	27	,	,	PUNCT
dpc-2650	132	28	0	0	NUM
dpc-2650	132	29	10,0	10,0	NUM
dpc-2650	132	30	20,0	20,0	NUM
dpc-2650	132	31	30,0	30,0	NUM
dpc-2650	132	32	40,0	40,0	NOUN
dpc-2650	132	33	er	er	INTJ
dpc-2650	132	34	eg	eg	NOUN
dpc-2650	132	35	,	,	PUNCT
dpc-2650	132	36	00	00	PROPN
dpc-2650	132	37	1,00	1,00	NUM
dpc-2650	132	38	-1,00	-1,00	PUNCT
dpc-2650	133	1	2,00	2,00	PROPN
dpc-2650	133	2	figure	figure	VERB
dpc-2650	133	3	4	4	NUM
dpc-2650	133	4	.	.	PUNCT
dpc-2650	134	1	the	the	DET
dpc-2650	134	2	correlation	correlation	NOUN
dpc-2650	134	3	graph	graph	NOUN
dpc-2650	134	4	between	between	ADP
dpc-2650	134	5	ereg	ereg	NOUN
dpc-2650	134	6	gene	gene	NOUN
dpc-2650	134	7	expression	expression	NOUN
dpc-2650	134	8	levels	level	NOUN
dpc-2650	134	9	and	and	CCONJ
dpc-2650	134	10	pasi	pasi	NOUN
dpc-2650	134	11	scores	score	NOUN
dpc-2650	134	12	(	(	PUNCT
dpc-2650	134	13	spearman	spearman	NOUN
dpc-2650	134	14	correlation	correlation	NOUN
dpc-2650	134	15	)	)	PUNCT
dpc-2650	134	16	.	.	PUNCT
dpc-2650	135	1	ereg	ereg	VERB
dpc-2650	136	1	=	=	PUNCT
dpc-2650	136	2	epiregulin	epiregulin	NOUN
dpc-2650	136	3	;	;	PUNCT
dpc-2650	136	4	pasi	pasi	NOUN
dpc-2650	136	5	=	=	SYM
dpc-2650	136	6	psoriasis	psoriasis	NOUN
dpc-2650	136	7	area	area	NOUN
dpc-2650	136	8	and	and	CCONJ
dpc-2650	136	9	severity	severity	NOUN
dpc-2650	136	10	index	index	NOUN
dpc-2650	136	11	.	.	PUNCT
dpc-2650	137	1	original	original	ADJ
dpc-2650	137	2	article	article	NOUN
dpc-2650	137	3	|	|	ADV
dpc-2650	137	4	dermatol	dermatol	ADJ
dpc-2650	137	5	pract	pract	NOUN
dpc-2650	137	6	concept	concept	NOUN
dpc-2650	137	7	.	.	PUNCT
dpc-2650	138	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	138	2	7	7	NUM
dpc-2650	138	3	with	with	ADP
dpc-2650	138	4	future	future	ADJ
dpc-2650	138	5	studies	study	NOUN
dpc-2650	138	6	.	.	PUNCT
dpc-2650	139	1	even	even	ADV
dpc-2650	139	2	though	though	SCONJ
dpc-2650	139	3	our	our	PRON
dpc-2650	139	4	study	study	NOUN
dpc-2650	139	5	is	be	AUX
dpc-2650	139	6	the	the	DET
dpc-2650	139	7	only	only	ADJ
dpc-2650	139	8	study	study	NOUN
dpc-2650	139	9	evaluating	evaluate	VERB
dpc-2650	139	10	serpinb7	serpinb7	NOUN
dpc-2650	139	11	gene	gene	NOUN
dpc-2650	139	12	in	in	ADP
dpc-2650	139	13	a	a	DET
dpc-2650	139	14	high	high	ADJ
dpc-2650	139	15	number	number	NOUN
dpc-2650	139	16	of	of	ADP
dpc-2650	139	17	real	real	ADJ
dpc-2650	139	18	patients	patient	NOUN
dpc-2650	139	19	lesional	lesional	ADJ
dpc-2650	139	20	,	,	PUNCT
dpc-2650	139	21	non	non	ADJ
dpc-2650	139	22	-	-	ADJ
dpc-2650	139	23	lesional	lesional	ADJ
dpc-2650	139	24	skins	skin	NOUN
dpc-2650	139	25	and	and	CCONJ
dpc-2650	139	26	normal	normal	ADJ
dpc-2650	139	27	skins	skin	NOUN
dpc-2650	139	28	of	of	ADP
dpc-2650	139	29	healthy	healthy	ADJ
dpc-2650	139	30	controls	control	NOUN
dpc-2650	139	31	,	,	PUNCT
dpc-2650	139	32	these	these	DET
dpc-2650	139	33	findings	finding	NOUN
dpc-2650	139	34	need	need	VERB
dpc-2650	139	35	to	to	PART
dpc-2650	139	36	be	be	AUX
dpc-2650	139	37	proven	prove	VERB
dpc-2650	139	38	in	in	ADP
dpc-2650	139	39	further	further	ADJ
dpc-2650	139	40	studies	study	NOUN
dpc-2650	139	41	.	.	PUNCT
dpc-2650	140	1	with	with	ADP
dpc-2650	140	2	this	this	DET
dpc-2650	140	3	study	study	NOUN
dpc-2650	140	4	,	,	PUNCT
dpc-2650	140	5	we	we	PRON
dpc-2650	140	6	demonstrated	demonstrate	VERB
dpc-2650	140	7	that	that	SCONJ
dpc-2650	140	8	balanced	balanced	ADJ
dpc-2650	140	9	function	function	NOUN
dpc-2650	140	10	of	of	ADP
dpc-2650	140	11	the	the	DET
dpc-2650	140	12	ereg	ereg	NOUN
dpc-2650	140	13	gene	gene	NOUN
dpc-2650	140	14	,	,	PUNCT
dpc-2650	140	15	decreased	decrease	VERB
dpc-2650	140	16	function	function	NOUN
dpc-2650	140	17	of	of	ADP
dpc-2650	140	18	the	the	DET
dpc-2650	140	19	ptpn1	ptpn1	NOUN
dpc-2650	140	20	gene	gene	NOUN
dpc-2650	140	21	,	,	PUNCT
dpc-2650	140	22	and	and	CCONJ
dpc-2650	140	23	normal	normal	ADJ
dpc-2650	140	24	function	function	NOUN
dpc-2650	140	25	of	of	ADP
dpc-2650	140	26	the	the	DET
dpc-2650	140	27	serpinb7	serpinb7	NOUN
dpc-2650	140	28	gene	gene	NOUN
dpc-2650	140	29	play	play	VERB
dpc-2650	140	30	a	a	DET
dpc-2650	140	31	critical	critical	ADJ
dpc-2650	140	32	role	role	NOUN
dpc-2650	140	33	in	in	ADP
dpc-2650	140	34	preventing	prevent	VERB
dpc-2650	140	35	the	the	DET
dpc-2650	140	36	development	development	NOUN
dpc-2650	140	37	of	of	ADP
dpc-2650	140	38	psoriasis	psoriasis	NOUN
dpc-2650	140	39	.	.	PUNCT
dpc-2650	141	1	we	we	PRON
dpc-2650	141	2	believe	believe	VERB
dpc-2650	141	3	that	that	SCONJ
dpc-2650	141	4	in	in	ADP
dpc-2650	141	5	the	the	DET
dpc-2650	141	6	future	future	NOUN
dpc-2650	141	7	,	,	PUNCT
dpc-2650	141	8	gene	gene	NOUN
dpc-2650	141	9	therapies	therapy	NOUN
dpc-2650	141	10	that	that	PRON
dpc-2650	141	11	can	can	AUX
dpc-2650	141	12	even	even	ADV
dpc-2650	141	13	cure	cure	VERB
dpc-2650	141	14	diseases	disease	NOUN
dpc-2650	141	15	will	will	AUX
dpc-2650	141	16	be	be	AUX
dpc-2650	141	17	more	more	ADV
dpc-2650	141	18	important	important	ADJ
dpc-2650	141	19	than	than	ADP
dpc-2650	141	20	inhibiting	inhibit	VERB
dpc-2650	141	21	the	the	DET
dpc-2650	141	22	underlying	underlie	VERB
dpc-2650	141	23	inflammatory	inflammatory	ADJ
dpc-2650	141	24	mechanism	mechanism	NOUN
dpc-2650	141	25	in	in	ADP
dpc-2650	141	26	chronic	chronic	ADJ
dpc-2650	141	27	inflammatory	inflammatory	ADJ
dpc-2650	141	28	diseases	disease	NOUN
dpc-2650	141	29	.	.	PUNCT
dpc-2650	142	1	acknowledgement	acknowledgement	NOUN
dpc-2650	142	2	:	:	PUNCT
dpc-2650	142	3	this	this	DET
dpc-2650	142	4	work	work	NOUN
dpc-2650	142	5	was	be	AUX
dpc-2650	142	6	supported	support	VERB
dpc-2650	142	7	by	by	ADP
dpc-2650	142	8	scholarship	scholarship	NOUN
dpc-2650	142	9	from	from	ADP
dpc-2650	142	10	turkish	turkish	ADJ
dpc-2650	142	11	dermatology	dermatology	NOUN
dpc-2650	142	12	association	association	NOUN
dpc-2650	142	13	.	.	PUNCT
dpc-2650	143	1	references	reference	NOUN
dpc-2650	143	2	1	1	NUM
dpc-2650	143	3	.	.	X
dpc-2650	143	4	gudjonsson	gudjonsson	PROPN
dpc-2650	143	5	je	je	PROPN
dpc-2650	143	6	,	,	PUNCT
dpc-2650	143	7	ding	ding	PROPN
dpc-2650	143	8	j	j	PROPN
dpc-2650	143	9	,	,	PUNCT
dpc-2650	143	10	johnston	johnston	PROPN
dpc-2650	143	11	a	a	PROPN
dpc-2650	143	12	,	,	PUNCT
dpc-2650	143	13	et	et	PROPN
dpc-2650	143	14	al	al	PROPN
dpc-2650	143	15	.	.	PROPN
dpc-2650	143	16	assessment	assessment	NOUN
dpc-2650	143	17	of	of	ADP
dpc-2650	143	18	the	the	DET
dpc-2650	143	19	psoriatic	psoriatic	ADJ
dpc-2650	143	20	transcriptome	transcriptome	NOUN
dpc-2650	143	21	in	in	ADP
dpc-2650	143	22	a	a	DET
dpc-2650	143	23	large	large	ADJ
dpc-2650	143	24	sample	sample	NOUN
dpc-2650	143	25	:	:	PUNCT
dpc-2650	143	26	additional	additional	ADJ
dpc-2650	143	27	regulated	regulated	ADJ
dpc-2650	143	28	genes	gene	NOUN
dpc-2650	143	29	and	and	CCONJ
dpc-2650	143	30	comparisons	comparison	NOUN
dpc-2650	143	31	with	with	ADP
dpc-2650	143	32	in	in	ADP
dpc-2650	143	33	vitro	vitro	X
dpc-2650	143	34	models	model	NOUN
dpc-2650	143	35	.	.	PUNCT
dpc-2650	144	1	j	j	PROPN
dpc-2650	144	2	invest	invest	VERB
dpc-2650	144	3	dermatol	dermatol	NOUN
dpc-2650	144	4	.	.	PUNCT
dpc-2650	145	1	2010;130(7):1829	2010;130(7):1829	NUM
dpc-2650	145	2	-	-	SYM
dpc-2650	145	3	1840	1840	NUM
dpc-2650	145	4	.	.	PUNCT
dpc-2650	146	1	doi	doi	NOUN
dpc-2650	146	2	:	:	PUNCT
dpc-2650	146	3	10.1038	10.1038	NUM
dpc-2650	146	4	/	/	SYM
dpc-2650	146	5	jid.2010.36	jid.2010.36	PROPN
dpc-2650	146	6	.	.	PUNCT
dpc-2650	147	1	pmid	pmid	NOUN
dpc-2650	147	2	:	:	PUNCT
dpc-2650	147	3	20220767	20220767	NUM
dpc-2650	147	4	.	.	PUNCT
dpc-2650	148	1	pmcid	pmcid	NOUN
dpc-2650	148	2	:	:	PUNCT
dpc-2650	148	3	pmc3128718	pmc3128718	NOUN
dpc-2650	148	4	.	.	PUNCT
dpc-2650	149	1	2	2	X
dpc-2650	149	2	.	.	X
dpc-2650	149	3	shirakata	shirakata	PROPN
dpc-2650	149	4	y	y	PROPN
dpc-2650	149	5	,	,	PUNCT
dpc-2650	149	6	kishimoto	kishimoto	PROPN
dpc-2650	149	7	j	j	PROPN
dpc-2650	149	8	,	,	PUNCT
dpc-2650	149	9	tokumaru	tokumaru	PROPN
dpc-2650	149	10	s	s	PROPN
dpc-2650	149	11	,	,	PUNCT
dpc-2650	149	12	et	et	PROPN
dpc-2650	149	13	al	al	PROPN
dpc-2650	149	14	.	.	PUNCT
dpc-2650	150	1	epiregulin	epiregulin	PROPN
dpc-2650	150	2	,	,	PUNCT
dpc-2650	150	3	a	a	DET
dpc-2650	150	4	member	member	NOUN
dpc-2650	150	5	of	of	ADP
dpc-2650	150	6	the	the	DET
dpc-2650	150	7	egf	egf	PROPN
dpc-2650	150	8	family	family	NOUN
dpc-2650	150	9	,	,	PUNCT
dpc-2650	150	10	is	be	AUX
dpc-2650	150	11	over	over	ADV
dpc-2650	150	12	-	-	PUNCT
dpc-2650	150	13	expressed	express	VERB
dpc-2650	150	14	in	in	ADP
dpc-2650	150	15	psoriatic	psoriatic	ADJ
dpc-2650	150	16	epidermis	epidermis	NOUN
dpc-2650	150	17	.	.	PUNCT
dpc-2650	151	1	j	j	PROPN
dpc-2650	151	2	dermatol	dermatol	NOUN
dpc-2650	151	3	sci	sci	PROPN
dpc-2650	151	4	.	.	PUNCT
dpc-2650	152	1	2007;45(1):69	2007;45(1):69	NUM
dpc-2650	152	2	-	-	SYM
dpc-2650	152	3	72	72	NUM
dpc-2650	152	4	.	.	PUNCT
dpc-2650	152	5	doi	doi	NOUN
dpc-2650	152	6	:	:	PUNCT
dpc-2650	152	7	10.1016	10.1016	NUM
dpc-2650	152	8	/	/	SYM
dpc-2650	152	9	j.	j.	PROPN
dpc-2650	152	10	jdermsci.2006.08.010	jdermsci.2006.08.010	PROPN
dpc-2650	152	11	.	.	PUNCT
dpc-2650	153	1	pmid	pmid	PROPN
dpc-2650	153	2	:	:	PUNCT
dpc-2650	153	3	16996251	16996251	NUM
dpc-2650	153	4	.	.	X
dpc-2650	154	1	3	3	X
dpc-2650	154	2	.	.	X
dpc-2650	154	3	hashimoto	hashimoto	NOUN
dpc-2650	154	4	k.	k.	PROPN
dpc-2650	154	5	regulation	regulation	PROPN
dpc-2650	154	6	of	of	ADP
dpc-2650	154	7	keratinocyte	keratinocyte	NOUN
dpc-2650	154	8	function	function	NOUN
dpc-2650	154	9	by	by	ADP
dpc-2650	154	10	growth	growth	NOUN
dpc-2650	154	11	factors	factor	NOUN
dpc-2650	154	12	.	.	PUNCT
dpc-2650	155	1	j	j	PROPN
dpc-2650	155	2	dermatol	dermatol	NOUN
dpc-2650	155	3	sci	sci	PROPN
dpc-2650	155	4	.	.	PROPN
dpc-2650	156	1	2000;24	2000;24	NUM
dpc-2650	157	1	suppl	suppl	ADJ
dpc-2650	157	2	1:46	1:46	NUM
dpc-2650	157	3	-	-	SYM
dpc-2650	157	4	50	50	NUM
dpc-2650	157	5	.	.	PUNCT
dpc-2650	158	1	doi	doi	NOUN
dpc-2650	158	2	:	:	PUNCT
dpc-2650	158	3	10.1016/	10.1016/	NUM
dpc-2650	158	4	s0923	s0923	NOUN
dpc-2650	158	5	-	-	PUNCT
dpc-2650	158	6	1811(00)00141	1811(00)00141	NUM
dpc-2650	158	7	-	-	SYM
dpc-2650	158	8	9	9	NUM
dpc-2650	158	9	.	.	PUNCT
dpc-2650	159	1	pmid	pmid	NOUN
dpc-2650	159	2	:	:	PUNCT
dpc-2650	159	3	11137396	11137396	NUM
dpc-2650	159	4	.	.	PUNCT
dpc-2650	160	1	4	4	X
dpc-2650	160	2	.	.	X
dpc-2650	160	3	kubo	kubo	PROPN
dpc-2650	160	4	a	a	PROPN
dpc-2650	160	5	,	,	PUNCT
dpc-2650	160	6	shiohama	shiohama	NOUN
dpc-2650	160	7	a	a	X
dpc-2650	160	8	,	,	PUNCT
dpc-2650	160	9	sasaki	sasaki	PROPN
dpc-2650	160	10	t	t	PROPN
dpc-2650	160	11	,	,	PUNCT
dpc-2650	160	12	et	et	PROPN
dpc-2650	160	13	al	al	PROPN
dpc-2650	160	14	.	.	PUNCT
dpc-2650	160	15	mutations	mutation	NOUN
dpc-2650	160	16	in	in	ADP
dpc-2650	160	17	serpinb7	serpinb7	NOUN
dpc-2650	160	18	,	,	PUNCT
dpc-2650	160	19	encoding	encode	VERB
dpc-2650	160	20	a	a	DET
dpc-2650	160	21	member	member	NOUN
dpc-2650	160	22	of	of	ADP
dpc-2650	160	23	the	the	DET
dpc-2650	160	24	serine	serine	NOUN
dpc-2650	160	25	protease	protease	NOUN
dpc-2650	160	26	inhibitor	inhibitor	NOUN
dpc-2650	160	27	superfamily	superfamily	ADV
dpc-2650	160	28	,	,	PUNCT
dpc-2650	160	29	cause	cause	VERB
dpc-2650	160	30	nagashima	nagashima	NOUN
dpc-2650	160	31	-	-	PUNCT
dpc-2650	160	32	type	type	NOUN
dpc-2650	160	33	palmoplantar	palmoplantar	NOUN
dpc-2650	160	34	keratosis	keratosis	NOUN
dpc-2650	160	35	.	.	PUNCT
dpc-2650	161	1	am	be	AUX
dpc-2650	161	2	j	j	PROPN
dpc-2650	161	3	hum	hum	PROPN
dpc-2650	161	4	genet	genet	PROPN
dpc-2650	161	5	.	.	PUNCT
dpc-2650	162	1	2013;93(5):945	2013;93(5):945	NUM
dpc-2650	162	2	-	-	SYM
dpc-2650	162	3	956	956	NUM
dpc-2650	162	4	.	.	PUNCT
dpc-2650	162	5	doi	doi	NOUN
dpc-2650	162	6	:	:	PUNCT
dpc-2650	162	7	10.1016	10.1016	NUM
dpc-2650	162	8	/	/	SYM
dpc-2650	162	9	j.ajhg.2013.09.015	j.ajhg.2013.09.015	PROPN
dpc-2650	162	10	.	.	PUNCT
dpc-2650	163	1	pmid	pmid	NOUN
dpc-2650	163	2	:	:	PUNCT
dpc-2650	163	3	24207119	24207119	NUM
dpc-2650	163	4	;	;	PUNCT
dpc-2650	163	5	pmcid	pmcid	NOUN
dpc-2650	163	6	:	:	PUNCT
dpc-2650	163	7	pmc3824127	pmc3824127	NOUN
dpc-2650	163	8	.	.	PUNCT
dpc-2650	164	1	5	5	X
dpc-2650	164	2	.	.	X
dpc-2650	164	3	alfadhli	alfadhli	PROPN
dpc-2650	164	4	s	s	PROPN
dpc-2650	164	5	,	,	PUNCT
dpc-2650	164	6	al	al	PROPN
dpc-2650	164	7	-	-	PUNCT
dpc-2650	164	8	zufairi	zufairi	NOUN
dpc-2650	164	9	aam	aam	PROPN
dpc-2650	164	10	,	,	PUNCT
dpc-2650	164	11	nizam	nizam	PROPN
dpc-2650	164	12	r	r	PROPN
dpc-2650	164	13	,	,	PUNCT
dpc-2650	164	14	alsaffar	alsaffar	ADV
dpc-2650	164	15	ha	ha	INTJ
dpc-2650	164	16	,	,	PUNCT
dpc-2650	164	17	al	al	PROPN
dpc-2650	164	18	-	-	PUNCT
dpc-2650	164	19	mutairi	mutairi	PROPN
dpc-2650	164	20	n.	n.	PROPN
dpc-2650	164	21	de	de	NOUN
dpc-2650	164	22	-	-	NOUN
dpc-2650	164	23	regulation	regulation	NOUN
dpc-2650	164	24	of	of	ADP
dpc-2650	164	25	diabetic	diabetic	ADJ
dpc-2650	164	26	regulatory	regulatory	ADJ
dpc-2650	164	27	genes	gene	NOUN
dpc-2650	164	28	in	in	ADP
dpc-2650	164	29	psoriasis	psoriasis	NOUN
dpc-2650	164	30	:	:	PUNCT
dpc-2650	164	31	deciphering	decipher	VERB
dpc-2650	164	32	the	the	DET
dpc-2650	164	33	unsolved	unsolved	ADJ
dpc-2650	164	34	riddle	riddle	PROPN
dpc-2650	164	35	.	.	PUNCT
dpc-2650	165	1	gene	gene	NOUN
dpc-2650	165	2	.	.	PUNCT
dpc-2650	166	1	2016;593(1):110	2016;593(1):110	NUM
dpc-2650	166	2	-	-	SYM
dpc-2650	166	3	116	116	NUM
dpc-2650	166	4	.	.	PUNCT
dpc-2650	167	1	doi	doi	NOUN
dpc-2650	167	2	:	:	PUNCT
dpc-2650	167	3	10.1016	10.1016	NUM
dpc-2650	167	4	/	/	SYM
dpc-2650	167	5	j.gene.2016.08.024	j.gene.2016.08.024	PROPN
dpc-2650	167	6	.	.	PUNCT
dpc-2650	168	1	pmid	pmid	NOUN
dpc-2650	168	2	:	:	PUNCT
dpc-2650	168	3	27530212	27530212	NUM
dpc-2650	168	4	.	.	PUNCT
dpc-2650	169	1	6	6	X
dpc-2650	169	2	.	.	X
dpc-2650	169	3	cheyssac	cheyssac	NOUN
dpc-2650	169	4	c	c	NOUN
dpc-2650	169	5	,	,	PUNCT
dpc-2650	169	6	lecoeur	lecoeur	PROPN
dpc-2650	169	7	c	c	PROPN
dpc-2650	169	8	,	,	PUNCT
dpc-2650	169	9	dechaume	dechaume	VERB
dpc-2650	169	10	a	a	PRON
dpc-2650	169	11	,	,	PUNCT
dpc-2650	169	12	et	et	PROPN
dpc-2650	169	13	al	al	PROPN
dpc-2650	169	14	.	.	PUNCT
dpc-2650	170	1	analysis	analysis	NOUN
dpc-2650	170	2	of	of	ADP
dpc-2650	170	3	common	common	ADJ
dpc-2650	170	4	ptpn1	ptpn1	NOUN
dpc-2650	170	5	gene	gene	NOUN
dpc-2650	170	6	variants	variant	NOUN
dpc-2650	170	7	in	in	ADP
dpc-2650	170	8	type	type	NOUN
dpc-2650	170	9	2	2	NUM
dpc-2650	170	10	diabetes	diabetes	NOUN
dpc-2650	170	11	,	,	PUNCT
dpc-2650	170	12	obesity	obesity	NOUN
dpc-2650	170	13	and	and	CCONJ
dpc-2650	170	14	associated	associated	ADJ
dpc-2650	170	15	phenotypes	phenotype	NOUN
dpc-2650	170	16	in	in	ADP
dpc-2650	170	17	the	the	DET
dpc-2650	170	18	french	french	ADJ
dpc-2650	170	19	population	population	NOUN
dpc-2650	170	20	.	.	PUNCT
dpc-2650	171	1	bmc	bmc	PROPN
dpc-2650	171	2	med	med	PROPN
dpc-2650	171	3	genet	genet	NOUN
dpc-2650	171	4	.	.	PUNCT
dpc-2650	172	1	2006;7:44	2006;7:44	NOUN
dpc-2650	172	2	.	.	PUNCT
dpc-2650	173	1	doi	doi	PROPN
dpc-2650	173	2	:	:	PUNCT
dpc-2650	173	3	10.1186/1471	10.1186/1471	NUM
dpc-2650	173	4	-	-	PUNCT
dpc-2650	173	5	2350	2350	NUM
dpc-2650	173	6	-	-	SYM
dpc-2650	173	7	7	7	NUM
dpc-2650	173	8	-	-	SYM
dpc-2650	173	9	44	44	NUM
dpc-2650	173	10	.	.	PUNCT
dpc-2650	174	1	pmid	pmid	NOUN
dpc-2650	174	2	:	:	PUNCT
dpc-2650	174	3	16677372	16677372	NUM
dpc-2650	174	4	.	.	PUNCT
dpc-2650	175	1	pmcid	pmcid	NOUN
dpc-2650	175	2	:	:	PUNCT
dpc-2650	175	3	pmc1525165	pmc1525165	NOUN
dpc-2650	175	4	.	.	PUNCT
dpc-2650	176	1	7	7	X
dpc-2650	176	2	.	.	X
dpc-2650	176	3	yin	yin	PROPN
dpc-2650	176	4	x	x	PROPN
dpc-2650	176	5	,	,	PUNCT
dpc-2650	176	6	lin	lin	PROPN
dpc-2650	176	7	y	y	PROPN
dpc-2650	176	8	,	,	PUNCT
dpc-2650	176	9	shen	shen	PROPN
dpc-2650	176	10	c	c	X
dpc-2650	176	11	,	,	PUNCT
dpc-2650	176	12	et	et	PROPN
dpc-2650	176	13	al	al	PROPN
dpc-2650	176	14	.	.	PUNCT
dpc-2650	176	15	integration	integration	NOUN
dpc-2650	176	16	of	of	ADP
dpc-2650	176	17	expression	expression	NOUN
dpc-2650	176	18	quantitative	quantitative	ADJ
dpc-2650	176	19	trait	trait	NOUN
dpc-2650	176	20	loci	locus	NOUN
dpc-2650	176	21	and	and	CCONJ
dpc-2650	176	22	pleiotropy	pleiotropy	NOUN
dpc-2650	176	23	identifies	identify	VERB
dpc-2650	176	24	a	a	DET
dpc-2650	176	25	novel	novel	ADJ
dpc-2650	176	26	psoriasis	psoriasis	NOUN
dpc-2650	176	27	susceptibility	susceptibility	NOUN
dpc-2650	176	28	gene	gene	NOUN
dpc-2650	176	29	,	,	PUNCT
dpc-2650	176	30	ptpn1	ptpn1	PROPN
dpc-2650	176	31	.	.	PUNCT
dpc-2650	177	1	j	j	PROPN
dpc-2650	177	2	gene	gene	PROPN
dpc-2650	177	3	med	me	VERB
dpc-2650	177	4	.	.	PUNCT
dpc-2650	178	1	2017;19(1	2017;19(1	NUM
dpc-2650	178	2	-	-	SYM
dpc-2650	178	3	2):10.1002	2):10.1002	NUM
dpc-2650	178	4	/	/	SYM
dpc-2650	178	5	jgm.2939	jgm.2939	NOUN
dpc-2650	178	6	.	.	PUNCT
dpc-2650	179	1	doi	doi	NOUN
dpc-2650	179	2	:	:	PUNCT
dpc-2650	179	3	10.1002	10.1002	NUM
dpc-2650	179	4	/	/	SYM
dpc-2650	179	5	jgm.2939	jgm.2939	NOUN
dpc-2650	179	6	.	.	PUNCT
dpc-2650	180	1	pmid	pmid	NOUN
dpc-2650	180	2	:	:	PUNCT
dpc-2650	180	3	27976820	27976820	NUM
dpc-2650	180	4	.	.	PUNCT
dpc-2650	181	1	8	8	X
dpc-2650	181	2	.	.	PUNCT
dpc-2650	182	1	wang	wang	PROPN
dpc-2650	182	2	z	z	PROPN
dpc-2650	182	3	,	,	PUNCT
dpc-2650	182	4	zheng	zheng	PROPN
dpc-2650	182	5	h	h	PROPN
dpc-2650	182	6	,	,	PUNCT
dpc-2650	182	7	zhou	zhou	PROPN
dpc-2650	182	8	h	h	PROPN
dpc-2650	182	9	,	,	PUNCT
dpc-2650	182	10	et	et	PROPN
dpc-2650	182	11	al	al	PROPN
dpc-2650	182	12	.	.	PUNCT
dpc-2650	182	13	systematic	systematic	ADJ
dpc-2650	182	14	screening	screening	NOUN
dpc-2650	182	15	and	and	CCONJ
dpc-2650	182	16	identification	identification	NOUN
dpc-2650	182	17	of	of	ADP
dpc-2650	182	18	novel	novel	ADJ
dpc-2650	182	19	psoriasis	psoriasis	NOUN
dpc-2650	182	20	-	-	PUNCT
dpc-2650	182	21	specific	specific	ADJ
dpc-2650	182	22	genes	gene	NOUN
dpc-2650	182	23	from	from	ADP
dpc-2650	182	24	the	the	DET
dpc-2650	182	25	transcriptome	transcriptome	NOUN
dpc-2650	182	26	of	of	ADP
dpc-2650	182	27	psoriasis	psoriasis	NOUN
dpc-2650	182	28	-	-	PUNCT
dpc-2650	182	29	like	like	ADJ
dpc-2650	182	30	keratinocytes	keratinocyte	NOUN
dpc-2650	182	31	.	.	PUNCT
dpc-2650	183	1	mol	mol	ADP
dpc-2650	183	2	med	med	PROPN
dpc-2650	183	3	rep	rep	PROPN
dpc-2650	183	4	.	.	PROPN
dpc-2650	183	5	2019;19(3):15291542	2019;19(3):15291542	NUM
dpc-2650	183	6	.	.	PUNCT
dpc-2650	184	1	doi	doi	NOUN
dpc-2650	184	2	:	:	PUNCT
dpc-2650	184	3	10.3892	10.3892	NUM
dpc-2650	184	4	/	/	SYM
dpc-2650	184	5	mmr.2018.9782	mmr.2018.9782	PROPN
dpc-2650	184	6	.	.	PUNCT
dpc-2650	185	1	pmid	pmid	NOUN
dpc-2650	185	2	:	:	PUNCT
dpc-2650	185	3	30592269	30592269	NUM
dpc-2650	185	4	.	.	PUNCT
dpc-2650	186	1	pmcid	pmcid	NOUN
dpc-2650	186	2	:	:	PUNCT
dpc-2650	186	3	pmc6390042	pmc6390042	NOUN
dpc-2650	186	4	.	.	PUNCT
dpc-2650	187	1	9	9	X
dpc-2650	187	2	.	.	X
dpc-2650	187	3	benezeder	benezeder	PROPN
dpc-2650	187	4	t	t	PROPN
dpc-2650	187	5	,	,	PUNCT
dpc-2650	187	6	painsi	painsi	NOUN
dpc-2650	187	7	c	c	NOUN
dpc-2650	187	8	,	,	PUNCT
dpc-2650	187	9	patra	patra	PROPN
dpc-2650	187	10	v	v	PROPN
dpc-2650	187	11	,	,	PUNCT
dpc-2650	187	12	et	et	PROPN
dpc-2650	187	13	al	al	PROPN
dpc-2650	187	14	.	.	PROPN
dpc-2650	187	15	dithranol	dithranol	PROPN
dpc-2650	187	16	targets	target	NOUN
dpc-2650	187	17	keratinocytes	keratinocyte	NOUN
dpc-2650	187	18	,	,	PUNCT
dpc-2650	187	19	their	their	PRON
dpc-2650	187	20	crosstalk	crosstalk	NOUN
dpc-2650	187	21	with	with	ADP
dpc-2650	187	22	neutrophils	neutrophil	NOUN
dpc-2650	187	23	and	and	CCONJ
dpc-2650	187	24	inhibits	inhibit	VERB
dpc-2650	187	25	the	the	DET
dpc-2650	187	26	il-36	il-36	CCONJ
dpc-2650	187	27	inflammatory	inflammatory	ADJ
dpc-2650	187	28	loop	loop	NOUN
dpc-2650	187	29	in	in	ADP
dpc-2650	187	30	psoriasis	psoriasis	NOUN
dpc-2650	187	31	.	.	PUNCT
dpc-2650	188	1	elife	elife	NOUN
dpc-2650	188	2	.	.	PUNCT
dpc-2650	189	1	2020;9	2020;9	NOUN
dpc-2650	189	2	:	:	PUNCT
dpc-2650	189	3	e56991	e56991	PROPN
dpc-2650	189	4	.	.	PUNCT
dpc-2650	189	5	doi	doi	PROPN
dpc-2650	189	6	:	:	PUNCT
dpc-2650	189	7	10.7554	10.7554	NUM
dpc-2650	189	8	/	/	SYM
dpc-2650	189	9	elife.56991	elife.56991	PROPN
dpc-2650	189	10	.	.	PUNCT
dpc-2650	190	1	pmid	pmid	PROPN
dpc-2650	190	2	:	:	PUNCT
dpc-2650	190	3	32484435	32484435	NUM
dpc-2650	190	4	.	.	PUNCT
dpc-2650	191	1	pmcid	pmcid	NOUN
dpc-2650	191	2	:	:	PUNCT
dpc-2650	191	3	pmc7266641	pmc7266641	PROPN
dpc-2650	191	4	.	.	PUNCT
dpc-2650	192	1	significantly	significantly	ADV
dpc-2650	192	2	upregulated	upregulate	VERB
dpc-2650	192	3	ptpn1	ptpn1	NOUN
dpc-2650	192	4	gene	gene	NOUN
dpc-2650	192	5	expression	expression	NOUN
dpc-2650	192	6	in	in	ADP
dpc-2650	192	7	the	the	DET
dpc-2650	192	8	lesional	lesional	ADJ
dpc-2650	192	9	psoriatic	psoriatic	ADJ
dpc-2650	192	10	skin	skin	NOUN
dpc-2650	192	11	than	than	ADP
dpc-2650	192	12	the	the	DET
dpc-2650	192	13	non	non	ADJ
dpc-2650	192	14	-	-	ADJ
dpc-2650	192	15	lesional	lesional	ADJ
dpc-2650	192	16	skin	skin	NOUN
dpc-2650	192	17	of	of	ADP
dpc-2650	192	18	the	the	DET
dpc-2650	192	19	same	same	ADJ
dpc-2650	192	20	patients	patient	NOUN
dpc-2650	192	21	,	,	PUNCT
dpc-2650	192	22	and	and	CCONJ
dpc-2650	192	23	also	also	ADV
dpc-2650	192	24	healthy	healthy	ADJ
dpc-2650	192	25	skin	skin	NOUN
dpc-2650	192	26	of	of	ADP
dpc-2650	192	27	controls	control	NOUN
dpc-2650	192	28	.	.	PUNCT
dpc-2650	193	1	moreover	moreover	ADV
dpc-2650	193	2	,	,	PUNCT
dpc-2650	193	3	to	to	ADP
dpc-2650	193	4	the	the	DET
dpc-2650	193	5	best	good	ADJ
dpc-2650	193	6	of	of	ADP
dpc-2650	193	7	our	our	PRON
dpc-2650	193	8	knowledge	knowledge	NOUN
dpc-2650	193	9	,	,	PUNCT
dpc-2650	193	10	the	the	DET
dpc-2650	193	11	present	present	ADJ
dpc-2650	193	12	study	study	NOUN
dpc-2650	193	13	is	be	AUX
dpc-2650	193	14	the	the	DET
dpc-2650	193	15	only	only	ADJ
dpc-2650	193	16	study	study	NOUN
dpc-2650	193	17	evaluating	evaluate	VERB
dpc-2650	193	18	ptpn1	ptpn1	NOUN
dpc-2650	193	19	gene	gene	NOUN
dpc-2650	193	20	expression	expression	NOUN
dpc-2650	193	21	at	at	ADP
dpc-2650	193	22	the	the	DET
dpc-2650	193	23	tissue	tissue	NOUN
dpc-2650	193	24	layer	layer	NOUN
dpc-2650	193	25	.	.	PUNCT
dpc-2650	194	1	in	in	ADP
dpc-2650	194	2	addition	addition	NOUN
dpc-2650	194	3	,	,	PUNCT
dpc-2650	194	4	even	even	ADV
dpc-2650	194	5	though	though	SCONJ
dpc-2650	194	6	we	we	PRON
dpc-2650	194	7	have	have	VERB
dpc-2650	194	8	yet	yet	ADV
dpc-2650	194	9	to	to	PART
dpc-2650	194	10	learn	learn	VERB
dpc-2650	194	11	very	very	ADV
dpc-2650	194	12	little	little	ADJ
dpc-2650	194	13	about	about	ADP
dpc-2650	194	14	how	how	SCONJ
dpc-2650	194	15	the	the	DET
dpc-2650	194	16	ptpn1	ptpn1	NOUN
dpc-2650	194	17	gene	gene	NOUN
dpc-2650	194	18	causes	cause	VERB
dpc-2650	194	19	psoriasis	psoriasis	NOUN
dpc-2650	194	20	development	development	NOUN
dpc-2650	194	21	,	,	PUNCT
dpc-2650	194	22	upregulation	upregulation	NOUN
dpc-2650	194	23	of	of	ADP
dpc-2650	194	24	ptpn1	ptpn1	NOUN
dpc-2650	194	25	might	might	AUX
dpc-2650	194	26	lead	lead	VERB
dpc-2650	194	27	to	to	ADP
dpc-2650	194	28	hyperproliferation	hyperproliferation	NOUN
dpc-2650	194	29	of	of	ADP
dpc-2650	194	30	epidermis	epidermis	NOUN
dpc-2650	194	31	via	via	ADP
dpc-2650	194	32	stat3	stat3	NOUN
dpc-2650	194	33	like	like	ADP
dpc-2650	194	34	ereg	ereg	NOUN
dpc-2650	194	35	gene	gene	NOUN
dpc-2650	194	36	,	,	PUNCT
dpc-2650	194	37	and	and	CCONJ
dpc-2650	194	38	therefore	therefore	ADV
dpc-2650	194	39	,	,	PUNCT
dpc-2650	194	40	upregulated	upregulated	ADJ
dpc-2650	194	41	expression	expression	NOUN
dpc-2650	194	42	of	of	ADP
dpc-2650	194	43	ptpn1	ptpn1	NOUN
dpc-2650	194	44	gene	gene	NOUN
dpc-2650	194	45	has	have	VERB
dpc-2650	194	46	crucial	crucial	ADJ
dpc-2650	194	47	roles	role	NOUN
dpc-2650	194	48	in	in	ADP
dpc-2650	194	49	the	the	DET
dpc-2650	194	50	psoriasis	psoriasis	NOUN
dpc-2650	194	51	pathogenesis	pathogenesis	NOUN
dpc-2650	194	52	as	as	ADV
dpc-2650	194	53	well	well	ADV
dpc-2650	194	54	.	.	PUNCT
dpc-2650	195	1	a	a	DET
dpc-2650	195	2	type	type	NOUN
dpc-2650	195	3	of	of	ADP
dpc-2650	195	4	hereditary	hereditary	ADJ
dpc-2650	195	5	palmoplantar	palmoplantar	NOUN
dpc-2650	195	6	keratoderma	keratoderma	PROPN
dpc-2650	195	7	(	(	PUNCT
dpc-2650	195	8	ppk	ppk	NOUN
dpc-2650	195	9	)	)	PUNCT
dpc-2650	195	10	with	with	ADP
dpc-2650	195	11	serpinb7	serpinb7	NOUN
dpc-2650	195	12	gene	gene	NOUN
dpc-2650	195	13	mutations	mutation	NOUN
dpc-2650	195	14	was	be	AUX
dpc-2650	195	15	identified	identify	VERB
dpc-2650	195	16	by	by	ADP
dpc-2650	195	17	kubo	kubo	PROPN
dpc-2650	195	18	et	et	PROPN
dpc-2650	195	19	al	al	PROPN
dpc-2650	195	20	and	and	CCONJ
dpc-2650	195	21	,	,	PUNCT
dpc-2650	195	22	they	they	PRON
dpc-2650	195	23	reported	report	VERB
dpc-2650	195	24	that	that	SCONJ
dpc-2650	195	25	mutations	mutation	NOUN
dpc-2650	195	26	in	in	ADP
dpc-2650	195	27	the	the	DET
dpc-2650	195	28	serpinb7	serpinb7	NOUN
dpc-2650	195	29	gene	gene	NOUN
dpc-2650	195	30	cause	cause	NOUN
dpc-2650	195	31	alteration	alteration	NOUN
dpc-2650	195	32	in	in	ADP
dpc-2650	195	33	the	the	DET
dpc-2650	195	34	epithelium	epithelium	NOUN
dpc-2650	195	35	of	of	ADP
dpc-2650	195	36	the	the	DET
dpc-2650	195	37	skin	skin	NOUN
dpc-2650	195	38	[	[	X
dpc-2650	195	39	4	4	NUM
dpc-2650	195	40	]	]	PUNCT
dpc-2650	195	41	.	.	PUNCT
dpc-2650	196	1	they	they	PRON
dpc-2650	196	2	also	also	ADV
dpc-2650	196	3	claimed	claim	VERB
dpc-2650	196	4	that	that	SCONJ
dpc-2650	196	5	the	the	DET
dpc-2650	196	6	normal	normal	ADJ
dpc-2650	196	7	functioned	function	VERB
dpc-2650	196	8	serpinb7	serpinb7	NOUN
dpc-2650	196	9	gene	gene	NOUN
dpc-2650	196	10	protects	protect	VERB
dpc-2650	196	11	keratinocytes	keratinocyte	NOUN
dpc-2650	196	12	from	from	ADP
dpc-2650	196	13	oxidative	oxidative	ADJ
dpc-2650	196	14	stress	stress	NOUN
dpc-2650	196	15	-	-	PUNCT
dpc-2650	196	16	mediated	mediate	VERB
dpc-2650	196	17	cellular	cellular	ADJ
dpc-2650	196	18	damage	damage	NOUN
dpc-2650	196	19	.	.	PUNCT
dpc-2650	197	1	therefore	therefore	ADV
dpc-2650	197	2	,	,	PUNCT
dpc-2650	197	3	the	the	DET
dpc-2650	197	4	most	most	ADV
dpc-2650	197	5	critical	critical	ADJ
dpc-2650	197	6	roles	role	NOUN
dpc-2650	197	7	of	of	ADP
dpc-2650	197	8	serpinb7	serpinb7	NOUN
dpc-2650	197	9	in	in	ADP
dpc-2650	197	10	the	the	DET
dpc-2650	197	11	pathogenesis	pathogenesis	NOUN
dpc-2650	197	12	of	of	ADP
dpc-2650	197	13	psoriasis	psoriasis	NOUN
dpc-2650	197	14	are	be	AUX
dpc-2650	197	15	mainly	mainly	ADV
dpc-2650	197	16	epidermis	epidermis	NOUN
dpc-2650	197	17	development	development	NOUN
dpc-2650	197	18	,	,	PUNCT
dpc-2650	197	19	epithelial	epithelial	ADJ
dpc-2650	197	20	cell	cell	NOUN
dpc-2650	197	21	differentiation	differentiation	NOUN
dpc-2650	197	22	,	,	PUNCT
dpc-2650	197	23	and	and	CCONJ
dpc-2650	197	24	keratinization	keratinization	NOUN
dpc-2650	197	25	[	[	X
dpc-2650	197	26	10	10	NUM
dpc-2650	197	27	]	]	PUNCT
dpc-2650	197	28	.	.	PUNCT
dpc-2650	198	1	wang	wang	PROPN
dpc-2650	198	2	et	et	PROPN
dpc-2650	198	3	al	al	PROPN
dpc-2650	198	4	showed	show	VERB
dpc-2650	198	5	upregulated	upregulated	ADJ
dpc-2650	198	6	expressions	expression	NOUN
dpc-2650	198	7	of	of	ADP
dpc-2650	198	8	serpinb7	serpinb7	NOUN
dpc-2650	198	9	,	,	PUNCT
dpc-2650	198	10	ereg	ereg	NOUN
dpc-2650	198	11	,	,	PUNCT
dpc-2650	198	12	nipal4	nipal4	NOUN
dpc-2650	198	13	,	,	PUNCT
dpc-2650	198	14	and	and	CCONJ
dpc-2650	198	15	wfdc12	wfdc12	NOUN
dpc-2650	198	16	in	in	ADP
dpc-2650	198	17	the	the	DET
dpc-2650	198	18	keratinocytes	keratinocyte	NOUN
dpc-2650	198	19	of	of	ADP
dpc-2650	198	20	psoriatic	psoriatic	ADJ
dpc-2650	198	21	skin	skin	NOUN
dpc-2650	198	22	,	,	PUNCT
dpc-2650	198	23	and	and	CCONJ
dpc-2650	198	24	they	they	PRON
dpc-2650	198	25	claimed	claim	VERB
dpc-2650	198	26	that	that	SCONJ
dpc-2650	198	27	serpinb7	serpinb7	PROPN
dpc-2650	198	28	and	and	CCONJ
dpc-2650	198	29	the	the	DET
dpc-2650	198	30	other	other	ADJ
dpc-2650	198	31	3	3	NUM
dpc-2650	198	32	genes	gene	NOUN
dpc-2650	198	33	lead	lead	VERB
dpc-2650	198	34	to	to	ADP
dpc-2650	198	35	hyperproliferation	hyperproliferation	NOUN
dpc-2650	198	36	and	and	CCONJ
dpc-2650	198	37	abnormal	abnormal	ADJ
dpc-2650	198	38	differentiation	differentiation	NOUN
dpc-2650	198	39	of	of	ADP
dpc-2650	198	40	keratinocytes	keratinocyte	NOUN
dpc-2650	198	41	in	in	ADP
dpc-2650	198	42	psoriatic	psoriatic	ADJ
dpc-2650	198	43	epidermis	epidermis	NOUN
dpc-2650	198	44	,	,	PUNCT
dpc-2650	198	45	and	and	CCONJ
dpc-2650	198	46	also	also	ADV
dpc-2650	198	47	migration	migration	NOUN
dpc-2650	198	48	of	of	ADP
dpc-2650	198	49	a	a	DET
dpc-2650	198	50	large	large	ADJ
dpc-2650	198	51	number	number	NOUN
dpc-2650	198	52	of	of	ADP
dpc-2650	198	53	inflammatory	inflammatory	ADJ
dpc-2650	198	54	cells	cell	NOUN
dpc-2650	198	55	into	into	ADP
dpc-2650	198	56	the	the	DET
dpc-2650	198	57	dermal	dermal	ADJ
dpc-2650	198	58	lesions	lesion	NOUN
dpc-2650	198	59	[	[	X
dpc-2650	198	60	8	8	NUM
dpc-2650	198	61	]	]	PUNCT
dpc-2650	198	62	.	.	PUNCT
dpc-2650	199	1	similar	similar	ADJ
dpc-2650	199	2	to	to	ADP
dpc-2650	199	3	this	this	DET
dpc-2650	199	4	study	study	NOUN
dpc-2650	199	5	,	,	PUNCT
dpc-2650	199	6	benezeder	benezeder	VERB
dpc-2650	199	7	et	et	PROPN
dpc-2650	199	8	al	al	PROPN
dpc-2650	199	9	reported	report	VERB
dpc-2650	199	10	after	after	SCONJ
dpc-2650	199	11	dithranol	dithranol	NOUN
dpc-2650	199	12	application	application	NOUN
dpc-2650	199	13	serpinb7	serpinb7	NOUN
dpc-2650	199	14	expressions	expression	NOUN
dpc-2650	199	15	and	and	CCONJ
dpc-2650	199	16	other	other	ADJ
dpc-2650	199	17	immunological	immunological	ADJ
dpc-2650	199	18	mechanisms	mechanism	NOUN
dpc-2650	199	19	including	include	VERB
dpc-2650	199	20	t	t	PROPN
dpc-2650	199	21	-	-	PUNCT
dpc-2650	199	22	cell	cell	NOUN
dpc-2650	199	23	infiltration	infiltration	NOUN
dpc-2650	199	24	were	be	AUX
dpc-2650	199	25	decreased	decrease	VERB
dpc-2650	199	26	in	in	ADP
dpc-2650	199	27	the	the	DET
dpc-2650	199	28	psoriatic	psoriatic	ADJ
dpc-2650	199	29	skin	skin	NOUN
dpc-2650	200	1	[	[	X
dpc-2650	200	2	9	9	NUM
dpc-2650	200	3	]	]	PUNCT
dpc-2650	200	4	.	.	PUNCT
dpc-2650	201	1	contrary	contrary	ADJ
dpc-2650	201	2	to	to	ADP
dpc-2650	201	3	these	these	DET
dpc-2650	201	4	studies	study	NOUN
dpc-2650	201	5	,	,	PUNCT
dpc-2650	201	6	zheng	zheng	PROPN
dpc-2650	201	7	reported	report	VERB
dpc-2650	201	8	that	that	SCONJ
dpc-2650	201	9	serpinb7	serpinb7	NOUN
dpc-2650	201	10	deficiency	deficiency	NOUN
dpc-2650	201	11	leads	lead	VERB
dpc-2650	201	12	to	to	ADP
dpc-2650	201	13	excessive	excessive	ADJ
dpc-2650	201	14	proliferation	proliferation	NOUN
dpc-2650	201	15	and	and	CCONJ
dpc-2650	201	16	impaired	impaired	ADJ
dpc-2650	201	17	differentiation	differentiation	NOUN
dpc-2650	201	18	of	of	ADP
dpc-2650	201	19	keratinocytes	keratinocyte	NOUN
dpc-2650	201	20	,	,	PUNCT
dpc-2650	201	21	and	and	CCONJ
dpc-2650	201	22	also	also	ADV
dpc-2650	201	23	excessive	excessive	ADJ
dpc-2650	201	24	production	production	NOUN
dpc-2650	201	25	of	of	ADP
dpc-2650	201	26	chemokines	chemokine	NOUN
dpc-2650	201	27	and	and	CCONJ
dpc-2650	201	28	antimicrobial	antimicrobial	ADJ
dpc-2650	201	29	peptides	peptide	NOUN
dpc-2650	201	30	via	via	ADP
dpc-2650	201	31	calcium	calcium	NOUN
dpc-2650	201	32	mediated	mediate	VERB
dpc-2650	201	33	pathways	pathway	NOUN
dpc-2650	201	34	and	and	CCONJ
dpc-2650	201	35	,	,	PUNCT
dpc-2650	201	36	as	as	SCONJ
dpc-2650	201	37	a	a	DET
dpc-2650	201	38	result	result	NOUN
dpc-2650	201	39	psoriasis	psoriasis	NOUN
dpc-2650	201	40	develops	develop	VERB
dpc-2650	201	41	[	[	PUNCT
dpc-2650	201	42	10	10	NUM
dpc-2650	201	43	]	]	PUNCT
dpc-2650	201	44	.	.	PUNCT
dpc-2650	202	1	similar	similar	ADJ
dpc-2650	202	2	to	to	ADP
dpc-2650	202	3	this	this	DET
dpc-2650	202	4	report	report	NOUN
dpc-2650	202	5	,	,	PUNCT
dpc-2650	202	6	our	our	PRON
dpc-2650	202	7	findings	finding	NOUN
dpc-2650	202	8	regarding	regard	VERB
dpc-2650	202	9	significantly	significantly	ADV
dpc-2650	202	10	down	down	ADV
dpc-2650	202	11	-	-	PUNCT
dpc-2650	202	12	regulated	regulate	VERB
dpc-2650	202	13	expression	expression	NOUN
dpc-2650	202	14	levels	level	NOUN
dpc-2650	202	15	of	of	ADP
dpc-2650	202	16	serpinb7	serpinb7	NOUN
dpc-2650	202	17	in	in	ADP
dpc-2650	202	18	the	the	DET
dpc-2650	202	19	lesional	lesional	ADJ
dpc-2650	202	20	skin	skin	NOUN
dpc-2650	202	21	of	of	ADP
dpc-2650	202	22	psoriatic	psoriatic	ADJ
dpc-2650	202	23	patients	patient	NOUN
dpc-2650	202	24	makes	make	VERB
dpc-2650	202	25	us	we	PRON
dpc-2650	202	26	think	think	VERB
dpc-2650	202	27	that	that	SCONJ
dpc-2650	202	28	serpinb7	serpinb7	NOUN
dpc-2650	202	29	has	have	VERB
dpc-2650	202	30	protective	protective	ADJ
dpc-2650	202	31	roles	role	NOUN
dpc-2650	202	32	for	for	ADP
dpc-2650	202	33	many	many	ADJ
dpc-2650	202	34	cells	cell	NOUN
dpc-2650	202	35	including	include	VERB
dpc-2650	202	36	keratinocytes	keratinocyte	NOUN
dpc-2650	202	37	.	.	PUNCT
dpc-2650	203	1	shiba	shiba	PROPN
dpc-2650	203	2	et	et	PROPN
dpc-2650	203	3	al	al	PROPN
dpc-2650	203	4	reported	report	VERB
dpc-2650	203	5	significant	significant	ADJ
dpc-2650	203	6	down	down	ADP
dpc-2650	203	7	-	-	PUNCT
dpc-2650	203	8	regulation	regulation	NOUN
dpc-2650	203	9	of	of	ADP
dpc-2650	203	10	serpinb7	serpinb7	ADJ
dpc-2650	203	11	gene	gene	NOUN
dpc-2650	203	12	expression	expression	NOUN
dpc-2650	203	13	in	in	ADP
dpc-2650	203	14	oral	oral	ADJ
dpc-2650	203	15	squamous	squamous	ADJ
dpc-2650	203	16	cell	cell	NOUN
dpc-2650	203	17	carcinoma	carcinoma	NOUN
dpc-2650	203	18	samples	sample	NOUN
dpc-2650	203	19	than	than	ADP
dpc-2650	203	20	in	in	ADP
dpc-2650	203	21	normal	normal	ADJ
dpc-2650	203	22	tissue	tissue	NOUN
dpc-2650	203	23	samples	sample	NOUN
dpc-2650	203	24	which	which	PRON
dpc-2650	203	25	also	also	ADV
dpc-2650	203	26	supports	support	VERB
dpc-2650	203	27	our	our	PRON
dpc-2650	203	28	findings	finding	NOUN
dpc-2650	203	29	about	about	ADP
dpc-2650	203	30	protective	protective	ADJ
dpc-2650	203	31	role	role	NOUN
dpc-2650	203	32	of	of	ADP
dpc-2650	203	33	serpinb7	serpinb7	ADJ
dpc-2650	203	34	gene	gene	NOUN
dpc-2650	203	35	[	[	X
dpc-2650	203	36	26	26	NUM
dpc-2650	203	37	]	]	PUNCT
dpc-2650	203	38	.	.	PUNCT
dpc-2650	204	1	furthermore	furthermore	ADV
dpc-2650	204	2	,	,	PUNCT
dpc-2650	204	3	we	we	PRON
dpc-2650	204	4	also	also	ADV
dpc-2650	204	5	found	find	VERB
dpc-2650	204	6	a	a	DET
dpc-2650	204	7	negative	negative	ADJ
dpc-2650	204	8	correlation	correlation	NOUN
dpc-2650	204	9	between	between	ADP
dpc-2650	204	10	the	the	DET
dpc-2650	204	11	severity	severity	NOUN
dpc-2650	204	12	of	of	ADP
dpc-2650	204	13	the	the	DET
dpc-2650	204	14	disease	disease	NOUN
dpc-2650	204	15	and	and	CCONJ
dpc-2650	204	16	serpinb7	serpinb7	NOUN
dpc-2650	204	17	gene	gene	NOUN
dpc-2650	204	18	expression	expression	NOUN
dpc-2650	204	19	levels	level	NOUN
dpc-2650	204	20	.	.	PUNCT
dpc-2650	205	1	nevertheless	nevertheless	ADV
dpc-2650	205	2	,	,	PUNCT
dpc-2650	205	3	the	the	DET
dpc-2650	205	4	contradictory	contradictory	ADJ
dpc-2650	205	5	results	result	NOUN
dpc-2650	205	6	about	about	ADP
dpc-2650	205	7	serpinb7	serpinb7	NOUN
dpc-2650	205	8	in	in	ADP
dpc-2650	205	9	the	the	DET
dpc-2650	205	10	literature	literature	NOUN
dpc-2650	205	11	may	may	AUX
dpc-2650	205	12	be	be	AUX
dpc-2650	205	13	related	relate	VERB
dpc-2650	205	14	to	to	ADP
dpc-2650	205	15	low	low	ADJ
dpc-2650	205	16	number	number	NOUN
dpc-2650	205	17	of	of	ADP
dpc-2650	205	18	tissue	tissue	NOUN
dpc-2650	205	19	sample	sample	NOUN
dpc-2650	205	20	or	or	CCONJ
dpc-2650	205	21	different	different	ADJ
dpc-2650	205	22	methods	method	NOUN
dpc-2650	205	23	of	of	ADP
dpc-2650	205	24	the	the	DET
dpc-2650	205	25	studies	study	NOUN
dpc-2650	205	26	such	such	ADJ
dpc-2650	205	27	as	as	ADP
dpc-2650	205	28	cell	cell	NOUN
dpc-2650	205	29	culture	culture	NOUN
dpc-2650	205	30	,	,	PUNCT
dpc-2650	205	31	mice	mice	NOUN
dpc-2650	205	32	tissues	tissue	NOUN
dpc-2650	205	33	in	in	ADP
dpc-2650	205	34	vitro	vitro	VERB
dpc-2650	205	35	.	.	PUNCT
dpc-2650	206	1	besides	besides	SCONJ
dpc-2650	206	2	the	the	DET
dpc-2650	206	3	protective	protective	ADJ
dpc-2650	206	4	roles	role	NOUN
dpc-2650	206	5	of	of	ADP
dpc-2650	206	6	serpinb7	serpinb7	NOUN
dpc-2650	206	7	,	,	PUNCT
dpc-2650	206	8	it	it	PRON
dpc-2650	206	9	also	also	ADV
dpc-2650	206	10	seems	seem	VERB
dpc-2650	206	11	to	to	PART
dpc-2650	206	12	be	be	AUX
dpc-2650	206	13	a	a	DET
dpc-2650	206	14	marker	marker	NOUN
dpc-2650	206	15	of	of	ADP
dpc-2650	206	16	disease	disease	NOUN
dpc-2650	206	17	severity	severity	NOUN
dpc-2650	206	18	.	.	PUNCT
dpc-2650	207	1	we	we	PRON
dpc-2650	207	2	also	also	ADV
dpc-2650	207	3	think	think	VERB
dpc-2650	207	4	that	that	SCONJ
dpc-2650	207	5	serpinb7	serpinb7	NOUN
dpc-2650	207	6	might	might	AUX
dpc-2650	207	7	be	be	AUX
dpc-2650	207	8	showed	show	VERB
dpc-2650	207	9	as	as	ADP
dpc-2650	207	10	a	a	DET
dpc-2650	207	11	determinant	determinant	NOUN
dpc-2650	207	12	of	of	ADP
dpc-2650	207	13	prognosis	prognosis	NOUN
dpc-2650	207	14	and	and	CCONJ
dpc-2650	207	15	response	response	NOUN
dpc-2650	207	16	to	to	ADP
dpc-2650	207	17	treatment	treatment	NOUN
dpc-2650	207	18	in	in	ADP
dpc-2650	207	19	patients	patient	NOUN
dpc-2650	207	20	with	with	ADP
dpc-2650	207	21	psoriasis	psoriasis	NOUN
dpc-2650	207	22	8	8	NUM
dpc-2650	207	23	original	original	ADJ
dpc-2650	207	24	article	article	NOUN
dpc-2650	207	25	|	|	ADV
dpc-2650	207	26	dermatol	dermatol	ADJ
dpc-2650	207	27	pract	pract	NOUN
dpc-2650	207	28	concept	concept	NOUN
dpc-2650	207	29	.	.	PUNCT
dpc-2650	208	1	2023;13(2):e2023085	2023;13(2):e2023085	NUM
dpc-2650	208	2	10	10	NUM
dpc-2650	208	3	.	.	PUNCT
dpc-2650	209	1	zheng	zheng	PROPN
dpc-2650	209	2	h.	h.	PROPN
dpc-2650	209	3	serpinb7	serpinb7	NOUN
dpc-2650	209	4	deficiency	deficiency	NOUN
dpc-2650	209	5	contributes	contribute	VERB
dpc-2650	209	6	to	to	ADP
dpc-2650	209	7	development	development	NOUN
dpc-2650	209	8	of	of	ADP
dpc-2650	209	9	psoriasis	psoriasis	NOUN
dpc-2650	209	10	via	via	ADP
dpc-2650	209	11	calcium	calcium	NOUN
dpc-2650	209	12	-	-	PUNCT
dpc-2650	209	13	mediated	mediate	VERB
dpc-2650	209	14	keratinocyte	keratinocyte	NOUN
dpc-2650	209	15	differentiation	differentiation	NOUN
dpc-2650	209	16	dysfunction	dysfunction	NOUN
dpc-2650	209	17	.	.	PUNCT
dpc-2650	210	1	cell	cell	NOUN
dpc-2650	210	2	death	death	NOUN
dpc-2650	210	3	dis	dis	PROPN
dpc-2650	210	4	.	.	PUNCT
dpc-2650	211	1	2022	2022	NUM
dpc-2650	211	2	21;13(7):635	21;13(7):635	NUM
dpc-2650	211	3	.	.	PUNCT
dpc-2650	212	1	doi	doi	PROPN
dpc-2650	212	2	:	:	PUNCT
dpc-2650	212	3	10.1038	10.1038	NUM
dpc-2650	212	4	/	/	SYM
dpc-2650	212	5	s41419	s41419	NUM
dpc-2650	212	6	-	-	NOUN
dpc-2650	212	7	022	022	NUM
dpc-2650	212	8	-	-	PUNCT
dpc-2650	212	9	05045	05045	NUM
dpc-2650	212	10	-	-	SYM
dpc-2650	212	11	8	8	NUM
dpc-2650	212	12	.	.	PUNCT
dpc-2650	213	1	pmid	pmid	NOUN
dpc-2650	213	2	:	:	PUNCT
dpc-2650	213	3	35864103	35864103	NUM
dpc-2650	213	4	.	.	PUNCT
dpc-2650	214	1	pmcid	pmcid	NOUN
dpc-2650	214	2	:	:	PUNCT
dpc-2650	214	3	pmc9304369	pmc9304369	NOUN
dpc-2650	214	4	.	.	PUNCT
dpc-2650	215	1	11	11	NUM
dpc-2650	215	2	.	.	X
dpc-2650	216	1	langley	langley	PROPN
dpc-2650	216	2	rg	rg	PROPN
dpc-2650	216	3	,	,	PUNCT
dpc-2650	216	4	ellis	ellis	PROPN
dpc-2650	216	5	cn	cn	AUX
dpc-2650	216	6	.	.	PROPN
dpc-2650	216	7	evaluating	evaluate	VERB
dpc-2650	216	8	psoriasis	psoriasis	NOUN
dpc-2650	216	9	with	with	ADP
dpc-2650	216	10	psoriasis	psoriasis	NOUN
dpc-2650	216	11	area	area	NOUN
dpc-2650	216	12	and	and	CCONJ
dpc-2650	216	13	severity	severity	NOUN
dpc-2650	216	14	index	index	NOUN
dpc-2650	216	15	,	,	PUNCT
dpc-2650	216	16	psoriasis	psoriasis	NOUN
dpc-2650	216	17	global	global	ADJ
dpc-2650	216	18	assessment	assessment	NOUN
dpc-2650	216	19	,	,	PUNCT
dpc-2650	216	20	and	and	CCONJ
dpc-2650	216	21	lattice	lattice	NOUN
dpc-2650	216	22	system	system	NOUN
dpc-2650	216	23	physician	physician	NOUN
dpc-2650	216	24	’s	’s	PART
dpc-2650	216	25	global	global	ADJ
dpc-2650	216	26	assessment	assessment	NOUN
dpc-2650	216	27	.	.	PUNCT
dpc-2650	217	1	j	j	PROPN
dpc-2650	217	2	am	be	AUX
dpc-2650	217	3	acad	acad	ADJ
dpc-2650	217	4	dermatol	dermatol	NOUN
dpc-2650	217	5	.	.	PUNCT
dpc-2650	218	1	2004;51(4):563	2004;51(4):563	NUM
dpc-2650	218	2	-	-	PUNCT
dpc-2650	218	3	569	569	NUM
dpc-2650	218	4	.	.	PUNCT
dpc-2650	219	1	doi	doi	NOUN
dpc-2650	219	2	:	:	PUNCT
dpc-2650	219	3	10.1016	10.1016	NUM
dpc-2650	219	4	/	/	SYM
dpc-2650	219	5	j.jaad.2004.04.012	j.jaad.2004.04.012	PROPN
dpc-2650	219	6	.	.	PUNCT
dpc-2650	220	1	pmid	pmid	NOUN
dpc-2650	220	2	:	:	PUNCT
dpc-2650	220	3	15389191	15389191	NUM
dpc-2650	220	4	12	12	NUM
dpc-2650	220	5	.	.	PUNCT
dpc-2650	221	1	ogawa	ogawa	PROPN
dpc-2650	221	2	k	k	PROPN
dpc-2650	221	3	,	,	PUNCT
dpc-2650	221	4	okada	okada	PROPN
dpc-2650	221	5	y.	y.	PROPN
dpc-2650	221	6	the	the	DET
dpc-2650	221	7	current	current	ADJ
dpc-2650	221	8	landscape	landscape	NOUN
dpc-2650	221	9	of	of	ADP
dpc-2650	221	10	psoriasis	psoriasis	NOUN
dpc-2650	221	11	genetics	genetic	NOUN
dpc-2650	221	12	in	in	ADP
dpc-2650	221	13	2020	2020	NUM
dpc-2650	221	14	.	.	PUNCT
dpc-2650	222	1	j	j	PROPN
dpc-2650	222	2	dermatol	dermatol	NOUN
dpc-2650	222	3	sci	sci	PROPN
dpc-2650	222	4	.	.	PUNCT
dpc-2650	223	1	2020;99(1):2	2020;99(1):2	NUM
dpc-2650	223	2	-	-	SYM
dpc-2650	223	3	8	8	NUM
dpc-2650	223	4	.	.	PUNCT
dpc-2650	224	1	doi	doi	NOUN
dpc-2650	224	2	:	:	PUNCT
dpc-2650	224	3	10.1016	10.1016	NUM
dpc-2650	224	4	/	/	SYM
dpc-2650	224	5	j.jdermsci.2020.05.008	j.jdermsci.2020.05.008	PROPN
dpc-2650	224	6	.	.	PUNCT
dpc-2650	225	1	pmid	pmid	NOUN
dpc-2650	225	2	:	:	PUNCT
dpc-2650	225	3	32536600	32536600	NUM
dpc-2650	225	4	.	.	PUNCT
dpc-2650	226	1	13	13	NUM
dpc-2650	226	2	.	.	PUNCT
dpc-2650	226	3	griffiths	griffiths	PROPN
dpc-2650	226	4	ce	ce	PROPN
dpc-2650	226	5	,	,	PUNCT
dpc-2650	226	6	barker	barker	PROPN
dpc-2650	227	1	jn	jn	PROPN
dpc-2650	227	2	.	.	PROPN
dpc-2650	228	1	pathogenesis	pathogenesis	PROPN
dpc-2650	228	2	and	and	CCONJ
dpc-2650	228	3	clinical	clinical	ADJ
dpc-2650	228	4	features	feature	NOUN
dpc-2650	228	5	of	of	ADP
dpc-2650	228	6	psoriasis	psoriasis	NOUN
dpc-2650	228	7	.	.	PUNCT
dpc-2650	229	1	lancet	lancet	NOUN
dpc-2650	229	2	.	.	PUNCT
dpc-2650	230	1	2007;370(9583):263	2007;370(9583):263	NUM
dpc-2650	230	2	-	-	SYM
dpc-2650	230	3	271	271	NUM
dpc-2650	230	4	.	.	PUNCT
dpc-2650	231	1	doi	doi	NOUN
dpc-2650	231	2	:	:	PUNCT
dpc-2650	231	3	10.1016/	10.1016/	NUM
dpc-2650	231	4	s0140	s0140	PROPN
dpc-2650	231	5	-	-	PUNCT
dpc-2650	231	6	6736(07)61128	6736(07)61128	NUM
dpc-2650	231	7	-	-	PUNCT
dpc-2650	231	8	3	3	NUM
dpc-2650	231	9	.	.	PUNCT
dpc-2650	232	1	pmid	pmid	NOUN
dpc-2650	232	2	:	:	PUNCT
dpc-2650	232	3	17658397	17658397	NUM
dpc-2650	232	4	.	.	PUNCT
dpc-2650	233	1	14	14	NUM
dpc-2650	233	2	.	.	PUNCT
dpc-2650	234	1	sagoo	sagoo	PROPN
dpc-2650	234	2	gs	gs	PROPN
dpc-2650	234	3	,	,	PUNCT
dpc-2650	234	4	tazi	tazi	NOUN
dpc-2650	234	5	-	-	PUNCT
dpc-2650	234	6	ahnini	ahnini	NOUN
dpc-2650	234	7	r	r	NOUN
dpc-2650	234	8	,	,	PUNCT
dpc-2650	234	9	barker	barker	PROPN
dpc-2650	234	10	jw	jw	PROPN
dpc-2650	234	11	,	,	PUNCT
dpc-2650	234	12	et	et	PROPN
dpc-2650	234	13	al	al	PROPN
dpc-2650	234	14	.	.	PUNCT
dpc-2650	235	1	meta	meta	VERB
dpc-2650	235	2	-	-	PUNCT
dpc-2650	235	3	analysis	analysis	NOUN
dpc-2650	235	4	of	of	ADP
dpc-2650	235	5	genome	genome	NOUN
dpc-2650	235	6	-	-	PUNCT
dpc-2650	235	7	wide	wide	ADJ
dpc-2650	235	8	studies	study	NOUN
dpc-2650	235	9	of	of	ADP
dpc-2650	235	10	psoriasis	psoriasis	NOUN
dpc-2650	235	11	susceptibility	susceptibility	NOUN
dpc-2650	235	12	reveals	reveal	VERB
dpc-2650	235	13	linkage	linkage	NOUN
dpc-2650	235	14	to	to	ADP
dpc-2650	235	15	chromosomes	chromosome	NOUN
dpc-2650	235	16	6p21	6p21	NOUN
dpc-2650	235	17	and	and	CCONJ
dpc-2650	235	18	4q28	4q28	NOUN
dpc-2650	235	19	-	-	PUNCT
dpc-2650	235	20	q31	q31	NUM
dpc-2650	235	21	in	in	ADP
dpc-2650	235	22	caucasian	caucasian	ADJ
dpc-2650	235	23	and	and	CCONJ
dpc-2650	235	24	chinese	chinese	PROPN
dpc-2650	235	25	hans	hans	PROPN
dpc-2650	235	26	population	population	NOUN
dpc-2650	235	27	.	.	PUNCT
dpc-2650	236	1	j	j	PROPN
dpc-2650	236	2	invest	invest	VERB
dpc-2650	236	3	dermatol	dermatol	NOUN
dpc-2650	236	4	.	.	PUNCT
dpc-2650	237	1	2004;122(6):1401	2004;122(6):1401	NUM
dpc-2650	237	2	-	-	SYM
dpc-2650	237	3	1405	1405	NUM
dpc-2650	237	4	.	.	PUNCT
dpc-2650	238	1	doi	doi	NOUN
dpc-2650	238	2	:	:	PUNCT
dpc-2650	238	3	10.1111	10.1111	NUM
dpc-2650	238	4	/	/	SYM
dpc-2650	238	5	j.0022	j.0022	NOUN
dpc-2650	238	6	-	-	PUNCT
dpc-2650	238	7	202x.2004.22607.x	202x.2004.22607.x	NOUN
dpc-2650	238	8	.	.	PUNCT
dpc-2650	239	1	pmid	pmid	NOUN
dpc-2650	239	2	:	:	PUNCT
dpc-2650	239	3	15175030	15175030	NUM
dpc-2650	239	4	.	.	PUNCT
dpc-2650	240	1	15	15	NUM
dpc-2650	240	2	.	.	X
dpc-2650	240	3	pastore	pastore	PROPN
dpc-2650	240	4	s	s	PROPN
dpc-2650	240	5	,	,	PUNCT
dpc-2650	240	6	mascia	mascia	NOUN
dpc-2650	240	7	f	f	NOUN
dpc-2650	240	8	,	,	PUNCT
dpc-2650	240	9	mariani	mariani	PROPN
dpc-2650	240	10	v	v	PROPN
dpc-2650	240	11	,	,	PUNCT
dpc-2650	240	12	girolomoni	girolomoni	PROPN
dpc-2650	240	13	g.	g.	NOUN
dpc-2650	240	14	the	the	DET
dpc-2650	240	15	epidermal	epidermal	ADJ
dpc-2650	240	16	growth	growth	NOUN
dpc-2650	240	17	factor	factor	NOUN
dpc-2650	240	18	receptor	receptor	NOUN
dpc-2650	240	19	system	system	NOUN
dpc-2650	240	20	in	in	ADP
dpc-2650	240	21	skin	skin	NOUN
dpc-2650	240	22	repair	repair	NOUN
dpc-2650	240	23	and	and	CCONJ
dpc-2650	240	24	inflammation	inflammation	NOUN
dpc-2650	240	25	.	.	PUNCT
dpc-2650	241	1	j	j	PROPN
dpc-2650	241	2	invest	invest	VERB
dpc-2650	241	3	dermatol	dermatol	NOUN
dpc-2650	241	4	.	.	PUNCT
dpc-2650	242	1	2008;128(6):1365	2008;128(6):1365	NUM
dpc-2650	242	2	-	-	SYM
dpc-2650	242	3	1374	1374	NUM
dpc-2650	242	4	.	.	PUNCT
dpc-2650	243	1	doi	doi	NOUN
dpc-2650	243	2	:	:	PUNCT
dpc-2650	243	3	10.1038	10.1038	NUM
dpc-2650	243	4	/	/	SYM
dpc-2650	243	5	sj	sj	NOUN
dpc-2650	243	6	.	.	PUNCT
dpc-2650	243	7	jid.5701184	jid.5701184	VERB
dpc-2650	243	8	.	.	PUNCT
dpc-2650	244	1	pmid	pmid	NOUN
dpc-2650	244	2	:	:	PUNCT
dpc-2650	244	3	18049451	18049451	NUM
dpc-2650	244	4	.	.	PUNCT
dpc-2650	245	1	16	16	NUM
dpc-2650	245	2	.	.	PUNCT
dpc-2650	246	1	iwata	iwata	PROPN
dpc-2650	246	2	h	h	PROPN
dpc-2650	246	3	,	,	PUNCT
dpc-2650	246	4	haga	haga	NOUN
dpc-2650	246	5	n	n	CCONJ
dpc-2650	246	6	,	,	PUNCT
dpc-2650	246	7	ujiie	ujiie	ADJ
dpc-2650	246	8	h.	h.	PROPN
dpc-2650	246	9	possible	possible	ADJ
dpc-2650	246	10	role	role	NOUN
dpc-2650	246	11	of	of	ADP
dpc-2650	246	12	epiregulin	epiregulin	NOUN
dpc-2650	246	13	from	from	ADP
dpc-2650	246	14	dermal	dermal	ADJ
dpc-2650	246	15	fibroblasts	fibroblast	NOUN
dpc-2650	246	16	in	in	ADP
dpc-2650	246	17	the	the	DET
dpc-2650	246	18	keratinocyte	keratinocyte	NOUN
dpc-2650	246	19	hyperproliferation	hyperproliferation	NOUN
dpc-2650	246	20	of	of	ADP
dpc-2650	246	21	psoriasis	psoriasis	NOUN
dpc-2650	246	22	.	.	PUNCT
dpc-2650	247	1	j	j	PROPN
dpc-2650	247	2	dermatol	dermatol	NOUN
dpc-2650	247	3	.	.	PUNCT
dpc-2650	248	1	2021;48(9):1433	2021;48(9):1433	NUM
dpc-2650	248	2	-	-	SYM
dpc-2650	248	3	1438	1438	NUM
dpc-2650	248	4	.	.	PUNCT
dpc-2650	249	1	doi	doi	NOUN
dpc-2650	249	2	:	:	PUNCT
dpc-2650	249	3	10.1111/1346	10.1111/1346	NUM
dpc-2650	249	4	-	-	SYM
dpc-2650	249	5	8138.16003	8138.16003	NOUN
dpc-2650	249	6	.	.	PUNCT
dpc-2650	250	1	pmid	pmid	NOUN
dpc-2650	250	2	:	:	PUNCT
dpc-2650	250	3	34128258	34128258	NUM
dpc-2650	250	4	.	.	PUNCT
dpc-2650	251	1	17	17	NUM
dpc-2650	251	2	.	.	X
dpc-2650	252	1	lu	lu	PROPN
dpc-2650	253	1	q	q	PROPN
dpc-2650	253	2	,	,	PUNCT
dpc-2650	253	3	jiang	jiang	PROPN
dpc-2650	253	4	g.	g.	PROPN
dpc-2650	253	5	progress	progress	NOUN
dpc-2650	253	6	in	in	ADP
dpc-2650	253	7	the	the	DET
dpc-2650	253	8	application	application	NOUN
dpc-2650	253	9	of	of	ADP
dpc-2650	253	10	reflectance	reflectance	NOUN
dpc-2650	253	11	confocal	confocal	ADJ
dpc-2650	253	12	microscopy	microscopy	NOUN
dpc-2650	253	13	in	in	ADP
dpc-2650	253	14	dermatology	dermatology	NOUN
dpc-2650	253	15	.	.	PUNCT
dpc-2650	254	1	postepy	postepy	ADJ
dpc-2650	254	2	dermatol	dermatol	NOUN
dpc-2650	254	3	alergol	alergol	NOUN
dpc-2650	254	4	.	.	PUNCT
dpc-2650	255	1	2021;38(5):709	2021;38(5):709	X
dpc-2650	255	2	-	-	PUNCT
dpc-2650	255	3	715	715	NUM
dpc-2650	255	4	.	.	PUNCT
dpc-2650	256	1	doi	doi	NOUN
dpc-2650	256	2	:	:	PUNCT
dpc-2650	256	3	10.5114	10.5114	NUM
dpc-2650	256	4	/	/	SYM
dpc-2650	256	5	ada.2021.110077	ada.2021.110077	PROPN
dpc-2650	256	6	.	.	PUNCT
dpc-2650	257	1	pmid	pmid	PROPN
dpc-2650	257	2	:	:	PUNCT
dpc-2650	257	3	34849113	34849113	NUM
dpc-2650	257	4	;	;	PUNCT
dpc-2650	257	5	pmcid	pmcid	ADJ
dpc-2650	257	6	:	:	PUNCT
dpc-2650	257	7	pmc8610039	pmc8610039	NOUN
dpc-2650	257	8	.	.	PUNCT
dpc-2650	258	1	18	18	NUM
dpc-2650	258	2	.	.	PUNCT
dpc-2650	259	1	shirasawa	shirasawa	PROPN
dpc-2650	259	2	s	s	PART
dpc-2650	259	3	,	,	PUNCT
dpc-2650	259	4	sugiyama	sugiyama	NOUN
dpc-2650	259	5	s	s	PROPN
dpc-2650	259	6	,	,	PUNCT
dpc-2650	259	7	baba	baba	PROPN
dpc-2650	259	8	i	i	PRON
dpc-2650	259	9	,	,	PUNCT
dpc-2650	259	10	et	et	PROPN
dpc-2650	259	11	al	al	PROPN
dpc-2650	259	12	.	.	PUNCT
dpc-2650	259	13	dermatitis	dermatitis	PROPN
dpc-2650	259	14	due	due	ADP
dpc-2650	259	15	to	to	ADP
dpc-2650	259	16	epiregulin	epiregulin	ADJ
dpc-2650	259	17	deficiency	deficiency	NOUN
dpc-2650	259	18	and	and	CCONJ
dpc-2650	259	19	a	a	DET
dpc-2650	259	20	critical	critical	ADJ
dpc-2650	259	21	role	role	NOUN
dpc-2650	259	22	of	of	ADP
dpc-2650	259	23	epiregulin	epiregulin	NOUN
dpc-2650	259	24	in	in	ADP
dpc-2650	259	25	immune	immune	NOUN
dpc-2650	259	26	-	-	PUNCT
dpc-2650	259	27	related	relate	VERB
dpc-2650	259	28	responses	response	NOUN
dpc-2650	259	29	of	of	ADP
dpc-2650	259	30	keratinocyte	keratinocyte	NOUN
dpc-2650	259	31	and	and	CCONJ
dpc-2650	259	32	macrophage	macrophage	ADJ
dpc-2650	259	33	.	.	PUNCT
dpc-2650	260	1	proc	proc	PROPN
dpc-2650	260	2	natl	natl	PROPN
dpc-2650	260	3	acad	acad	PROPN
dpc-2650	260	4	sci	sci	PROPN
dpc-2650	260	5	usa	usa	PROPN
dpc-2650	260	6	.	.	PROPN
dpc-2650	261	1	2004;101(38):13921	2004;101(38):13921	PROPN
dpc-2650	261	2	-	-	SYM
dpc-2650	261	3	13926	13926	NUM
dpc-2650	261	4	.	.	PUNCT
dpc-2650	262	1	doi	doi	NOUN
dpc-2650	262	2	:	:	PUNCT
dpc-2650	262	3	10.1073/	10.1073/	NUM
dpc-2650	262	4	pnas.0404217101	pnas.0404217101	PROPN
dpc-2650	262	5	pmid	pmid	PROPN
dpc-2650	262	6	:	:	PUNCT
dpc-2650	262	7	15365177	15365177	NUM
dpc-2650	262	8	.	.	PUNCT
dpc-2650	263	1	pmcid	pmcid	NOUN
dpc-2650	263	2	:	:	PUNCT
dpc-2650	263	3	pmc518854	pmc518854	NOUN
dpc-2650	263	4	.	.	PUNCT
dpc-2650	264	1	19	19	NUM
dpc-2650	264	2	.	.	X
dpc-2650	265	1	wittmann	wittmann	PROPN
dpc-2650	265	2	m	m	PROPN
dpc-2650	265	3	,	,	PUNCT
dpc-2650	265	4	macdonald	macdonald	PROPN
dpc-2650	265	5	a	a	PROPN
dpc-2650	265	6	,	,	PUNCT
dpc-2650	265	7	renne	renne	PROPN
dpc-2650	265	8	j.	j.	PROPN
dpc-2650	265	9	il-18	il-18	PROPN
dpc-2650	265	10	and	and	CCONJ
dpc-2650	265	11	skin	skin	NOUN
dpc-2650	265	12	inflammation	inflammation	NOUN
dpc-2650	265	13	.	.	PUNCT
dpc-2650	266	1	autoimmun	autoimmun	PROPN
dpc-2650	266	2	rev	rev	PROPN
dpc-2650	266	3	.	.	PUNCT
dpc-2650	267	1	2009;9(1):45	2009;9(1):45	NUM
dpc-2650	267	2	-	-	SYM
dpc-2650	267	3	48	48	NUM
dpc-2650	267	4	.	.	PUNCT
dpc-2650	268	1	doi	doi	NOUN
dpc-2650	268	2	:	:	PUNCT
dpc-2650	268	3	10.1016	10.1016	NUM
dpc-2650	268	4	/	/	SYM
dpc-2650	268	5	j.autrev.2009.03.003	j.autrev.2009.03.003	PROPN
dpc-2650	268	6	.	.	PROPN
dpc-2650	269	1	pmid	pmid	NOUN
dpc-2650	269	2	:	:	PUNCT
dpc-2650	269	3	19285156	19285156	NUM
dpc-2650	269	4	.	.	PUNCT
dpc-2650	270	1	20	20	NUM
dpc-2650	270	2	.	.	PUNCT
dpc-2650	271	1	sedimbi	sedimbi	NOUN
dpc-2650	271	2	sk	sk	PROPN
dpc-2650	271	3	,	,	PUNCT
dpc-2650	271	4	hagglof	hagglof	PROPN
dpc-2650	271	5	t	t	PROPN
dpc-2650	271	6	,	,	PUNCT
dpc-2650	271	7	karlsson	karlsson	PROPN
dpc-2650	271	8	mc	mc	PROPN
dpc-2650	271	9	.	.	PROPN
dpc-2650	271	10	il-18	il-18	PUNCT
dpc-2650	271	11	in	in	ADP
dpc-2650	271	12	inflammatory	inflammatory	ADJ
dpc-2650	271	13	and	and	CCONJ
dpc-2650	271	14	autoimmune	autoimmune	ADJ
dpc-2650	271	15	disease	disease	NOUN
dpc-2650	271	16	.	.	PUNCT
dpc-2650	272	1	cell	cell	NOUN
dpc-2650	272	2	mol	mol	ADP
dpc-2650	272	3	life	life	PROPN
dpc-2650	272	4	sci	sci	PROPN
dpc-2650	272	5	.	.	PROPN
dpc-2650	272	6	2013	2013	NUM
dpc-2650	272	7	;	;	PUNCT
dpc-2650	273	1	70:4795–4808	70:4795–4808	X
dpc-2650	273	2	.	.	PUNCT
dpc-2650	273	3	doi	doi	NOUN
dpc-2650	273	4	:	:	PUNCT
dpc-2650	273	5	10.1007	10.1007	NUM
dpc-2650	273	6	/	/	SYM
dpc-2650	273	7	s00018	s00018	NOUN
dpc-2650	273	8	-	-	PUNCT
dpc-2650	273	9	013	013	NUM
dpc-2650	273	10	-	-	PUNCT
dpc-2650	273	11	1425	1425	NUM
dpc-2650	273	12	-	-	PUNCT
dpc-2650	273	13	y.	y.	NOUN
dpc-2650	273	14	pmid	pmid	PROPN
dpc-2650	273	15	:	:	PUNCT
dpc-2650	273	16	23892891	23892891	NUM
dpc-2650	273	17	.	.	PUNCT
dpc-2650	274	1	21	21	NUM
dpc-2650	274	2	.	.	X
dpc-2650	275	1	combs	combs	PROPN
dpc-2650	275	2	ap	ap	PROPN
dpc-2650	275	3	.	.	PUNCT
dpc-2650	276	1	recent	recent	ADJ
dpc-2650	276	2	advances	advance	NOUN
dpc-2650	276	3	in	in	ADP
dpc-2650	276	4	the	the	DET
dpc-2650	276	5	discovery	discovery	NOUN
dpc-2650	276	6	of	of	ADP
dpc-2650	276	7	competitive	competitive	ADJ
dpc-2650	276	8	protein	protein	NOUN
dpc-2650	276	9	tyrosine	tyrosine	NOUN
dpc-2650	276	10	phosphatase	phosphatase	NOUN
dpc-2650	276	11	1b	1b	NUM
dpc-2650	276	12	inhibitors	inhibitor	NOUN
dpc-2650	276	13	for	for	ADP
dpc-2650	276	14	the	the	DET
dpc-2650	276	15	treatment	treatment	NOUN
dpc-2650	276	16	of	of	ADP
dpc-2650	276	17	diabetes	diabetes	NOUN
dpc-2650	276	18	,	,	PUNCT
dpc-2650	276	19	obesity	obesity	NOUN
dpc-2650	276	20	,	,	PUNCT
dpc-2650	276	21	and	and	CCONJ
dpc-2650	276	22	cancer	cancer	NOUN
dpc-2650	276	23	.	.	PUNCT
dpc-2650	277	1	j	j	PROPN
dpc-2650	277	2	med	med	PROPN
dpc-2650	277	3	chem	chem	NOUN
dpc-2650	277	4	.	.	PUNCT
dpc-2650	278	1	2010;53(6):2333	2010;53(6):2333	NOUN
dpc-2650	278	2	-	-	SYM
dpc-2650	278	3	2344	2344	NUM
dpc-2650	278	4	.	.	PUNCT
dpc-2650	279	1	doi	doi	NOUN
dpc-2650	279	2	.	.	PROPN
dpc-2650	279	3	10.1021	10.1021	NUM
dpc-2650	279	4	/	/	SYM
dpc-2650	279	5	jm901090b	jm901090b	PROPN
dpc-2650	279	6	.	.	PUNCT
dpc-2650	280	1	pmid	pmid	NOUN
dpc-2650	280	2	:	:	PUNCT
dpc-2650	280	3	20000419	20000419	NUM
dpc-2650	280	4	.	.	PUNCT
dpc-2650	281	1	22	22	NUM
dpc-2650	281	2	.	.	PUNCT
dpc-2650	281	3	kipfer	kipfer	VERB
dpc-2650	281	4	-	-	PUNCT
dpc-2650	281	5	coudreau	coudreau	PROPN
dpc-2650	281	6	s	s	PROPN
dpc-2650	281	7	,	,	PUNCT
dpc-2650	281	8	eberlé	eberlé	PROPN
dpc-2650	281	9	d	d	PROPN
dpc-2650	281	10	,	,	PUNCT
dpc-2650	281	11	sahbatou	sahbatou	PROPN
dpc-2650	281	12	m	m	PROPN
dpc-2650	281	13	,	,	PUNCT
dpc-2650	281	14	et	et	PROPN
dpc-2650	281	15	al	al	PROPN
dpc-2650	281	16	.	.	PROPN
dpc-2650	282	1	single	single	ADJ
dpc-2650	282	2	nucleotide	nucleotide	ADJ
dpc-2650	282	3	polymorphisms	polymorphism	NOUN
dpc-2650	282	4	of	of	ADP
dpc-2650	282	5	protein	protein	NOUN
dpc-2650	282	6	tyrosine	tyrosine	NOUN
dpc-2650	282	7	phosphatase	phosphatase	NOUN
dpc-2650	282	8	1b	1b	NUM
dpc-2650	282	9	gene	gene	NOUN
dpc-2650	282	10	are	be	AUX
dpc-2650	282	11	associated	associate	VERB
dpc-2650	282	12	with	with	ADP
dpc-2650	282	13	obesity	obesity	NOUN
dpc-2650	282	14	in	in	ADP
dpc-2650	282	15	morbidly	morbidly	ADV
dpc-2650	282	16	obese	obese	ADJ
dpc-2650	282	17	french	french	ADJ
dpc-2650	282	18	subjects	subject	NOUN
dpc-2650	282	19	.	.	PUNCT
dpc-2650	283	1	diabetologia	diabetologia	NOUN
dpc-2650	283	2	.	.	PUNCT
dpc-2650	284	1	2004;47(7):1278	2004;47(7):1278	NUM
dpc-2650	284	2	-	-	PUNCT
dpc-2650	284	3	1284	1284	NUM
dpc-2650	284	4	.	.	PUNCT
dpc-2650	285	1	doi	doi	NOUN
dpc-2650	285	2	:	:	PUNCT
dpc-2650	285	3	10.1007	10.1007	NUM
dpc-2650	285	4	/	/	SYM
dpc-2650	285	5	s00125004	s00125004	NOUN
dpc-2650	285	6	-	-	PUNCT
dpc-2650	285	7	1432	1432	NUM
dpc-2650	285	8	-	-	SYM
dpc-2650	285	9	5	5	NUM
dpc-2650	285	10	.	.	PUNCT
dpc-2650	286	1	pmid	pmid	NOUN
dpc-2650	286	2	:	:	PUNCT
dpc-2650	286	3	15235769	15235769	NUM
dpc-2650	286	4	.	.	PUNCT
dpc-2650	287	1	23	23	NUM
dpc-2650	287	2	.	.	PUNCT
dpc-2650	287	3	bento	bento	NOUN
dpc-2650	287	4	jl	jl	PROPN
dpc-2650	287	5	,	,	PUNCT
dpc-2650	287	6	palmer	palmer	PROPN
dpc-2650	287	7	nd	nd	NUM
dpc-2650	287	8	,	,	PUNCT
dpc-2650	287	9	mychaleckyj	mychaleckyj	PROPN
dpc-2650	287	10	jc	jc	PROPN
dpc-2650	287	11	,	,	PUNCT
dpc-2650	287	12	et	et	PROPN
dpc-2650	287	13	al	al	PROPN
dpc-2650	287	14	.	.	PROPN
dpc-2650	287	15	association	association	PROPN
dpc-2650	287	16	of	of	ADP
dpc-2650	287	17	protein	protein	NOUN
dpc-2650	287	18	tyrosine	tyrosine	NOUN
dpc-2650	287	19	phosphatase	phosphatase	NOUN
dpc-2650	287	20	1b	1b	NUM
dpc-2650	287	21	gene	gene	NOUN
dpc-2650	287	22	polymorphisms	polymorphism	NOUN
dpc-2650	287	23	with	with	ADP
dpc-2650	287	24	type	type	NOUN
dpc-2650	287	25	2	2	NUM
dpc-2650	287	26	diabetes	diabetes	NOUN
dpc-2650	287	27	.	.	PUNCT
dpc-2650	288	1	diabetes	diabetes	NOUN
dpc-2650	288	2	.	.	PUNCT
dpc-2650	289	1	2004;53(11):3007	2004;53(11):3007	NUM
dpc-2650	289	2	-	-	SYM
dpc-2650	289	3	3012	3012	NUM
dpc-2650	289	4	.	.	PUNCT
dpc-2650	290	1	doi	doi	NOUN
dpc-2650	290	2	:	:	PUNCT
dpc-2650	290	3	10.2337	10.2337	NUM
dpc-2650	290	4	/	/	SYM
dpc-2650	290	5	diabetes.53.11.3007	diabetes.53.11.3007	NOUN
dpc-2650	290	6	.	.	PUNCT
dpc-2650	291	1	pmid	pmid	NOUN
dpc-2650	291	2	:	:	PUNCT
dpc-2650	291	3	15504984	15504984	NUM
dpc-2650	291	4	.	.	PUNCT
dpc-2650	292	1	24	24	NUM
dpc-2650	292	2	.	.	PUNCT
dpc-2650	293	1	buerger	buerger	PROPN
dpc-2650	293	2	c	c	PROPN
dpc-2650	293	3	,	,	PUNCT
dpc-2650	293	4	richter	richter	PROPN
dpc-2650	293	5	b	b	PROPN
dpc-2650	293	6	,	,	PUNCT
dpc-2650	293	7	woth	woth	PROPN
dpc-2650	293	8	k	k	NOUN
dpc-2650	293	9	,	,	PUNCT
dpc-2650	293	10	et	et	PROPN
dpc-2650	293	11	al	al	PROPN
dpc-2650	293	12	.	.	PROPN
dpc-2650	293	13	interleukin-1β	interleukin-1β	PROPN
dpc-2650	293	14	interferes	interfere	VERB
dpc-2650	293	15	with	with	ADP
dpc-2650	293	16	epidermal	epidermal	ADJ
dpc-2650	293	17	homeostasis	homeostasis	NOUN
dpc-2650	293	18	through	through	ADP
dpc-2650	293	19	induction	induction	NOUN
dpc-2650	293	20	of	of	ADP
dpc-2650	293	21	insulin	insulin	NOUN
dpc-2650	293	22	resistance	resistance	NOUN
dpc-2650	293	23	:	:	PUNCT
dpc-2650	293	24	implications	implication	NOUN
dpc-2650	293	25	for	for	ADP
dpc-2650	293	26	psoriasis	psoriasis	NOUN
dpc-2650	293	27	pathogenesis	pathogenesis	NOUN
dpc-2650	293	28	.	.	PUNCT
dpc-2650	294	1	j	j	PROPN
dpc-2650	294	2	invest	invest	VERB
dpc-2650	294	3	dermatol	dermatol	NOUN
dpc-2650	294	4	.	.	PUNCT
dpc-2650	295	1	2012;132(9):2206	2012;132(9):2206	NUM
dpc-2650	295	2	-	-	SYM
dpc-2650	295	3	2214	2214	NUM
dpc-2650	295	4	.	.	PUNCT
dpc-2650	296	1	doi	doi	NOUN
dpc-2650	296	2	:	:	PUNCT
dpc-2650	296	3	10.1038	10.1038	NUM
dpc-2650	296	4	/	/	SYM
dpc-2650	296	5	jid.2012.123	jid.2012.123	NOUN
dpc-2650	296	6	.	.	PUNCT
dpc-2650	297	1	pmid	pmid	NOUN
dpc-2650	297	2	:	:	PUNCT
dpc-2650	297	3	22513786	22513786	NUM
dpc-2650	297	4	.	.	PUNCT
dpc-2650	298	1	25	25	NUM
dpc-2650	298	2	.	.	PUNCT
dpc-2650	299	1	holm	holm	PROPN
dpc-2650	299	2	jg	jg	PROPN
dpc-2650	299	3	,	,	PUNCT
dpc-2650	299	4	thomsen	thomsen	PROPN
dpc-2650	299	5	sf	sf	PROPN
dpc-2650	299	6	.	.	PUNCT
dpc-2650	299	7	type	type	NOUN
dpc-2650	299	8	2	2	NUM
dpc-2650	299	9	diabetes	diabetes	NOUN
dpc-2650	299	10	and	and	CCONJ
dpc-2650	299	11	psoriasis	psoriasis	NOUN
dpc-2650	299	12	:	:	PUNCT
dpc-2650	299	13	links	link	NOUN
dpc-2650	299	14	and	and	CCONJ
dpc-2650	299	15	risks	risk	NOUN
dpc-2650	299	16	.	.	PUNCT
dpc-2650	300	1	psoriasis	psoriasis	NOUN
dpc-2650	300	2	(	(	PUNCT
dpc-2650	300	3	auckl	auckl	NOUN
dpc-2650	300	4	)	)	PUNCT
dpc-2650	300	5	.	.	PUNCT
dpc-2650	301	1	2019;9:1	2019;9:1	X
dpc-2650	301	2	-	-	PUNCT
dpc-2650	301	3	6	6	NUM
dpc-2650	301	4	.	.	PUNCT
dpc-2650	301	5	doi	doi	NOUN
dpc-2650	301	6	:	:	PUNCT
dpc-2650	301	7	10.2147	10.2147	NUM
dpc-2650	301	8	/	/	SYM
dpc-2650	301	9	ptt	ptt	NOUN
dpc-2650	301	10	.	.	PUNCT
dpc-2650	302	1	s159163	s159163	PROPN
dpc-2650	302	2	.	.	PUNCT
dpc-2650	303	1	pmid	pmid	NOUN
dpc-2650	303	2	:	:	PUNCT
dpc-2650	303	3	30697518	30697518	NUM
dpc-2650	303	4	.	.	PUNCT
dpc-2650	304	1	pmcid	pmcid	NOUN
dpc-2650	304	2	:	:	PUNCT
dpc-2650	304	3	pmc6340647	pmc6340647	NOUN
dpc-2650	304	4	.	.	PUNCT
dpc-2650	305	1	26	26	NUM
dpc-2650	305	2	.	.	PUNCT
dpc-2650	306	1	shiiba	shiiba	PROPN
dpc-2650	306	2	m	m	PROPN
dpc-2650	306	3	,	,	PUNCT
dpc-2650	306	4	nomura	nomura	NOUN
dpc-2650	306	5	h	h	PROPN
dpc-2650	306	6	,	,	PUNCT
dpc-2650	306	7	shinozuka	shinozuka	PROPN
dpc-2650	306	8	k	k	PROPN
dpc-2650	306	9	,	,	PUNCT
dpc-2650	306	10	et	et	PROPN
dpc-2650	306	11	al	al	PROPN
dpc-2650	306	12	.	.	PROPN
dpc-2650	306	13	down	down	ADV
dpc-2650	306	14	-	-	PUNCT
dpc-2650	306	15	regulated	regulate	VERB
dpc-2650	306	16	expression	expression	NOUN
dpc-2650	306	17	of	of	ADP
dpc-2650	306	18	serpin	serpin	PROPN
dpc-2650	306	19	genes	gene	NOUN
dpc-2650	306	20	located	locate	VERB
dpc-2650	306	21	on	on	ADP
dpc-2650	306	22	chromosome	chromosome	NOUN
dpc-2650	306	23	18q21	18q21	NUM
dpc-2650	306	24	in	in	ADP
dpc-2650	306	25	oral	oral	ADJ
dpc-2650	306	26	squamous	squamous	ADJ
dpc-2650	306	27	cell	cell	NOUN
dpc-2650	306	28	carcinomas	carcinoma	NOUN
dpc-2650	306	29	.	.	PUNCT
dpc-2650	307	1	oncol	oncol	PROPN
dpc-2650	307	2	rep	rep	PROPN
dpc-2650	307	3	.	.	PROPN
dpc-2650	307	4	2010;24(1):241	2010;24(1):241	PROPN
dpc-2650	307	5	-	-	SYM
dpc-2650	307	6	249	249	NUM
dpc-2650	307	7	.	.	PUNCT
dpc-2650	308	1	doi	doi	NOUN
dpc-2650	308	2	:	:	PUNCT
dpc-2650	308	3	10.3892	10.3892	NUM
dpc-2650	308	4	/	/	SYM
dpc-2650	308	5	or_00000852	or_00000852	PROPN
dpc-2650	308	6	.	.	PUNCT
dpc-2650	309	1	pmid	pmid	NOUN
dpc-2650	309	2	:	:	PUNCT
dpc-2650	309	3	20514468	20514468	NUM
dpc-2650	309	4	.	.	PUNCT